The	O
cytochrome	B
P450	B
enzymes	I
might	O
be	O
the	O
most	O
significant	O
class	O
of	O
enzyme	O
to	O
study	O
the	O
metabolic	O
behavior	O
of	O
lead	O
compounds	O
.	O

Most	O
antidepressant	O
and	O
antipsychotic	O
drugs	O
are	O
metabolized	O
by	O
cytochrome	B
P450	B
enzymes	I
and	O
,	O
where	O
cytochrome	B
P450	I
inhibitors	O
are	O
co	O
-	O
ingested	O
,	O
serial	O
plasma	O
concentrations	O
should	O
optimally	O
be	O
obtained	O
in	O
order	O
to	O
assess	O
a	O
suitable	O
time	O
for	O
reintroduction	O
of	O
the	O
psychoactive	O
drugs	O
.	O

Consequently	O
,	O
search	O
terms	O
used	O
included	O
names	O
of	O
individual	O
drugs	O
AND	O
overdose	O
,	O
toxicokinetics	O
,	O
pharmacokinetics	O
,	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzyme	O
,	O
metabolism	O
,	O
or	O
active	O
metabolites	O
.	O

Function	O
,	O
essentiality	O
,	O
and	O
expression	O
of	O
cytochrome	B
P450	B
enzymes	I
and	O
their	O
cognate	O
redox	O
partners	O
in	O
Mycobacterium	O
tuberculosis	O
:	O
are	O
they	O
drug	O
targets	O
?	O
.	O

This	O
review	O
covers	O
the	O
current	O
knowledge	O
of	O
the	O
cytochrome	B
P450	B
enzymes	I
(	O
CYPs	O
)	O
of	O
the	O
human	O
pathogen	O
Mycobacterium	O
tuberculosis	O
(	O
Mtb	O
)	O
and	O
their	O
endogenous	O
redox	O
partners	O
,	O
focusing	O
on	O
their	O
biological	O
function	O
,	O
expression	O
,	O
regulation	O
,	O
involvement	O
in	O
antibiotic	O
resistance	O
,	O
and	O
suitability	O
for	O
exploitation	O
as	O
antitubercular	O
targets	O
.	O

Genome	O
mapping	O
revealed	O
that	O
Mtb	O
encodes	O
a	O
high	O
number	O
of	O
cytochrome	B
P450	B
enzymes	I
(	O
CYPs	O
or	O
P450s	O
)	O
.	O

Moreover	O
,	O
seventy	O
-	O
eight	O
cytochrome	O
P450s	O
and	O
multiple	O
transcription	O
factors	O
(	O
five	O
MYB	O
,	O
two	O
bHLH	O
,	O
and	O
three	O
WD40	O
family	O
genes	O
)	O
may	O
be	O
associated	O
with	O
the	O
regulation	O
of	O
the	O
flavonoid	O
biosynthesis	O
process	O
.	O

In	O
addition	O
,	O
glycosyltransferases	O
and	O
cytochrome	O
P450s	O
also	O
contribute	O
to	O
flavonoid	O
regulation	O
in	O
plants	O
.	O

These	O
enzymes	O
belong	O
to	O
three	O
pathways	O
,	O
namely	O
(	O
a	O
)	O
the	O
COX	O
pathway	O
(	O
COX1	O
,	O
COX2	O
)	O
resulting	O
in	O
production	O
of	O
prostaglandins	O
,	O
(	O
b	O
)	O
the	O
Lipoxygenases	O
pathway	O
(	O
5	O
-	O
LOX	O
,	O
1LOX	O
,	O
15LOX	O
)	O
resulting	O
in	O
production	O
of	O
leukotrienes	O
and	O
lipoxins	O
,	O
and	O
(	O
c	O
)	O
the	O
cytochrome	B
P450	I
pathway	O
which	O
forms	O
the	O
hydroxyeicosotetranoic	O
acids	O
and	O
the	O
epoxyeicosotrienoic	O
acids	O
(	O
Hanna	O
and	O
Hafez	O
,	O
.	O

The	O
MPB	O
genome	O
contains	O
86	O
different	O
cytochrome	B
P450	I
genes	O
,	O
and	O
three	O
of	O
these	O
P450s	O
have	O
previously	O
been	O
shown	O
to	O
function	O
in	O
terpenoid	O
metabolism	O
or	O
terpenoid	O
pheromone	O
biosynthesis	O
in	O
the	O
MPB	O
.	O

Second	O
,	O
an	O
oxidative	O
cyclisation	O
cascade	O
consisting	O
typically	O
of	O
three	O
to	O
four	O
cytochrome	B
P450	I
(	O
Oxy	O
)	O
enzymes	O
(	O
one	O
enzyme	O
per	O
ring	O
formed	O
,	O
see	O
Fig	O
)	O
is	O
then	O
recruited	O
to	O
the	O
NRPS	O
-	O
bound	O
heptapeptide	O
in	O
order	O
to	O
perform	O
the	O
stepwise	O
cyclisation	O
of	O
the	O
peptide	O
into	O
a	O
rigid	O
,	O
active	O
antibiotic	O
^	O
,	O
.	O

Strikingly	O
,	O
the	O
biosynthetic	O
gene	O
cluster	O
of	O
this	O
GPA	O
encodes	O
only	O
two	O
cytochrome	B
P450	B
enzymes	I
(	O
KisN	O
and	O
KisO	O
)	O
implicated	O
in	O
the	O
crosslinking	O
of	O
the	O
aromatic	O
side	O
chains	O
of	O
the	O
peptide	O
,	O
despite	O
there	O
being	O
three	O
crosslinks	O
in	O
kistamicin	O
.	O

For	O
isoflavones	O
,	O
the	O
gut	O
microbiome	O
and	O
phase	O
I	O
cytochrome	B
P450	I
enzymes	I
in	O
human	O
liver	O
microsome	O
were	O
responsible	O
for	O
O	O
-	O
demethylation	O
at	O
4	O
carbon	O
;	O
hence	O
formononetin	O
is	O
converted	O
to	O
daidzein	O
and	O
biochanin	O
A	O
to	O
genistein	O
Anthocyanidins	O
,	O
or	O
their	O
monoglucosides	O
of	O
anthocyanins	O
,	O
remained	O
unchanged	O
when	O
incubated	O
with	O
rat	O
liver	O
microsomes	O
in	O
the	O
presence	O
of	O
NADPH	O
,	O
which	O
suggests	O
that	O
anthocyanidins	O
are	O
not	O
affected	O
by	O
phase	O
I	O
enzymes	O
.	O

Markers	O
of	O
pharmacokinetics	O
/	O
toxicity	O
:	O
(	O
1	O
)	O
Sofarenib	O
metabolism	O
:	O
The	O
metabolism	O
of	O
sorafenib	O
is	O
well	O
-	O
established	O
and	O
occurs	O
mainly	O
in	O
the	O
liver	O
through	O
two	O
pathways	O
:	O
Phase	O
I	O
oxidation	O
mediated	O
by	O
cytochrome	B
P450	I
3A4	O
,	O
and	O
phase	O
II	O
conjugation	O
mediated	O
by	O
UDP	O
glucuronosyltransferase	O
1A9	O
.	O

Insects	O
have	O
employed	O
cytochrome	B
P450	I
monooxygenases	O
(	O
P450s	O
)	O
that	O
promote	O
more	O
a	O
rapid	O
metabolism	O
to	O
defer	O
the	O
cost	O
of	O
a	O
counter	O
-	O
defence	O
against	O
toxic	O
plant	O
compounds	O
.	O

The	O
AhR	O
/	O
ARNT	O
heterodimer	O
binds	O
the	O
xenobiotic	O
responsive	O
elements	O
in	O
the	O
promoter	O
,	O
leading	O
to	O
the	O
transcription	O
of	O
genes	O
that	O
encode	O
xenobiotic	O
metabolism	O
enzymes	O
,	O
such	O
as	O
cytochrome	B
P450	I
genes	O
,	O
which	O
in	O
mammals	O
include	O
CYP1A1	B
,	O
CYP1A2	B
,	O
and	O
CYP1B1	O
.	O

The	O
expression	O
of	O
cytochrome	B
P450	I
,	O
sodA	O
(	O
encoding	O
Fe	O
/	O
Mn	O
superoxide	O
dismutase	O
)	O
,	O
recA	O
,	O
and	O
superoxide	O
anion	O
radical	O
generation	O
rate	O
increased	O
after	O
the	O
addition	O
of	O
all	O
studied	O
hydrocarbons	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
expression	O
of	O
genes	O
,	O
cytochrome	B
P450	I
,	O
superoxide	O
dismutases	O
A	O
and	O
C	O
,	O
recA	O
,	O
as	O
well	O
as	O
generation	O
of	O
superoxide	O
anion	O
radical	O
and	O
hydrogen	O
peroxide	O
under	O
the	O
influence	O
of	O
hydrocarbons	O
on	O
Rhodococcus	O
.	O

It	O
is	O
well	O
known	O
that	O
in	O
the	O
course	O
of	O
enzymatic	O
reactions	O
of	O
cytochrome	B
P450	I
the	O
socalled	O
disjunction	O
of	O
the	O
cycle	O
may	O
occur	O
when	O
the	O
flow	O
of	O
electrons	O
derived	O
from	O
NAD	O
(	O
P	O
)	O
H	O
to	O
P450	O
molecules	O
leads	O
to	O
the	O
generation	O
of	O
superoxide	O
anion	O
radical	O
and	O
/	O
or	O
hydrogen	O
peroxide	O
instead	O
of	O
the	O
products	O
of	O
monooxygenase	O
reaction	O
(	O
Guengerich	O
,	O
;	O
Goeptar	O
,	O
Scheerens	O
,	O
&	O
Vermeulen	O
,	O
.	O

The	O
ROS	O
produced	O
by	O
cytochrome	B
P450	I
are	O
likely	O
to	O
cause	O
DNA	O
damage	O
.	O

A	O
growing	O
amount	O
of	O
data	O
have	O
demonstrated	O
the	O
biosynthesis	O
of	O
flavonoids	O
through	O
multienzyme	O
complexes	O
of	O
which	O
the	O
membrane	O
-	O
bounded	O
cytochrome	B
P450	I
supergene	O
family	O
shares	O
a	O
crucial	O
part	O
.	O

The	O
ER	O
-	O
bound	O
enzyme	O
complex	O
belongs	O
to	O
the	O
cytochrome	B
P450	I
superfamily	O
.	O

In	O
most	O
of	O
the	O
plant	O
species	O
,	O
cytochrome	B
P450	I
is	O
found	O
abundantly	O
and	O
produces	O
multiple	O
groups	O
of	O
secondary	O
metabolites	O
through	O
hydroxylation	O
and	O
monooxygenation	O
reactions	O
.	O

CYP701	O
,	O
a	O
member	O
of	O
cytochrome	B
P450	I
encoding	O
ent	O
-	O
kaurene	O
oxidase	O
,	O
is	O
essential	O
for	O
the	O
biosynthesis	O
of	O
gibberellins	O
.	O

Furthermore	O
,	O
several	O
other	O
studies	O
have	O
discovered	O
the	O
pharmacological	O
importance	O
of	O
the	O
cytochrome	B
P450	I
supergene	O
family	O
by	O
stimulating	O
plant	O
immunity	O
against	O
various	O
pathogens	O
.	O

Though	O
the	O
diversity	O
of	O
flavonoid	O
biosynthesis	O
has	O
been	O
reported	O
in	O
Arabidopsis	O
thaliana	O
seeds	O
,	O
the	O
mechanism	O
of	O
stress	O
-	O
responsive	O
cytochrome	B
P450	I
genes	O
encoding	O
a	O
single	O
or	O
group	O
of	O
enzymes	O
promoting	O
the	O
flavonoid	O
biosynthesis	O
pathway	O
in	O
Arabidopsis	O
remains	O
unexplained	O
.	O

As	O
a	O
point	O
of	O
paramount	O
significance	O
,	O
it	O
is	O
important	O
to	O
focus	O
on	O
studies	O
related	O
to	O
identification	O
and	O
characterization	O
of	O
putative	O
cytochrome	B
P450	I
genes	O
promoting	O
the	O
flavonoid	O
biosynthetic	O
pathway	O
in	O
plants	O
.	O

Based	O
on	O
predicted	O
open	O
-	O
reading	O
frames	O
,	O
the	O
unigenes	O
were	O
further	O
subjected	O
to	O
cytochrome	B
P450	I
database	O
(	O
http	O
:	O
/	O
/	O
drnelson	O
.	O
uthsc	O
.	O
edu	O
/	O
CytochromeP450	O
.	O
html	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
also	O
predicted	O
the	O
computational	O
structure	O
of	O
rutin	O
against	O
a	O
comprehensive	O
metabolite	O
prediction	O
tool	O
(	O
GLORY	O
)	O
that	O
contained	O
the	O
cytochrome	B
P450	I
prediction	O
module	O
according	O
to	O
the	O
instructions	O
of	O
.	O

These	O
findings	O
provide	O
a	O
theoretical	O
and	O
practical	O
basis	O
for	O
identifying	O
the	O
intrinsic	O
relation	O
of	O
a	O
stress	O
-	O
responsive	O
cytochrome	B
P450	I
gene	O
during	O
flavonoid	O
biosynthesis	O
in	O
plants	O
.	O

Heme	O
enzymes	O
,	O
such	O
as	O
the	O
cytochrome	O
P450s	O
,	O
are	O
involved	O
in	O
the	O
metabolism	O
/	O
breakdown	O
of	O
approximately	O
90	O
%	O
of	O
small	O
-	O
molecule	O
drugs	O
,	O
and	O
are	O
more	O
generally	O
themselves	O
drug	O
targets	O
in	O
yeast	O
,	O
fungi	O
and	O
tuberculosis	O
infections	O
(	O
McLean	O
&	O
Munro	O
,	O
2017	O
;	O
Guengerich	O
et	O
al	O
.	O
,	O
2016	O
;	O
Rendic	O
&	O
Guengerich	O
,	O
2015	O
)	O
.	O

Two	O
major	O
functional	O
classes	O
of	O
enzymes	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
all	O
steroid	O
hormones	O
,	O
namely	O
the	O
cytochrome	B
P450	I
and	O
hydroxysteroid	O
dehydrogenase	O
enzymes	O
.	O

Cytochrome	B
P450	I
type	O
II	O
enzymes	O
are	O
found	O
in	O
the	O
Endoplasmic	O
Reticulum	O
and	O
are	O
dependent	O
on	O
the	O
electron	O
donor	O
enzyme	O
cytochrome	B
P450	I
oxidoreductase	O
for	O
electron	O
delivery	O
.	O

Phenobarbital	O
metabolism	O
is	O
highly	O
dependent	O
upon	O
the	O
cytochrome	B
P450	I
and	O
genetic	O
polymorphisms	O
can	O
lead	O
to	O
variability	O
in	O
active	O
drug	O
levels	O
.	O

The	O
sequences	O
for	O
all	O
promoters	O
in	O
CYP2C19	B
gene	O
are	O
as	O
follows	O
:	O
CYP2C19	B
-	O
201	O
identified	O
in	O
chromosome	O
position	O
at	O
94762681	O
(	O
ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG	O
)	O
,	O
CYP2C19	B
-	O
202	O
chromosome	O
position	O
94842926	O
(	O
ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA	O
)	O
,	O
and	O
CYP2C19	B
-	O
203	O
chromosome	O
position	O
94775489	O
(	O
ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG	O
)	O
In	O
addition	O
,	O
we	O
identified	O
the	O
following	O
Kyoto	O
Encyclopedia	O
Of	O
Genes	O
And	O
Genomes	O
pathways	O
of	O
CYP2C19	B
which	O
include	O
arachidonic	O
acid	O
metabolism	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
chemical	O
carcinogenesis	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
drug	O
metabolism	O
(	O
cytochrome	B
P450	I
)	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
linoleic	O
acid	O
metabolism	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
metabolic	O
pathways	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
and	O
serotonergic	O
synapse	O
.	O

Celastrol	O
biosynthesis	O
likely	O
adheres	O
to	O
the	O
common	O
triterpenoid	O
scheme	O
that	O
starts	O
with	O
cycloisomerization	O
of	O
2	O
,	O
3	O
-	O
oxidosqualene	O
by	O
an	O
oxidosqualene	O
cyclase	O
(	O
OSC	O
)	O
and	O
continues	O
with	O
oxidative	O
decoration	O
(	O
s	O
)	O
of	O
the	O
30	O
-	O
carbon	O
triterpenoid	O
core	O
structure	O
by	O
cytochrome	B
P450	I
enzymes	I
[	O
,	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
impact	O
of	O
co	O
-	O
administration	O
of	O
pomegranate	O
peel	O
and	O
guava	O
leaves	O
extracts	O
,	O
including	O
their	O
quality	O
markers	O
namely	O
;	O
ellagic	O
acid	O
and	O
quercetin	O
,	O
respectively	O
,	O
on	O
warfarins	O
in	O
vivo	O
dynamic	O
activity	O
and	O
pharmacokinetic	O
actions	O
,	O
in	O
addition	O
to	O
potential	O
in	O
vitro	O
cytochrome	O
P450	B
enzymes	I
inhibition	O
.	O

This	O
study	O
includes	O
the	O
quantitative	O
measurement	O
of	O
drug	O
-	O
like	O
properties	O
such	O
as	O
,	O
lipophilicity	O
,	O
solubility	O
,	O
pKa	O
(	O
negative	O
logarithmic	O
measure	O
of	O
acid	O
dissociation	O
constant	O
)	O
,	O
permeability	O
,	O
absorption	O
,	O
bioavailability	O
,	O
blood	O
-	O
brain	O
barrier	O
penetration	O
,	O
transporters	O
,	O
dermal	O
and	O
ocular	O
penetration	O
,	O
plasma	O
-	O
protein	O
binding	O
,	O
metabolism	O
and	O
drug	O
-	O
drug	O
interaction	O
,	O
volume	O
of	O
distribution	O
(	O
V_d	O
)	O
,	O
clearance	O
,	O
half	O
-	O
life	O
,	O
p	O
-	O
glycoprotein	O
efflux	O
and	O
inhibition	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
hepatic	O
organic	O
anion	O
transporting	O
polypeptide	O
(	O
OATP	O
-	O
1B1	O
)	O
transporter	O
,	O
cytochromes	O
P450	B
enzymes	I
,	O
and	O
UDP	O
-	O
glucuronosyltransferases	O
.	O

In	O
identifying	O
the	O
affinity	O
of	O
studies	O
compound	O
with	O
CYP	O
-	O
P450	B
enzymes	I
in	O
quantitative	O
terms	O
,	O
the	O
Michaelis	O
-	O
Menten	O
constant	O
(	O
K_m	O
)	O
,	O
maximum	O
metabolic	O
rate	O
(	O
V_max	O
)	O
and	O
intrinsic	O
clearance	O
(	O
C_Lint	O
)	O
calculated	O
,	O
which	O
provide	O
the	O
knowledge	O
of	O
the	O
rate	O
of	O
metabolism	O
.	O

The	O
lipophilic	O
sterol	O
metabolites	O
produced	O
by	O
IFN	O
signaling	O
including	O
oxysterols	O
are	O
substrates	O
for	O
Cytochrome	B
P450	I
enzymes	I
and	O
they	O
profoundly	O
influence	O
cellular	O
metabolism	O
(	O
Newmark	O
et	O
al	O
.	O
,	O
)	O
which	O
in	O
turn	O
has	O
been	O
shown	O
to	O
influence	O
Mycobacterium	O
Tuberculosis	O
replication	O
inside	O
cells	O
(	O
Huang	O
et	O
al	O
.	O
,	O
.	O

The	O
Cytochrome	B
P450	I
enzymes	I
are	O
heme	O
containing	O
monooxygenases	O
involved	O
in	O
the	O
pathways	O
associated	O
with	O
the	O
metabolism	O
of	O
fatty	O
acids	O
,	O
steroids	O
and	O
other	O
lipophilic	O
molecules	O
(	O
Pikuleva	O
,	O
.	O

The	O
loss	O
of	O
Cytochrome	B
P450	I
enzymes	I
prevents	O
Apolipoprotein	O
(	O
Apo	O
)	O
A1	O
synthesis	O
thus	O
affecting	O
the	O
removal	O
of	O
cholesterol	O
from	O
the	O
cells	O
to	O
the	O
liver	O
for	O
biliary	O
excretion	O
(	O
Rubin	O
et	O
al	O
.	O
,	O
;	O
Nebert	O
and	O
Russell	O
,	O
;	O
Guan	O
et	O
al	O
.	O
,	O
.	O

Since	O
the	O
activity	O
of	O
the	O
Cytochrome	B
P450	I
enzymes	I
can	O
be	O
modulated	O
post	O
-	O
translationally	O
,	O
they	O
are	O
targets	O
to	O
manipulate	O
cholesterol	O
homeostasis	O
(	O
Luoma	O
,	O
.	O

For	O
example	O
,	O
Mycobacterium	O
Tuberculosis	O
has	O
about	O
20	O
different	O
Cytochrome	B
P450	I
enzymes	I
,	O
and	O
several	O
Cytochrome	B
P450	I
genes	O
have	O
been	O
associated	O
with	O
mycobacterial	O
viability	O
(	O
Mclean	O
et	O
al	O
.	O
,	O
.	O

have	O
reported	O
that	O
the	O
Mycobacterium	O
Tuberculosis	O
genome	O
sequence	O
has	O
a	O
very	O
high	O
number	O
of	O
Cytochrome	B
P450	I
enzymes	I
,	O
with	O
Cyp128	O
contributing	O
to	O
synthesis	O
of	O
cell	O
wall	O
sulpholipid	O
and	O
being	O
necessary	O
for	O
in	O
-	O
vitro	O
growth	O
of	O
the	O
bacterium	O
(	O
Cole	O
et	O
al	O
.	O
,	O
;	O
Holsclaw	O
et	O
al	O
.	O
,	O
;	O
Sogi	O
et	O
al	O
.	O
,	O
.	O

Cytochrome	B
P450	I
enzymes	I
(	O
P450s	O
)	O
of	O
the	O
MPB	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
at	O
least	O
some	O
of	O
these	O
defense	O
compounds	O
.	O

The	O
active	O
site	O
heme	O
iron	O
is	O
coordinated	O
by	O
the	O
thiolate	O
of	O
the	O
conserved	O
,	O
proximal	O
Cys332	O
residue	O
,	O
whilst	O
the	O
I	O
-	O
helix	O
that	O
runs	O
across	O
the	O
top	O
of	O
the	O
heme	O
contains	O
the	O
Glu	O
/	O
Gln	O
pair	O
of	O
residues	O
(	O
Glu228	O
,	O
Gln229	O
)	O
that	O
are	O
required	O
in	O
P450	B
enzymes	I
to	O
maintain	O
an	O
effective	O
protonation	O
cascade	O
during	O
oxygen	O
activation	O
.	O

Cytochrome	B
P450	I
enzymes	I
,	O
responsible	O
for	O
the	O
biotransformation	O
of	O
more	O
than	O
85	O
%	O
of	O
existing	O
drugs	O
,	O
may	O
contain	O
genetic	O
variants	O
that	O
result	O
in	O
poor	O
,	O
intermediate	O
,	O
extensive	O
or	O
ultra	O
-	O
rapid	O
metabolic	O
rates	O
^	O
,	O
.	O

Inhibition	O
of	O
CYP2C8	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
BACULOSOMES	O
^	O
was	O
quantified	O
,	O
as	O
described	O
in	O
.	O

The	O
data	O
generated	O
were	O
exported	O
to	O
an	O
Excel	O
(	O
Microsoft	O
Headquarters	O
,	O
One	O
Microsoft	O
Way	O
,	O
Redmond	O
,	O
WA	O
,	O
USA	O
)	O
worksheet	O
and	O
the	O
amount	O
of	O
metabolite	O
formed	O
at	O
various	O
concentrations	O
relative	O
to	O
the	O
control	O
was	O
calculated	O
using	O
the	O
following	O
equation	O
:	O
The	O
relative	O
percentage	O
activity	O
was	O
plotted	O
against	O
the	O
log	O
transformed	O
concentrations	O
of	O
the	O
extracts	O
,	O
compounds	O
and	O
positive	O
controls	O
,	O
ie	O
quercetin	O
(	O
positive	O
CYP2C8	B
inhibitor	O
)	O
,	O
sulfaphenazole	O
(	O
positive	O
CYP2C9	B
inhibitor	O
)	O
,	O
and	O
ketoconazole	O
(	O
positive	O
CYP3A4	B
inhibitor	O
)	O
.	O

This	O
in	O
vitro	O
study	O
indicated	O
that	O
combining	O
nutraceuticals	O
containing	O
rooibos	O
extracts	O
with	O
drugs	O
metabolized	O
by	O
CYP2C8	B
and	O
CYP3A4	B
could	O
potentially	O
alter	O
the	O
pharmacodynamics	O
and	O
safety	O
of	O
these	O
drugs	O
.	O

456255	O
)	O
,	O
CYP2C8	B
(	O
Lot	O
No	O
.	O

Flucloxacillin	O
was	O
incubated	O
at	O
substrate	O
concentrations	O
of	O
10	O
and	O
100	O
M	O
with	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
HLM	O
,	O
as	O
described	O
above	O
,	O
and	O
in	O
the	O
absence	O
or	O
presence	O
of	O
the	O
following	O
inhibitors	O
:	O
10	O
M	O
ALPHAnaphtoflavone	O
(	O
CYP1A2	B
)	O
,	O
3	O
M	O
ticlopidine	O
(	O
CYP2B6	O
)	O
,	O
15	O
M	O
quercetin	O
(	O
CYP2C8	B
)	O
,	O
10	O
M	O
sulfaphenazole	O
(	O
CYP2C9	B
)	O
,	O
10	O
M	O
fluvoxamine	O
(	O
CYP2C9	B
/	O
CYP1A2	B
)	O
,	O
1	O
M	O
(	O
+	O
)	O
N3benzylnirvanol	O
(	O
CYP2C19	O
)	O
,	O
2	O
M	O
quinidine	O
(	O
CYP2D6	B
)	O
,	O
20	O
M	O
diethylthiocarbamate	O
(	O
CYP2E1	B
)	O
,	O
3	O
M	O
troleandomycin	O
(	O
CYP3A4	O
)	O
;	O
2	O
M	O
miconazole	O
(	O
CYP3A4	O
/	O
CYP2C9	B
)	O
and	O
0	O
.	O
1	O
M	O
(	O
CYP3A4	O
)	O
and	O
1	O
M	O
(	O
CYP3A	B
)	O
ketoconazole	O
respectively	O
.	O

To	O
determine	O
the	O
variability	O
of	O
5hydroxylation	O
of	O
flucloxacillin	O
,	O
the	O
substrate	O
was	O
incubated	O
(	O
10	O
and	O
100	O
M	O
)	O
with	O
a	O
panel	O
of	O
individual	O
HLM	O
fractions	O
from	O
16	O
donors	O
(	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
)	O
which	O
were	O
phenotyped	O
with	O
respect	O
to	O
activities	O
of	O
CYP1A2	B
(	O
phenacetin	O
Odeethylation	O
)	O
,	O
CYP2A6	O
(	O
coumarin	O
7hydroxylation	O
)	O
,	O
CYP2B6	O
(	O
bupropion	O
hydroxylation	O
)	O
,	O
CYP2C8	B
(	O
amodiaquine	O
Ndeethylation	O
)	O
,	O
CYP2C9	B
(	O
diclofenac	O
4hydroxylation	O
)	O
,	O
CYP2C19	O
(	O
mephenytoin	O
4hydroxylation	O
)	O
,	O
CYP2D6	B
(	O
bufuralol	O
1hydroxylation	O
)	O
,	O
CYP2E1	B
(	O
chlorzoxazone	O
6hydroxylation	O
)	O
and	O
CYP3A4	O
(	O
midazolam	O
1hydroxylation	O
and	O
testosterone	O
6BETAhydroxylation	O
)	O
using	O
the	O
concentrations	O
described	O
previously	O
(	O
den	O
BraverSewradj	O
et	O
al	O
.	O
,	O
.	O

Low	O
activities	O
of	O
5HMFLX	O
formation	O
were	O
observed	O
,	O
in	O
decreasing	O
order	O
,	O
in	O
incubations	O
with	O
CYP2C9	B
,	O
CYP2J2	O
,	O
CYP2C8	B
,	O
CYP2E1	B
,	O
CYP3A5	B
,	O
CYP1A1	B
,	O
CYP2D6	B
and	O
CYP1A2	B
.	O

At	O
100	O
M	O
flucloxacillin	O
,	O
low	O
activities	O
were	O
also	O
observed	O
with	O
CYP1A1	B
,	O
CYP1A2	B
,	O
CYP2C8	B
,	O
CYP2E1	B
,	O
CYP2J2	O
and	O
CYP3A5	B
.	O

Significant	O
reduction	O
in	O
CYP2C8	B
,	O
2C9	O
,	O
and	O
3A4	O
was	O
seen	O
upon	O
concomitant	O
use	O
of	O
warfarin	O
with	O
ellagic	O
acid	O
,	O
guava	O
leaves	O
and	O
quercetin	O
,	O
unlike	O
pomegranate	O
that	O
insignificantly	O
affected	O
Cytochrome	B
P450	I
Enzymes	O
activities	O
.	O

Combination	O
of	O
ellagic	O
acid	O
with	O
warfarin	O
significantly	O
inhibited	O
activities	O
of	O
CYP2C8	B
,	O
2C9	O
and	O
3A4	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
however	O
treatment	O
of	O
cells	O
with	O
ellagic	O
acid	O
alone	O
presented	O
significant	O
inhibition	O
on	O
CYP2C9	O
activity	O
despite	O
other	O
CYPs	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Although	O
guava	O
leaves	O
extract	O
showed	O
an	O
insignificant	O
effect	O
on	O
CYP2C8	B
when	O
used	O
alone	O
,	O
it	O
significantly	O
reduced	O
its	O
activity	O
when	O
combined	O
with	O
warfarin	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
however	O
,	O
inhibited	O
the	O
activities	O
of	O
CYP2C9	O
and	O
3A4	O
when	O
used	O
alone	O
and	O
concomitantly	O
with	O
warfarin	O
(	O
p	O
-	O
values	O
are	O
marked	O
in	O
Figs	O
.	O

A	O
mixture	O
containing	O
0	O
.	O
1	O
%	O
of	O
organic	O
solvent	O
,	O
reaction	O
buffer	O
(	O
200	O
mM	O
potassium	O
phosphate	O
(	O
reaction	O
buffer	O
I	O
)	O
or	O
100	O
mM	O
potassium	O
phosphate	O
(	O
reaction	O
buffer	O
II	O
)	O
)	O
and	O
regeneration	O
system	O
(	O
333	O
mM	O
glucose	O
-	O
6	O
-	O
phosphate	O
and	O
30	O
U	O
/	O
mL	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
in	O
100	O
mM	O
potassium	O
phosphate	O
,	O
pH	O
8	O
.	O
0	O
)	O
solution	O
with	O
the	O
addition	O
of	O
each	O
enzyme	O
(	O
CYP2C8	O
,	O
CYP2C9	B
,	O
or	O
CYP3A4	B
)	O
was	O
prepared	O
.	O

Compounds	O
,	O
PPAG	O
and	O
ASP	O
,	O
and	O
the	O
rooibos	O
extracts	O
,	O
GRT	O
and	O
FRE	O
,	O
were	O
screened	O
for	O
their	O
inhibitory	O
effects	O
on	O
CYP2C8	O
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
using	O
one	O
-	O
point	O
screening	O
kinetics	O
.	O

Briefly	O
,	O
inhibitors	O
,	O
extracts	O
,	O
and	O
compounds	O
were	O
pre	O
-	O
incubated	O
with	O
either	O
CYP2C8	O
or	O
CYP2C9	B
at	O
a	O
concentration	O
of	O
100	O
g	O
/	O
mL	O
,	O
or	O
CYP3A4	B
at	O
a	O
concentration	O
of	O
200	O
g	O
/	O
mL	O
.	O

As	O
per	O
the	O
manufacturers	O
instruction	O
,	O
50	O
L	O
of	O
Vivid	O
^	O
Master	O
Pre	O
-	O
Mix	O
(	O
BACULOSOMES	O
^	O
enzymes	O
(	O
CYP2C8	O
,	O
CYP2C9	B
or	O
CYP3A4	B
)	O
,	O
regeneration	O
system	O
,	O
reaction	O
buffer	O
(	O
I	O
/	O
II	O
)	O
,	O
and	O
NADP	O
^	O
+	O
)	O
was	O
added	O
to	O
each	O
well	O
.	O

After	O
incubation	O
,	O
10	O
L	O
reconstituted	O
DBOMF	O
(	O
CYP2C8	O
)	O
or	O
BOMCC	O
(	O
CYP2C9	B
and	O
CYP3A4	B
)	O
and	O
NADP	O
^	O
+	O
in	O
Vivid	O
^	O
reaction	O
buffer	O
I	O
/	O
II	O
were	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
30	O
min	O
at	O
37	O
C	O
.	O
Fluorescence	O
was	O
measured	O
on	O
a	O
SpectraMax	O
i3	O
plate	O
reader	O
at	O
5	O
min	O
intervals	O
to	O
determine	O
reaction	O
kinetics	O
.	O

Enzyme	O
activity	O
was	O
measured	O
by	O
formation	O
of	O
the	O
metabolites	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
485	O
/	O
530	O
nm	O
(	O
CYP2C8	O
)	O
and	O
406	O
/	O
460	O
nm	O
(	O
CYP2C9	B
and	O
CYP3A4	B
)	O
,	O
respectively	O
.	O

A	O
three	O
-	O
fold	O
serial	O
dilution	O
of	O
PPAG	O
,	O
ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
was	O
added	O
to	O
CYP2C8	O
and	O
CYP2C9	B
(	O
concentration	O
range	O
100	O
-	O
0	O
.	O
41	O
g	O
/	O
mL	O
)	O
and	O
CYP3A4	B
(	O
concentration	O
range	O
200	O
-	O
0	O
.	O
82	O
g	O
/	O
mL	O
)	O
to	O
determine	O
their	O
respective	O
IC_50	O
concentrations	O
.	O

CYP2C8	O
,	O
CYP2C9	B
,	O
or	O
CYP3A4	B
BACULOSOMES	O
^	O
plus	O
reagent	O
and	O
regeneration	O
system	O
in	O
Vivid	O
^	O
reaction	O
buffer	O
I	O
/	O
II	O
added	O
to	O
a	O
black	O
Costar	O
96	O
-	O
well	O
plate	O
containing	O
test	O
extracts	O
and	O
compounds	O
were	O
incubated	O
for	O
15	O
min	O
at	O
37	O
C	O
.	O
Thereafter	O
,	O
as	O
previously	O
described	O
,	O
the	O
reaction	O
was	O
initiated	O
by	O
adding	O
a	O
mixture	O
of	O
reconstituted	O
DBOMF	O
(	O
CYP2C8	O
)	O
or	O
BOMCC	O
(	O
CYP2C9	B
and	O
CYP3A4	B
)	O
and	O
NADP	O
^	O
+	O
in	O
Vivid	O
^	O
reaction	O
buffer	O
I	O
/	O
II	O
and	O
incubated	O
for	O
30	O
min	O
at	O
37	O
C	O
.	O
After	O
addition	O
of	O
the	O
stop	O
solution	O
to	O
terminate	O
the	O
reaction	O
,	O
fluorescence	O
was	O
determined	O
at	O
the	O
relative	O
excitation	O
/	O
emission	O
wavelengths	O
described	O
in	O
.	O

Time	O
-	O
dependent	O
inhibition	O
(	O
TDI	O
)	O
using	O
the	O
respective	O
serial	O
dilutions	O
employed	O
for	O
IC_50	O
determination	O
(	O
CYP2C8	O
and	O
CYP2C9	B
;	O
100	O
-	O
0	O
.	O
41	O
g	O
/	O
mL	O
and	O
for	O
CYP3A4	B
;	O
200	O
-	O
0	O
.	O
82	O
g	O
/	O
mL	O
)	O
was	O
performed	O
.	O

The	O
extracts	O
and	O
compounds	O
were	O
pre	O
-	O
incubated	O
with	O
CYP2C8	O
,	O
CYP2C9	B
,	O
or	O
CYP3A4	B
BACULOSOMES	O
^	O
and	O
NADPH	O
for	O
30	O
min	O
.	O

Queried	O
databases	O
included	O
,	O
eg	O
,	O
PharmGKB	O
,	O
PharmVar	O
(	O
available	O
only	O
for	O
CYP2C9	B
,	O
2C19	O
,	O
2D6	O
genes	O
)	O
,	O
ADReCS	O
-	O
Target	O
an	O
Adverse	O
Drug	O
Reaction	O
Classification	O
System	O
-	O
Target	O
Profile	O
(	O
http	O
:	O
/	O
/	O
bioinf	O
.	O
xmu	O
.	O
edu	O
.	O
cn	O
/	O
ADReCS	O
-	O
Target	O
)	O
,	O
which	O
provides	O
comprehensive	O
information	O
about	O
ADRs	O
caused	O
by	O
drug	O
interaction	O
with	O
protein	O
,	O
gene	O
and	O
genetic	O
variation	O
,	O
PheWas	O
Resources	O
(	O
phenome	O
-	O
wide	O
association	O
studies	O
with	O
antineoplastic	O
drugs	O
)	O
,	O
Clinvar	O
and	O
dbSNP	O
.	O

Recombinant	O
CYPs	O
showing	O
the	O
highest	O
specific	O
activity	O
were	O
CYP3A4	O
,	O
CYP3A7	O
and	O
to	O
lower	O
extent	O
CYP2C9	B
and	O
CTP2C8	O
.	O

Michaelis	O
-	O
Menten	O
enzyme	O
kinetics	O
were	O
determined	O
for	O
pooled	O
human	O
liver	O
microsomes	O
,	O
recombinant	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
.	O

The	O
combined	O
results	O
show	O
that	O
the	O
5hydroxylation	O
of	O
flucloxacillin	O
is	O
primarily	O
catalysed	O
by	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
.	O

Quantification	O
of	O
specific	O
activities	O
and	O
enzyme	O
kinetics	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
HLM	O
and	O
14	O
recombinant	O
human	O
CYPs	O
.	O
Next	O
to	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
may	O
contribute	O
significantly	O
to	O
flucloxacillin	O
hydroxylation	O
.	O
Sulfaphenazole	O
,	O
considered	O
as	O
a	O
selective	O
CYP2C9	B
inhibitor	O
,	O
strongly	O
inhibits	O
CYP3Amediated	O
flucloxacillin	O
hydroxylation	O
.	O

Interindividual	O
variability	O
and	O
drugdrug	O
interactions	O
at	O
the	O
level	O
of	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
may	O
be	O
important	O
factors	O
determining	O
the	O
risk	O
of	O
flucloxacillininduced	O
liver	O
injury	O
.	O

456252	O
)	O
,	O
CYP2C9	B
*	O
1	O
(	O
Arg144	O
)	O
(	O
Lot	O
No	O
.	O

Because	O
these	O
incubations	O
were	O
only	O
performed	O
to	O
identify	O
the	O
most	O
active	O
enzymes	O
,	O
duplicate	O
experiments	O
were	O
deemed	O
sufficient	O
since	O
reproducibility	O
of	O
incubations	O
with	O
recombinant	O
enzymes	O
from	O
the	O
same	O
source	O
was	O
always	O
within	O
5	O
%	O
,	O
For	O
the	O
most	O
active	O
Gentest	O
Supersomes	O
and	O
pooled	O
HLM	O
,	O
the	O
enzyme	O
kinetics	O
of	O
the	O
formation	O
of	O
5HMFLX	O
were	O
determined	O
by	O
incubating	O
with	O
11	O
concentrations	O
of	O
flucloxacillin	O
,	O
ranging	O
from	O
0	O
to	O
500	O
M	O
.	O
Each	O
flucloxacillin	O
concentration	O
was	O
incubated	O
in	O
duplicate	O
for	O
10	O
min	O
with	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
pooled	O
HLM	O
,	O
100	O
nM	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
Supersomes	O
in	O
100	O
mM	O
potassium	O
phosphate	O
buffer	O
,	O
pH	O
7	O
.	O
4	O
supplemented	O
with	O
5	O
mM	O
MgCl_2	O
and	O
2	O
mM	O
EDTA	O
.	O

Because	O
the	O
CYP2C9specific	O
inhibitor	O
sulfaphenazole	O
appeared	O
to	O
almost	O
completely	O
block	O
formation	O
of	O
5HMFLX	O
by	O
pooled	O
HLM	O
,	O
it	O
was	O
also	O
added	O
at	O
different	O
concentrations	O
to	O
incubations	O
of	O
CYP3A4	O
and	O
CYP3A7	O
Supersomes	O
with	O
flucloxacillin	O
(	O
10	O
M	O
)	O
and	O
testosterone	O
(	O
50	O
M	O
)	O
.	O

At	O
a	O
flucloxacillin	O
concentration	O
of	O
10	O
M	O
,	O
recombinant	O
CYP3A4	O
,	O
CYP3A7	O
and	O
to	O
a	O
lesser	O
extent	O
CYP2C9	B
showed	O
the	O
highest	O
activity	O
,	O
in	O
terms	O
of	O
the	O
formation	O
of	O
5HMFLX	O
.	O

As	O
CYP3A4	O
,	O
CYP3A7	O
and	O
CYP2C9	B
Supersomes	O
showed	O
highest	O
activity	O
at	O
both	O
concentrations	O
,	O
the	O
enzyme	O
kinetics	O
of	O
5HMFLX	O
formation	O
was	O
also	O
determined	O
for	O
these	O
recombinant	O
CYPs	O
.	O

Using	O
the	O
Michaelis	O
-	O
Menten	O
model	O
,	O
the	O
following	O
enzyme	O
kinetic	O
parameters	O
were	O
determined	O
:	O
CYP3A4	O
,	O
K	O
_M	O
124	O
15	O
M	O
,	O
V_max	O
197	O
9	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
;	O
CYP3A7	O
:	O
K	O
_M	O
65	O
8	O
M	O
,	O
V_max	O
193	O
7	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
;	O
and	O
CYP2C9	B
:	O
K	O
_M	O
of	O
508	O
82	O
M	O
,	O
V_max	O
67	O
7	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
.	O

Although	O
recombinant	O
CYP2C9	B
showed	O
much	O
lower	O
activity	O
when	O
compared	O
to	O
CYP3A4	O
,	O
an	O
almost	O
90	O
%	O
inhibition	O
of	O
5HMFLX	O
formation	O
was	O
observed	O
in	O
the	O
presence	O
of	O
sulfaphenazole	O
,	O
which	O
is	O
considered	O
to	O
be	O
a	O
selective	O
CYP2C9	B
inhibitor	O
.	O

However	O
,	O
fluvoxamine	O
,	O
the	O
other	O
CYP2C9	B
inhibitor	O
used	O
,	O
did	O
not	O
show	O
significant	O
inhibition	O
of	O
5HMFLX	O
formation	O
.	O

At	O
both	O
concentrations	O
of	O
flucloxacillin	O
,	O
the	O
highest	O
correlation	O
coefficients	O
were	O
found	O
with	O
CYP2C9catalysed	O
diclofenac	O
4hydroxylation	O
,	O
with	O
Pearson	O
correlation	O
coefficients	O
of	O
0	O
.	O
78	O
and	O
0	O
.	O
58	O
,	O
respectively	O
,	O
and	O
CYP3Acatalysed	O
6BETAhydroxylation	O
,	O
with	O
correlation	O
coefficients	O
of	O
0	O
.	O
69	O
and	O
0	O
.	O
58	O
respectively	O
.	O

The	O
localization	O
images	O
of	O
CYP1A1	B
and	O
3A4	O
showed	O
no	O
preferential	O
localization	O
of	O
these	O
isoforms	O
for	O
either	O
mitochondria	O
or	O
Endoplasmic	O
Reticulum	O
,	O
as	O
also	O
shown	O
by	O
other	O
groups	O
in	O
several	O
models	O
.	O

The	O
quantification	O
of	O
relative	O
mRNA	O
levels	O
for	O
the	O
isoforms	O
CYP1A1	B
,	O
2D6	O
and	O
2E1	O
was	O
carried	O
out	O
after	O
incubation	O
of	O
SH	O
-	O
SY5Y	O
cells	O
for	O
48	O
h	O
with	O
BETA	O
-	O
NF	O
(	O
4	O
M	O
)	O
,	O
dissolved	O
in	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
;	O
0	O
.	O
1	O
%	O
maximum	O
final	O
concentration	O
used	O
,	O
v	O
/	O
v	O
)	O
,	O
and	O
EtOH	O
(	O
100	O
mM	O
)	O
,	O
dissolved	O
in	O
water	O
.	O

The	O
following	O
probes	O
for	O
Cytochrome	B
P450	I
isoforms	O
were	O
used	O
,	O
CYP1A1	B
(	O
Life	O
Technologies	O
,	O
Assay	O
ID	O
Hs01054797_g1	O
,	O
#	O
4331182	O
)	O
,	O
CYP2D6	O
(	O
Life	O
Technologies	O
,	O
Assay	O
ID	O
Hs03043790_g1	O
,	O
#	O
4331182	O
)	O
,	O
and	O
CYP2E1	B
(	O
Life	O
Technologies	O
,	O
Assay	O
ID	O
Hs00559368_m1	O
,	O
#	O
4453320	O
)	O
.	O

The	O
analysis	O
of	O
protein	O
levels	O
was	O
performed	O
for	O
isoforms	O
CYP1A1	B
,	O
2D6	O
,	O
2E1	O
,	O
and	O
3A4	O
in	O
both	O
undifferentiated	O
and	O
differentiated	O
SH	O
-	O
SY5Y	O
cells	O
.	O

They	O
were	O
incubated	O
with	O
one	O
of	O
the	O
following	O
primary	O
antibodies	O
overnight	O
,	O
anti	O
-	O
CYP1A1	B
(	O
Life	O
Technologies	O
,	O
#	O
PA515213	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
,	O
anti	O
-	O
CYP2D6	O
(	O
Life	O
Technologies	O
,	O
#	O
PA535148	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
,	O
anti	O
-	O
CYP2E1	B
(	O
Life	O
Technologies	O
,	O
#	O
PA535351	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
,	O
or	O
anti	O
-	O
CYP3A4	B
(	O
Life	O
Technologies	O
,	O
#	O
PA514896	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
rabbit	O
)	O
mixed	O
with	O
anti	O
-	O
BETA	O
-	O
actin	O
primary	O
antibody	O
(	O
Life	O
Technologies	O
,	O
#	O
PA516914	O
,	O
1	O
:	O
1000	O
,	O
polyclonal	O
mouse	O
)	O
as	O
an	O
endogenous	O
housekeeping	O
protein	O
.	O

To	O
determine	O
the	O
effect	O
of	O
B	O
[	O
ALPHA	O
]	O
P	O
on	O
the	O
gene	O
signature	O
in	O
human	O
T	O
lymphocytes	O
,	O
primary	O
cultures	O
of	O
T	O
lymphocytes	O
purified	O
from	O
healthy	O
blood	O
donors	O
and	O
activated	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
antibodies	O
for	O
72	O
h	O
,	O
were	O
used	O
and	O
co	O
-	O
exposed	O
to	O
2	O
M	O
B	O
[	O
ALPHA	O
]	O
P	O
for	O
the	O
last	O
48	O
h	O
.	O
We	O
previously	O
reported	O
an	O
early	O
and	O
functional	O
up	O
-	O
regulation	O
of	O
the	O
Aryl	O
Hydrocarbon	O
by	O
such	O
human	O
T	O
lymphocyte	O
activation	O
during	O
24	O
h	O
,	O
followed	O
by	O
a	O
maximal	O
response	O
of	O
target	O
genes	O
such	O
as	O
CYP1A1	B
and	O
CYP1B1	O
after	O
exposure	O
to	O
2	O
M	O
B	O
[	O
ALPHA	O
]	O
P	O
.	O
Such	O
a	O
2	O
M	O
concentration	O
is	O
in	O
the	O
range	O
of	O
B	O
[	O
ALPHA	O
]	O
P	O
concentrations	O
known	O
to	O
lead	O
to	O
maximal	O
response	O
of	O
target	O
genes	O
in	O
cultured	O
human	O
cells	O
.	O

Among	O
these	O
genes	O
,	O
as	O
expected	O
,	O
CYP1A1	B
and	O
CYP1B1	O
,	O
well	O
-	O
known	O
targets	O
of	O
Aryl	O
Hydrocarbon	O
,	O
appear	O
as	O
the	O
top	O
genes	O
over	O
-	O
expressed	O
after	O
exposure	O
to	O
B	O
[	O
ALPHA	O
]	O
P	O
,	O
thus	O
validating	O
our	O
experimental	O
conditions	O
.	O

We	O
thus	O
selected	O
the	O
most	O
significantly	O
affected	O
genes	O
:	O
CYP1A1	B
and	O
1B1	O
,	O
gap	O
junction	O
beta	O
-	O
2	O
and	O
beta	O
-	O
6	O
(	O
GJB6	O
)	O
proteins	O
,	O
TCDD	O
-	O
inducible	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
TIPARP	O
)	O
,	O
transmembrane	O
protein	O
167A	O
,	O
oligodendrocyte	O
transcription	O
factor	O
3	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
-	O
binding	O
protein	O
(	O
CABLES1	O
)	O
,	O
proto	O
-	O
oncogene	O
c	O
-	O
KIT	O
and	O
E3	O
ubiquitin	O
ligase	O
specificity	O
subunit	O
(	O
ASB2	O
)	O
for	O
the	O
10	O
most	O
up	O
-	O
regulated	O
genes	O
;	O
IFN	O
-	O
induced	O
proteins	O
44L	O
,	O
44	O
(	O
IFI44	O
)	O
,	O
p78	O
(	O
MX1	O
)	O
with	O
tetratricopeptide	O
repeats	O
2	O
(	O
IFIT2	O
)	O
,	O
collagen	O
(	O
COL6A3	O
)	O
,	O
microcephalin	O
MCPH1	O
,	O
lysosomal	O
trafficking	O
regulator	O
,	O
enzyme	O
oligoadenylate	O
synthetase	O
like	O
,	O
proteoglycan	O
(	O
PRG4	O
)	O
,	O
and	O
cell	O
surface	O
antigen	O
(	O
THY1	O
)	O
for	O
the	O
10	O
most	O
down	O
-	O
regulated	O
ones	O
.	O

Thus	O
,	O
CYP1A1	B
,	O
CYP1B1	O
,	O
Gap	O
Junction	O
Beta	O
-	O
2	O
,	O
GJB6	O
,	O
TIPARP	O
,	O
Oligodendrocyte	O
Transcription	O
Factor	O
3	O
,	O
CABLES1	O
,	O
KIT	O
and	O
ASB2	O
transcriptional	O
levels	O
were	O
confirmed	O
to	O
be	O
up	O
-	O
regulated	O
after	O
B	O
[	O
ALPHA	O
]	O
P	O
exposure	O
;	O
with	O
inductions	O
reaching	O
a	O
significant	O
level	O
for	O
all	O
these	O
genes	O
except	O
for	O
Oligodendrocyte	O
Transcription	O
Factor	O
3	O
and	O
TIPARP	O
(	O
A	O
)	O
.	O

Among	O
genes	O
belonging	O
to	O
Aryl	O
Hydrocarbon	O
signaling	O
,	O
we	O
recently	O
reported	O
the	O
regulation	O
of	O
CYP1A1	B
,	O
CYP1B1	O
and	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
1A	O
in	O
human	O
T	O
lymphocytes	O
upon	O
exposure	O
to	O
B	O
[	O
ALPHA	O
]	O
P	O
.	O
The	O
Aryl	O
Hydrocarbon	O
repressor	O
,	O
the	O
cyclin	O
E2	O
and	O
the	O
NAD	O
(	O
P	O
)	O
H	O
dehydrogenase	O
(	O
NQO1	O
)	O
have	O
already	O
been	O
reported	O
to	O
be	O
robust	O
targets	O
of	O
B	O
[	O
ALPHA	O
]	O
P	O
but	O
,	O
in	O
different	O
cell	O
types	O
,	O
but	O
not	O
in	O
primary	O
T	O
lymphocytes	O
.	O

We	O
then	O
validated	O
by	O
RT	O
-	O
qPCR	O
assays	O
these	O
changes	O
in	O
Ahr	O
Repressor	O
,	O
Cyclin	O
E2	O
,	O
Cyclin	O
-	O
Dependent	O
Kinase	O
Inhibitor	O
1a	O
,	O
CYP1A1	B
,	O
CYP1B1	O
,	O
and	O
NQO1	O
gene	O
expression	O
changes	O
using	O
the	O
16	O
individual	O
RNA	O
samples	O
isolated	O
from	O
Concentration	O
Of	O
Dmso	O
and	O
B	O
[	O
ALPHA	O
]	O
P	O
-	O
treated	O
T	O
lymphocyte	O
cultures	O
(	O
A	O
)	O
.	O

Additionally	O
,	O
except	O
for	O
the	O
Aryl	O
Hydrocarbon	O
target	O
genes	O
,	O
CYP1A1	B
and	O
CYP1B1	O
,	O
few	O
of	O
the	O
158	O
differentially	O
expressed	O
transcripts	O
displayed	O
strong	O
amplitude	O
in	O
the	O
changes	O
observed	O
.	O

Among	O
genes	O
identified	O
by	O
our	O
study	O
,	O
some	O
have	O
already	O
been	O
described	O
to	O
be	O
targeted	O
by	O
B	O
[	O
ALPHA	O
]	O
P	O
.	O
This	O
is	O
notably	O
true	O
for	O
CYP1A1	B
,	O
CYP1B1	O
,	O
the	O
ferredoxin	O
reductase	O
,	O
NQO1	O
,	O
Cyclin	O
-	O
Dependent	O
Kinase	O
Inhibitor	O
1a	O
,	O
Ahr	O
Repressor	O
,	O
ASB2	O
or	O
TIPARP	O
up	O
-	O
regulated	O
genes	O
and	O
MX1	O
or	O
the	O
solute	O
carrier	O
SLC25A37	O
,	O
regarding	O
the	O
down	O
-	O
regulated	O
ones	O
.	O

Nevertheless	O
,	O
AhR	O
-	O
and	O
p53	O
-	O
target	O
genes	O
such	O
as	O
CYP1A1	B
,	O
CYP1B1	O
,	O
Ahr	O
Repressor	O
,	O
ASB2	O
or	O
Cyclin	O
-	O
Dependent	O
Kinase	O
Inhibitor	O
1a	O
and	O
the	O
ribonucleotide	O
reductase	O
RRM2B	O
were	O
shown	O
to	O
be	O
modulated	O
in	O
both	O
type	O
of	O
cells	O
,	O
all	O
encoding	O
enzymes	O
important	O
in	O
the	O
detoxication	O
and	O
the	O
DNA	O
damage	O
response	O
induced	O
after	O
B	O
[	O
ALPHA	O
]	O
P	O
exposure	O
.	O

Hitoshi	O
et	O
al	O
reported	O
that	O
SWCNT	O
also	O
downregulated	O
genes	O
coding	O
other	O
CYP	O
isoenzymes	O
,	O
namely	O
,	O
CYP1A1	B
and	O
CYP1B1	O
.	O

In	O
other	O
studies	O
by	O
Hitoshi	O
et	O
al	O
,	O
multi	O
-	O
walled	O
carbon	O
nanotubes	O
downregulated	O
CYP1A1	B
and	O
in	O
HepG2	O
cells	O
by	O
repression	O
of	O
AhR	O
binding	O
to	O
the	O
enhancer	O
region	O
.	O

The	O
enzymes	O
used	O
were	O
CYP1A1	B
(	O
Lot	O
No	O
.	O

CYP3A4	O
is	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
estrone	O
in	O
adults	O
,	O
though	O
CYP1A1	B
,	O
CYP2C19	O
and	O
CYP3A5	O
can	O
also	O
catalyze	O
the	O
reaction	O
.	O

Conversely	O
,	O
CYP1A2	B
is	O
the	O
dominant	O
enzyme	O
catalyzing	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
17BETA	O
-	O
estradiol	O
,	O
with	O
CYP3A4	O
,	O
CYP1A1	B
and	O
CYP1B1	O
also	O
demonstrating	O
this	O
activity	O
.	O

These	O
reactions	O
are	O
catalyzed	O
by	O
a	O
variety	O
of	O
CYPs	O
,	O
including	O
CYP3A4	O
and	O
CYP1A2	B
in	O
the	O
liver	O
,	O
or	O
CYP1A1	B
and	O
CYP3A4	O
in	O
peripheral	O
tissues	O
.	O

CYP1A	O
subfamily	O
contains	O
only	O
two	O
functional	O
genes	O
,	O
CYP1A1	B
and	O
CYP1A2	B
,	O
which	O
are	O
highly	O
conserved	O
among	O
species	O
.	O

Phylogenetic	O
analysis	O
of	O
CYP1A	O
gene	O
shows	O
that	O
the	O
CYP1A2	B
gene	O
may	O
rise	O
from	O
CYP1A1	B
and	O
they	O
have	O
a	O
common	O
5	O
-	O
anking	O
region	O
,	O
which	O
has	O
been	O
proved	O
to	O
contain	O
bidirectional	O
regulators	O
both	O
for	O
CYP1A1	B
and	O
CYP1A2	B
^	O
,	O
.	O

Although	O
the	O
transcriptional	O
regulation	O
of	O
CYP1A1	B
and	O
1A2	O
may	O
be	O
simultaneously	O
controlled	O
by	O
bidirectional	O
gene	O
elements	O
,	O
their	O
expression	O
patterns	O
are	O
different	O
.	O

For	O
example	O
,	O
CYP1A2	B
is	O
constitutively	O
and	O
specifically	O
expressed	O
in	O
the	O
liver	O
,	O
while	O
CYP1A1	B
is	O
mainly	O
expressed	O
outside	O
the	O
liver	O
^	O
,	O
.	O

Interestingly	O
,	O
we	O
observed	O
induction	O
of	O
CYP1A2	B
upon	O
treatment	O
with	O
GN	O
.	O

A	O
known	O
inducer	O
of	O
CYP1A2	B
is	O
cigarette	O
smoke	O
containing	O
a	O
significant	O
amount	O
of	O
nanoparticulated	O
carbon	O
black	O
and	O
PAH	O
.	O
,	O
Thus	O
,	O
it	O
might	O
be	O
related	O
to	O
GN	O
structure	O
,	O
more	O
similar	O
to	O
compounds	O
found	O
in	O
the	O
cigarette	O
smoke	O
,	O
when	O
compared	O
to	O
the	O
DN	O
or	O
GO	O
used	O
in	O
this	O
study	O
,	O
as	O
PAH	O
structure	O
also	O
consists	O
of	O
sp	O
^	O
2	O
-	O
hybridized	O
carbon	O
atoms	O
with	O
delocalized	O
electrons	O
,	O
which	O
is	O
a	O
reason	O
for	O
naming	O
PAH	O
nanographenes	O
or	O
cutouts	O
of	O
graphene	O
.	O

456211	O
)	O
,	O
CYP1A2	B
(	O
Lot	O
No	O
.	O

did	O
not	O
detect	O
5HMFLX	O
in	O
incubations	O
with	O
recombinant	O
CYP1A2	B
,	O
CYP2C9	O
and	O
CYP3A5	B
might	O
be	O
attributed	O
to	O
the	O
less	O
sensitive	O
analytical	O
method	O
used	O
(	O
HPLC	O
-	O
UV	O
detection	O
versus	O
LC	O
-	O
MS	O
)	O
and	O
/	O
or	O
the	O
use	O
of	O
yeastexpressed	O
CYPs	O
with	O
lower	O
specific	O
activity	O
than	O
the	O
Supersomes	O
used	O
in	O
the	O
present	O
study	O
.	O

Mostly	O
all	O
the	O
compounds	O
were	O
found	O
to	O
be	O
a	O
substrate	O
of	O
CYP1A2	B
,	O
except	O
F25	O
,	O
whereas	O
,	O
for	O
CYP2C8	O
,	O
only	O
compound	O
F2	O
was	O
found	O
to	O
be	O
the	O
substrate	O
.	O

Results	O
revealed	O
that	O
for	O
predicting	O
the	O
site	O
of	O
enzyme	O
CYP1A2	B
,	O
the	O
K_m	O
value	O
was	O
28	O
.	O
53	O
,	O
33	O
.	O
79	O
,	O
18	O
.	O
55	O
,	O
16	O
.	O
59	O
,	O
7	O
.	O
42	O
,	O
158	O
.	O
31	O
and	O
49	O
.	O
91	O
M	O
,	O
whereas	O
the	O
V_max	O
constant	O
was	O
1	O
.	O
76	O
,	O
4	O
.	O
22	O
,	O
5	O
.	O
34	O
,	O
1	O
.	O
18	O
,	O
1	O
.	O
99	O
,	O
5	O
.	O
19	O
and	O
8	O
.	O
04	O
nM	O
/	O
min	O
/	O
nM	O
and	O
the	O
C_Lint	O
was	O
3	O
.	O
21	O
,	O
6	O
.	O
49	O
,	O
14	O
.	O
96	O
,	O
3	O
.	O
69	O
,	O
13	O
.	O
92	O
,	O
1	O
.	O
70	O
,	O
and	O
8	O
.	O
37	O
L	O
/	O
min	O
/	O
mg	O
for	O
compounds	O
F2	O
,	O
F3	O
,	O
F8	O
,	O
F11	O
,	O
F13	O
,	O
F20	O
,	O
and	O
F21	O
,	O
respectively	O
.	O

However	O
,	O
results	O
of	O
inhibition	O
studies	O
showed	O
that	O
all	O
the	O
compound	O
might	O
inhibit	O
CYP1A2	B
,	O
CYP2C9	O
,	O
and	O
CYP2D6	B
,	O
except	O
compound	O
F2	O
which	O
did	O
not	O
inhibit	O
the	O
CYP2D6	B
.	O

^	O
,	O
Chronic	O
tobacco	O
smokers	O
have	O
induced	O
hepatic	O
CYP	O
enzymes	O
,	O
particularly	O
CYP1A2	B
.	O

CYP1A2	B
is	O
a	O
relevant	O
enzyme	O
in	O
the	O
metabolism	O
of	O
commonly	O
prescribed	O
psychoactive	O
medications	O
,	O
including	O
clozapine	O
,	O
duloxetine	O
,	O
olanzapine	O
and	O
imipramine	O
are	O
not	O
metabolized	O
by	O
CYP1A2	B
.	O

PharmG	O
+	O
clozapine	O
treated	O
patients	O
with	O
CYP1A2	B
or	O
CYP2C19	O
UM	O
and	O
PMs	O
variants	O
also	O
showed	O
higher	O
reductions	O
in	O
UKU	O
scores	O
than	O
PharmG	O
clozapine	O
patients	O
in	O
general	O
.	O

CYPs	O
are	O
responsible	O
for	O
the	O
biotransformation	O
of	O
widely	O
used	O
antipsychotics	O
such	O
as	O
clozapine	O
(	O
CYP1A2	B
and	O
CYP2C19	O
)	O
,	O
olanzapine	O
(	O
CYP1A2	B
)	O
,	O
risperidone	O
and	O
haloperidol	O
(	O
CYP2D6	B
)	O
,	O
quetiapine	O
and	O
ziprasidone	O
(	O
CYP3A5	B
)	O
amongst	O
others	O
^	O
,	O
.	O

A	O
commercial	O
pharmacogenetic	O
test	O
(	O
Brainchip	O
,	O
Brainco	O
,	O
Bilbao	O
,	O
Spain	O
)	O
was	O
used	O
to	O
characterise	O
common	O
and	O
functional	O
polymorphisms	O
in	O
CYP1A2	B
,	O
CYP2D6	B
,	O
CYP2C19	O
and	O
CYP3A5	O
enzymes	O
,	O
the	O
main	O
metabolic	O
pathways	O
of	O
currently	O
available	O
antipsychotics	O
.	O

Doses	O
were	O
adjusted	O
according	O
to	O
main	O
metabolic	O
pathways	O
:	O
^	O
,	O
clozapine	O
doses	O
were	O
adjusted	O
according	O
to	O
the	O
genotypic	O
variants	O
observed	O
in	O
CYP1A2	B
and	O
CYP2C19	O
;	O
olanzapine	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP1A2	B
polymorphisms	O
;	O
risperidone	O
,	O
aripiprazole	O
,	O
haloperidol	O
,	O
pimozide	O
and	O
trifluoperazine	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP2D6	B
polymorphisms	O
;	O
finally	O
,	O
quetiapine	O
and	O
ziprasidone	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP3A5	O
genetic	O
variants	O
.	O

When	O
analysing	O
patients	O
with	O
functional	O
variants	O
in	O
CYP1A2	B
,	O
CYP2D6	B
and	O
/	O
or	O
CYP2C19	O
(	O
N	O
=	O
155	O
)	O
,	O
no	O
differences	O
were	O
observed	O
between	O
PharmG	O
+	O
and	O
PharmG	O
patients	O
in	O
PANSS	O
improvement	O
,	O
nor	O
was	O
it	O
observed	O
in	O
the	O
subgroups	O
of	O
patients	O
treated	O
with	O
clozapine	O
(	O
p	O
>	O
0	O
.	O
05	O
for	O
all	O
comparisons	O
,	O
see	O
Table	O
.	O

Analyses	O
of	O
patients	O
with	O
functional	O
variants	O
in	O
CYP1A2	B
,	O
CYP2D6	B
or	O
CYP2C19	O
revealed	O
clearer	O
improvements	O
in	O
the	O
profile	O
of	O
side	O
effects	O
in	O
the	O
PharmG	O
+	O
patients	O
in	O
comparison	O
to	O
PharmG	O
patients	O
.	O

However	O
,	O
those	O
differences	O
were	O
not	O
statistically	O
significant	O
,	O
even	O
when	O
considering	O
patients	O
with	O
CYP1A2	B
or	O
CYP2C19	O
UM	O
and	O
PMs	O
variants	O
(	O
p	O
>	O
0	O
.	O
05	O
in	O
all	O
comparisons	O
)	O
.	O

Several	O
studies	O
have	O
proven	O
the	O
clinical	O
value	O
of	O
a	O
commercial	O
array	O
combining	O
genetic	O
information	O
in	O
metabolic	O
enzymes	O
(	O
CYP1A2	B
,	O
CYP2D6	B
and	O
CYP2C19	O
)	O
and	O
antidepressant	O
targets	O
(	O
serotonin	O
transporter	O
,	O
SLC6A4	O
and	O
serotonin	O
receptor	O
2A	O
,	O
HTR2A	O
)	O
.	O

Regorafenib	O
and	O
its	O
major	O
metabolites	O
are	O
also	O
reported	O
to	O
inhibit	O
a	O
number	O
of	O
cytochromes	O
(	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2B6	O
,	O
Cytochrome	B
P450	I
3a4	O
,	O
CYP2D6	O
)	O
,	O
UGT1A	O
enzymes	O
(	O
UGT1A9	O
,	O
UGT1A1	O
)	O
,	O
and	O
transporters	O
(	O
BCRP	O
)	O
and	O
induce	O
others	O
(	O
CYP1A2	B
,	O
CYP2B6	O
,	O
CYP2C19	O
,	O
CYP3A4	O
)	O
with	O
potential	O
alteration	O
in	O
the	O
exposure	O
of	O
co	O
-	O
administered	O
drugs	O
.	O

There	O
are	O
more	O
than	O
50	O
Cytochrome	B
P450	I
enzymes	I
,	O
but	O
the	O
CYP1A2	B
,	O
CYP2C9	O
,	O
CYP2C19	B
,	O
CYP2D6	O
,	O
CYP3A4	O
,	O
and	O
CYP3A5	O
enzymes	O
metabolize	O
90	O
percent	O
of	O
drugs	O
.	O

Similar	O
serum	O
antibodies	O
to	O
drug	O
-	O
modified	O
and	O
/	O
or	O
unmodified	O
P450s	O
and	O
other	O
native	O
cellular	O
proteins	O
have	O
also	O
been	O
detected	O
in	O
idiosyncratic	O
liver	O
injury	O
upon	O
halothane	O
-	O
exposure	O
(	O
anti	O
-	O
trifluoroacetyl	O
-	O
CYP2E1	O
)	O
,	O
aromatic	O
anti	O
-	O
convulsant	O
(	O
anti	O
-	O
CYP3A	O
)	O
,	O
dihydralazine	O
(	O
anti	O
-	O
CYP1A2	B
)	O
,	O
tienilic	O
acid	O
(	O
anti	O
-	O
tienilic	O
acid	O
-	O
CYP2C9	O
)	O
and	O
/	O
or	O
chronic	O
alcohol	O
intake	O
(	O
anti	O
-	O
acetaldehyde	O
-	O
CYP2E1	O
and	O
anti	O
-	O
hydroxyethyl	O
-	O
CYP2E1	O
)	O
,	O
.	O

CYP1A	O
-	O
catalyzed	O
reactions	O
include	O
hydroxylation	O
and	O
oxidation	O
of	O
aromatic	O
compounds	O
,	O
in	O
which	O
CYP1A1	O
is	O
mainly	O
involved	O
in	O
the	O
metabolism	O
of	O
aromatic	O
hydrocarbon	O
,	O
while	O
CYP1A2	B
prefers	O
aromatic	O
amines	O
and	O
heterocyclic	O
compounds	O
.	O

Compared	O
with	O
CYP1A2	B
,	O
CYP1A1	O
is	O
the	O
main	O
isoform	O
mediating	O
the	O
biotransformation	O
of	O
pregnenolone	O
.	O

The	O
highly	O
polymorphic	O
CYP2C19	B
isozymes	O
are	O
responsible	O
for	O
metabolizing	O
a	O
large	O
portion	O
of	O
routinely	O
prescribed	O
drugs	O
and	O
variants	O
contribute	O
significantly	O
to	O
adverse	O
drug	O
reactions	O
and	O
therapeutic	O
failures	O
.	O

A	O
limited	O
number	O
of	O
CYP2C19	B
single	O
nucleotide	O
polymorphisms	O
are	O
involved	O
in	O
drug	O
metabolism	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
better	O
understand	O
and	O
provide	O
further	O
knowledge	O
about	O
the	O
metabolism	O
and	O
interactions	O
between	O
phenobarbital	O
and	O
CYP2C19	B
polymorphisms	O
in	O
children	O
with	O
epilepsy	O
,	O
interplay	O
between	O
sleep	O
,	O
and	O
Eversus	O
Understanding	O
this	O
interplay	O
between	O
epilepsy	O
and	O
sleep	O
is	O
helpful	O
in	O
the	O
optimal	O
treatment	O
of	O
all	O
patients	O
with	O
epileptic	O
seizures	O
.	O

In	O
the	O
report	O
we	O
will	O
only	O
discuss	O
the	O
CYP2C19	B
gene	O
as	O
outlined	O
in	O
.	O

The	O
Cytochrome	O
P450	O
,	O
family	O
2	O
,	O
subfamily	O
C	O
,	O
polypeptide	O
19	O
(	O
CYP2C19	B
gene	O
)	O
is	O
located	O
within	O
a	O
cluster	O
of	O
Cytochrome	O
P450	O
genes	O
(	O
CYP2C19	B
)	O
on	O
chromosome	O
10q23	O
.	O
33	O
with	O
reference	O
sequence	O
number	O
(	O
NM_000769	O
)	O
and	O
ensemble	O
accession	O
number	O
ENST00000371321	O
.	O
8	O
.	O

CYP2C19	B
is	O
expressed	O
in	O
the	O
liver	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
small	O
intestine	O
,	O
contributing	O
to	O
the	O
metabolism	O
of	O
a	O
large	O
number	O
of	O
clinically	O
relevant	O
drugs	O
and	O
drug	O
classes	O
including	O
phenytoin	O
and	O
phenobarbital	O
.	O

The	O
CYP2C19	B
gene	O
is	O
part	O
of	O
the	O
CYP2C	O
cluster	O
comprising	O
four	O
genes	O
(	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2C18	O
and	O
CYP2C19	B
)	O
.	O

This	O
CYP2C19	B
gene	O
encompasses	O
90	O
,	O
637	O
bases	O
and	O
is	O
composed	O
of	O
nine	O
exons	O
encoding	O
490	O
amino	O
acids	O
.	O

We	O
checked	O
nucleotide	O
human	O
sequence	O
homology	O
of	O
CYP2C19	B
(	O
NP_000760	O
.	O
1	O
)	O
with	O
National	O
Institute	O
of	O
Health	O
databases	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
)	O
,	O
and	O
we	O
found	O
that	O
84	O
%	O
of	O
CYPC29	O
(	O
NP_000760	O
.	O
1	O
)	O
,	O
81	O
%	O
of	O
CYP2C18	O
isoform	O
2	O
precursor	O
(	O
NP_000762	O
.	O
2	O
)	O
,	O
81	O
%	O
of	O
Cytochrome	O
P450	O
2C8	O
isoform	O
c	O
(	O
NP_000763	O
.	O
1	O
)	O
,	O
79	O
%	O
of	O
Cytochrome	O
P450	O
2C8	O
isoform	O
b	O
(	O
NP_001185783	O
.	O
1	O
)	O
,	O
78	O
%	O
Cytochrome	O
P450	O
2C8	O
isoform	O
a	O
precursor	O
(	O
NP_000761	O
.	O
3	O
)	O
,	O
58	O
%	O
Cytochrome	O
P450	O
2E1	O
precursor	O
(	O
NP_000764	O
.	O
1	O
)	O
,	O
56	O
%	O
Cytochrome	O
P450	O
2F1	O
isoform	O
X7	O
(	O
XP_016881875	O
.	O
1	O
)	O
,	O
and	O
48	O
%	O
CYPP450	O
2F1	O
isoform	O
X4	O
(	O
XP_011524855	O
.	O
1	O
)	O
.	O

Understanding	O
the	O
biological	O
function	O
of	O
CYP2C19	B
gene	O
can	O
provide	O
a	O
good	O
foundation	O
for	O
subsequently	O
interpreting	O
the	O
potential	O
influence	O
of	O
genetic	O
associations	O
on	O
a	O
disease	O
phenotype	O
and	O
so	O
can	O
greatly	O
support	O
any	O
identified	O
genetic	O
association	O
.	O

Potential	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
such	O
as	O
GATA	O
proteins	O
,	O
progesterone	O
receptor	O
,	O
TATA	O
box	O
elements	O
and	O
nuclear	O
factors	O
in	O
CYP2C19	B
promoter	O
region	O
has	O
been	O
described	O
.	O

This	O
CYP2C19	B
gene	O
(	O
RefSeq	O
accession	O
number	O
NM_000769	O
.	O
4	O
)	O
has	O
three	O
promoter	O
regions	O
.	O

As	O
shown	O
in	O
,	O
CYP2C19	B
-	O
201	O
has	O
nine	O
exons	O
and	O
eight	O
introns	O
and	O
consists	O
of	O
490	O
amino	O
acids	O
,	O
while	O
CYP2C10	O
-	O
202	O
has	O
162	O
amino	O
acids	O
,	O
however	O
,	O
CYP2C19	B
-	O
203	O
does	O
not	O
produce	O
protein	O
products	O
.	O

For	O
the	O
cellular	O
component	O
,	O
the	O
CYP2C19	B
gene	O
is	O
found	O
in	O
different	O
part	O
of	O
the	O
cells	O
:	O
cytoplasm	O
(	O
GO	O
:	O
0005737	O
)	O
,	O
endoplasmic	O
reticulum	O
(	O
GO	O
:	O
0005783	O
)	O
,	O
endoplasmic	O
reticulum	O
membrane	O
(	O
GO	O
:	O
0005789	O
)	O
,	O
membrane	O
(	O
GO	O
:	O
0016020	O
)	O
,	O
and	O
organelle	O
membrane	O
(	O
GO	O
:	O
0031090	O
)	O
.	O

Next	O
,	O
we	O
used	O
STRING	O
software	O
to	O
build	O
a	O
gene	O
network	O
of	O
the	O
CYP2C19	B
gene	O
and	O
other	O
neighbor	O
genes	O
using	O
https	O
:	O
/	O
/	O
string	O
-	O
db	O
.	O
org	O
/	O
as	O
shown	O
in	O
.	O

This	O
network	O
shows	O
high	O
interaction	O
between	O
CYP2C19	B
and	O
other	O
genes	O
such	O
as	O
glutathione	O
S	O
-	O
transferase	O
mu	O
1	O
,	O
glutathione	O
S	O
-	O
transferase	O
mu	O
2	O
(	O
muscle	O
)	O
,	O
glutathione	O
S	O
-	O
transferase	O
mu	O
3	O
(	O
brain	O
)	O
,	O
glutathione	O
S	O
-	O
transferase	O
theta	O
1	O
.	O

Next	O
,	O
we	O
used	O
genome	O
at	O
USSC	O
to	O
find	O
out	O
the	O
CYP2C19	B
tagged	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
https	O
:	O
/	O
/	O
genome	O
.	O
ucsc	O
.	O
edu	O
/	O
cgi	O
-	O
bin	O
/	O
hgGateway	O
)	O
.	O

The	O
tagged	O
Single	O
Nucleotide	O
Polymorphisms	O
associated	O
with	O
the	O
CYP2C19	B
gene	O
are	O
shown	O
in	O
.	O

In	O
this	O
report	O
,	O
we	O
will	O
focus	O
only	O
on	O
CYP2C19	B
Single	O
Nucleotide	O
Polymorphisms	O
that	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
drug	O
metabolism	O
as	O
shown	O
in	O
.	O

We	O
identified	O
the	O
position	O
of	O
each	O
amino	O
acid	O
for	O
each	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
the	O
upstream	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
downstream	O
Single	O
Nucleotide	O
Polymorphisms	O
including	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs28399504	O
(	O
CYP2C19	B
*	O
4	O
)	O
located	O
on	O
amino	O
acid	O
number	O
1	O
(	O
valine	O
)	O
,	O
rs17878459	O
(	O
CYP2C19	B
*	O
17	O
)	O
,	O
located	O
on	O
amino	O
acid	O
92	O
,	O
(	O
aspartic	O
,	O
D	O
)	O
,	O
rs4986893	O
CYP2C19	B
*	O
3	O
located	O
on	O
amino	O
acid	O
number	O
212	O
(	O
NA	O
)	O
,	O
rs4244285	O
(	O
CYP2C19	B
*	O
2	O
)	O
located	O
on	O
amino	O
acid	O
227	O
(	O
proline	O
)	O
,	O
and	O
rs56337013	O
(	O
CYP2C19	B
*	O
5	O
)	O
located	O
on	O
amino	O
acid	O
number	O
433	O
(	O
tryptophan	O
,	O
W	O
)	O
.	O

Then	O
,	O
50	O
L	O
of	O
Master	O
Pre	O
-	O
Mix	O
consisting	O
of	O
Baculosomes	O
(	O
containing	O
either	O
CYP1A2	O
,	O
CYP2D6	B
or	O
CYP3A4	O
isoenzyme	O
and	O
NADPH	O
reductase	O
)	O
in	O
working	O
buffer	O
and	O
the	O
regeneration	O
system	O
(	O
consisting	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

In	O
the	O
experiment	O
,	O
the	O
expression	O
levels	O
of	O
genes	O
for	O
the	O
previously	O
studied	O
cytochromes	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
for	O
two	O
other	O
cytochromes	O
vastly	O
expressed	O
in	O
the	O
liver	O
:	O
CYP2B6	O
and	O
CYP2E1	B
,	O
as	O
well	O
as	O
the	O
receptors	O
responsible	O
for	O
cytochrome	O
gene	O
expression	O
regulation	O
:	O
pregnane	O
X	O
receptor	O
(	O
PXR	O
)	O
,	O
constitutive	O
androstane	O
receptor	O
(	O
CAR	O
)	O
and	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
were	O
measured	O
.	O

DN	O
almost	O
did	O
not	O
affect	O
the	O
diameter	O
or	O
zeta	O
potential	O
of	O
the	O
microsomes	O
expressing	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
isoenzymes	O
,	O
whereas	O
GO	O
and	O
GN	O
visibly	O
increased	O
the	O
diameter	O
of	O
the	O
microsomes	O
,	O
especially	O
for	O
the	O
Baculosomes	O
expressing	O
CYP1A2	O
and	O
CYP3A4	O
isoenzymes	O
(	O
>	O
1	O
,	O
000	O
nm	O
in	O
comparison	O
to	O
~	O
300	O
nm	O
in	O
0	O
mg	O
/	O
L	O
samples	O
)	O
.	O

GN	O
also	O
shifted	O
zeta	O
potential	O
of	O
the	O
microsomes	O
from	O
highly	O
negative	O
(	O
37	O
,	O
31	O
and	O
42	O
mV	O
for	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
respectively	O
)	O
toward	O
more	O
positive	O
values	O
(	O
2	O
,	O
16	O
and	O
30	O
mV	O
for	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
respectively	O
)	O
and	O
GO	O
shifted	O
the	O
values	O
toward	O
more	O
negative	O
values	O
(	O
43	O
,	O
44	O
and	O
48	O
mV	O
for	O
1A2	O
,	O
2D6	O
and	O
3A4	O
,	O
respectively	O
)	O
,	O
which	O
indicates	O
the	O
impact	O
of	O
GO	O
and	O
GN	O
on	O
the	O
stability	O
of	O
microsome	O
hydrocolloids	O
and	O
the	O
occurrence	O
of	O
physicochemical	O
interactions	O
between	O
the	O
nanostructures	O
and	O
microsomes	O
expressing	O
the	O
CYP	O
enzymes	O
.	O

However	O
,	O
additional	O
measurements	O
performed	O
with	O
the	O
control	O
Baculosomes	O
,	O
which	O
did	O
not	O
express	O
any	O
recombinant	O
CYP	O
isoenzyme	O
,	O
revealed	O
that	O
the	O
binding	O
might	O
not	O
be	O
specific	O
for	O
the	O
CYP1A2	O
,	O
CYP2D6	B
or	O
CYP3A4	O
proteins	O
,	O
since	O
a	O
similar	O
decrease	O
in	O
the	O
protein	O
level	O
was	O
observed	O
.	O

In	O
the	O
enzymatic	O
test	O
based	O
on	O
Baculosomes	O
,	O
all	O
three	O
types	O
of	O
nanostructures	O
inhibited	O
reactions	O
by	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
isoenzymes	O
.	O

Inhibition	O
rate	O
was	O
compared	O
to	O
inhibition	O
in	O
positive	O
control	O
samples	O
with	O
the	O
known	O
specific	O
inhibitors	O
miconazole	O
,	O
quinidine	O
and	O
ketoconazole	O
for	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
respectively	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
for	O
CYP2D6	B
;	O
however	O
,	O
in	O
other	O
studied	O
members	O
of	O
the	O
CYP2	O
subfamily	O
(	O
2B6	O
and	O
2E1	O
)	O
,	O
we	O
observed	O
lower	O
expression	O
of	O
both	O
genes	O
in	O
HepaRG	O
cells	O
,	O
while	O
in	O
HepG2	O
cells	O
,	O
the	O
2B6	O
level	O
was	O
increased	O
.	O

In	O
this	O
study	O
,	O
we	O
presented	O
interactions	O
among	O
three	O
nanostructures	O
of	O
different	O
carbon	O
allotropes	O
,	O
namely	O
,	O
DN	O
,	O
GO	O
and	O
GN	O
,	O
and	O
isoenzymes	O
of	O
CYP450	O
,	O
namely	O
,	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
,	O
in	O
the	O
model	O
of	O
Baculosomes	O
.	O

The	O
most	O
important	O
evidence	O
for	O
the	O
direct	O
interaction	O
between	O
CYP	O
-	O
expressing	O
microsomes	O
and	O
DN	O
,	O
GO	O
and	O
GN	O
is	O
inhibition	O
of	O
the	O
catalytic	O
activity	O
of	O
CYP1A2	O
,	O
CYP2D6	B
and	O
CYP3A4	O
measured	O
separately	O
for	O
all	O
three	O
isoforms	O
and	O
revealing	O
subtle	O
differences	O
among	O
the	O
isoenzymes	O
.	O

Product	O
formation	O
on	O
CYP1A2	O
was	O
highly	O
inhibited	O
by	O
DN	O
and	O
GN	O
,	O
while	O
on	O
CYP2D6	B
and	O
CYP3A4	O
,	O
all	O
nanostructures	O
inhibited	O
the	O
reaction	O
at	O
similar	O
levels	O
.	O

456259	O
)	O
,	O
CYP2D6	B
*	O
1	O
(	O
Lot	O
No	O
.	O

Most	O
antidepressant	O
and	O
antipsychotic	O
drugs	O
have	O
moderately	O
long	O
half	O
-	O
lives	O
in	O
the	O
range	O
of	O
12	O
-	O
36	O
h	O
;	O
poor	O
(	O
with	O
either	O
inactive	O
or	O
low	O
-	O
activity	O
CYP2D6	B
)	O
;	O
or	O
ultrarapid	O
metabolizers	O
owing	O
to	O
genetic	O
polymorphisms	O
.	O

Thus	O
,	O
relatively	O
slow	O
recovery	O
is	O
anticipated	O
from	O
overdoses	O
if	O
the	O
patient	O
carries	O
the	O
low	O
-	O
activity	O
or	O
absent	O
CYP2D6	B
,	O
with	O
more	O
rapid	O
recovery	O
in	O
extensive	O
or	O
ultrarapid	O
metabolizers	O
.	O

Between	O
5	O
%	O
and	O
10	O
%	O
of	O
Europeans	O
and	O
approximately	O
1	O
%	O
of	O
Asians	O
are	O
poor	O
metabolizers	O
via	O
CYP2D6	B
.	O

Genetic	O
polymorphisms	O
of	O
the	O
CYPs	O
contribute	O
to	O
drug	O
clearance	O
,	O
particularly	O
for	O
CYP2D6	B
and	O
CYP2C19	O
.	O

However	O
,	O
PharmG	O
+	O
patients	O
treated	O
with	O
CYP2D6	B
substrates	O
that	O
were	O
carriers	O
of	O
CYP2D6	B
UMs	O
or	O
PMs	O
variants	O
showed	O
a	O
significantly	O
higher	O
improvement	O
in	O
global	O
,	O
psychic	O
and	O
other	O
UKU	O
side	O
effects	O
than	O
PharmG	O
patients	O
(	O
p	O
=	O
0	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
05	O
and	O
p	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Analyses	O
within	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
drugs	O
mainly	O
metabolised	O
by	O
the	O
enzyme	O
CYP2D6	B
(	O
risperidone	O
,	O
haloperidol	O
,	O
aripiprazole	O
,	O
pimozide	O
and	O
trifluoperazine	O
)	O
also	O
showed	O
no	O
differences	O
with	O
PharmG	O
+	O
and	O
PharmG	O
patients	O
showing	O
similar	O
variations	O
in	O
PANSS	O
scores	O
(	O
24	O
.	O
33	O
3	O
vs	O
26	O
.	O
47	O
2	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
when	O
analysing	O
PANSS	O
score	O
improvement	O
between	O
PharmG	O
+	O
patients	O
(	O
26	O
.	O
6	O
3	O
.	O
5	O
)	O
and	O
PharmG	O
patients	O
(	O
28	O
.	O
63	O
3	O
.	O
7	O
)	O
treated	O
with	O
CYP2D6	B
substrates	O
.	O

The	O
PI	O
was	O
significantly	O
associated	O
to	O
improvements	O
in	O
total	O
(	O
6	O
.	O
92	O
improvement	O
in	O
PharmG	O
+	O
vs	O
1	O
.	O
27	O
in	O
PharmG	O
,	O
Wald	O
=	O
5	O
.	O
56	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
psychic	O
(	O
2	O
.	O
50	O
vs	O
0	O
.	O
53	O
improvement	O
,	O
Wald	O
=	O
3	O
.	O
96	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
and	O
other	O
UKU	O
side	O
effects	O
(	O
1	O
.	O
08	O
vs	O
0	O
.	O
3	O
,	O
Wald	O
=	O
6	O
.	O
19	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
in	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
CYP2D6	B
substrates	O
(	O
see	O
Table	O
.	O

The	O
subgroup	O
of	O
patients	O
treated	O
with	O
CYP2D6	B
substrates	O
(	O
risperidone	O
,	O
haloperidol	O
,	O
aripiprazole	O
,	O
pimozide	O
and	O
trifluoperazine	O
)	O
that	O
were	O
carriers	O
of	O
CYP2D6	B
UMs	O
or	O
PMs	O
variants	O
clearly	O
benefited	O
from	O
the	O
intervention	O
:	O
model	O
regression	O
analyses	O
showed	O
that	O
the	O
PI	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
global	O
,	O
psychic	O
and	O
other	O
UKU	O
side	O
effects	O
(	O
p	O
=	O
0	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
05	O
and	O
p	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

A	O
recent	O
study	O
in	O
which	O
clinicians	O
were	O
provided	O
pharmacogenetic	O
information	O
based	O
on	O
CYP2D6	B
and	O
CYP2C19	O
variants	O
to	O
adjust	O
antipsychotic	O
and	O
antidepressant	O
treatments	O
in	O
80	O
psychiatric	O
patients	O
suggested	O
a	O
favourable	O
opinion	O
on	O
the	O
outcome	O
of	O
the	O
intervention	O
,	O
although	O
no	O
control	O
group	O
was	O
considered	O
in	O
the	O
study	O
^	O
.	O

showed	O
in	O
a	O
previous	O
study	O
that	O
the	O
adjustment	O
of	O
clinical	O
doses	O
according	O
to	O
CYP2D6	B
and	O
CYP2C19	O
polymorphisms	O
resulted	O
in	O
a	O
reduction	O
of	O
treatment	O
costs	O
in	O
schizophrenia	O
patients	O
showing	O
poor	O
or	O
ultra	O
-	O
rapid	O
metabolism	O
^	O
.	O

Nevertheless	O
,	O
we	O
performed	O
analyses	O
on	O
the	O
subgroups	O
of	O
patients	O
carrying	O
CYPs	O
functional	O
variants	O
(	O
either	O
UMs	O
or	O
PMs	O
)	O
,	O
and	O
investigated	O
the	O
two	O
largest	O
antipsychotic	O
groups	O
within	O
the	O
study	O
(	O
clozapine	O
and	O
CYP2D6	B
substrates	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
study	O
of	O
six	O
Parkinsons	O
Disease	O
patients	O
showed	O
a	O
lower	O
DNA	O
methylation	O
at	O
the	O
promoter	O
region	O
of	O
CYP2E1	B
gene	O
in	O
both	O
cortex	O
and	O
putamen	O
,	O
and	O
an	O
increase	O
of	O
mRNA	O
levels	O
in	O
cortex	O
,	O
suggesting	O
that	O
epigenetic	O
variations	O
of	O
this	O
isoform	O
may	O
contribute	O
to	O
Parkinsons	O
Disease	O
susceptibility	O
,	O
but	O
they	O
did	O
not	O
study	O
the	O
correlation	O
between	O
mRNA	O
levels	O
and	O
proteins	O
or	O
enzymatic	O
activity	O
.	O

In	O
contrast	O
,	O
CYP2E1	B
appeared	O
to	O
partially	O
localize	O
in	O
the	O
Endoplasmic	O
Reticulum	O
,	O
as	O
it	O
has	O
been	O
reported	O
in	O
other	O
cell	O
types	O
and	O
tissues	O
.	O

Moreover	O
,	O
other	O
groups	O
have	O
indicated	O
the	O
possibility	O
that	O
CYP2E1	B
,	O
and	O
other	O
isoforms	O
,	O
may	O
target	O
the	O
mitochondria	O
in	O
other	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O

However	O
,	O
the	O
intracellular	O
location	O
of	O
CYP2E1	B
is	O
still	O
a	O
subject	O
of	O
debate	O
.	O

On	O
the	O
other	O
hand	O
,	O
CYP2E1	B
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
intracellular	O
accumulation	O
of	O
this	O
toxin	O
rather	O
than	O
in	O
the	O
metabolism	O
itself	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
CYP2D6	O
can	O
be	O
induced	O
by	O
EtOH	O
and	O
CYP2E1	B
by	O
BETA	O
-	O
NF	O
and	O
EtOH	O
.	O

General	O
downregulation	O
of	O
the	O
genes	O
was	O
especially	O
visible	O
in	O
HepaRG	O
cells	O
,	O
which	O
probably	O
results	O
from	O
a	O
weaker	O
expression	O
of	O
genes	O
encoding	O
enzymes	O
of	O
Phases	O
I	O
and	O
II	O
of	O
the	O
xenobiotic	O
metabolism	O
in	O
the	O
HepG2	O
cell	O
line	O
,	O
making	O
HepaRG	O
a	O
more	O
suitable	O
model	O
for	O
drug	O
metabolism	O
studies	O
.	O
-	O
The	O
strongest	O
downregulation	O
of	O
CYP	O
genes	O
was	O
induced	O
by	O
GO	O
,	O
which	O
influenced	O
not	O
only	O
CYP1A2	O
and	O
CYP3A4	O
genes	O
,	O
but	O
also	O
CYP2B6	O
,	O
CYP2E1	B
and	O
AhR	O
,	O
CAR	O
and	O
PXR	O
,	O
which	O
are	O
responsive	O
elements	O
regulating	O
the	O
expression	O
of	O
CYP	O
genes	O
.	O

456217	O
)	O
,	O
CYP2E1	B
(	O
Lot	O
No	O
.	O

Employing	O
mice	O
with	O
genetic	O
ablation	O
of	O
CHIP	O
and	O
gp78	O
/	O
AMFR	O
E3	O
ubiquitin	O
-	O
ligases	O
that	O
stabilize	O
hepatic	O
CYP2E1	B
,	O
we	O
document	O
why	O
this	O
stabilization	O
not	O
always	O
leads	O
to	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
:	O
It	O
requires	O
concomitantly	O
enhanced	O
hepatic	O
lipogenesis	O
.	O
Image	O
1	O
The	O
ubiquitous	O
hemoproteins	O
cytochromes	O
P450	O
(	O
P450s	O
or	O
CYPs	O
;	O
MW	O
50	O
kDa	O
)	O
are	O
enzymes	O
engaged	O
both	O
in	O
synthetic	O
and	O
degradative	O
functions	O
critically	O
important	O
to	O
the	O
cellular	O
integrity	O
,	O
physiology	O
and	O
defense	O
,	O
.	O

Accordingly	O
,	O
the	O
dominant	O
human	O
liver	O
/	O
intestinal	O
CYP3A4	O
and	O
human	O
liver	O
CYP2E1	B
are	O
found	O
to	O
be	O
prototypic	O
ERAD	O
-	O
C	O
substrates	O
.	O

CYP3A4	O
,	O
accounting	O
for	O
30	O
%	O
of	O
the	O
hepatic	O
P450	O
content	O
,	O
is	O
engaged	O
in	O
the	O
metabolism	O
of	O
>	O
50	O
%	O
of	O
clinically	O
relevant	O
drugs	O
and	O
other	O
xenobiotics	O
,	O
whereas	O
CYP2E1	B
biotransforms	O
clinically	O
relevant	O
drugs	O
(	O
acetaminophen	O
,	O
halothane	O
)	O
,	O
EtOH	O
,	O
and	O
other	O
xenobiotics	O
,	O
carcinogens	O
(	O
nitrosamines	O
)	O
,	O
endogenous	O
acetone	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
to	O
toxic	O
/	O
reactive	O
intermediates	O
,	O
.	O

Hepatic	O
CYP2E1	B
similarly	O
exhibits	O
a	O
high	O
propensity	O
for	O
ROS	O
generation	O
and	O
is	O
labile	O
in	O
the	O
absence	O
of	O
relevant	O
substrates	O
and	O
/	O
or	O
inducers	O
that	O
stabilize	O
the	O
protein	O
,	O
.	O

Systematic	O
dissection	O
of	O
the	O
hepatic	O
CYP3A	O
and	O
CYP2E1	B
ERAD	O
-	O
C	O
process	O
employing	O
various	O
in	O
vivo	O
and	O
in	O
vitro	O
reconstituted	O
eukaryotic	O
systems	O
has	O
revealed	O
that	O
it	O
involves	O
initial	O
post	O
-	O
translational	O
phosphorylation	O
by	O
cytosolic	O
protein	O
kinases	O
A	O
and	O
C	O
of	O
P450	O
Ser	O
/	O
Thr	O
residues	O
,	O
.	O

In	O
vitro	O
functional	O
reconstitution	O
studies	O
,	O
of	O
E1	O
/	O
E2	O
/	O
E3	O
-	O
mediated	O
CYP3A4	O
and	O
CYP2E1	B
ubiquitination	O
have	O
identified	O
UbcH5a	O
/	O
Hsc70	O
/	O
Hsp40	O
/	O
CHIP	O
and	O
UBC7	O
/	O
AMFR	O
/	O
gp78	O
complexes	O
as	O
two	O
relevant	O
E2	O
/	O
E3	O
systems	O
in	O
CYP3A4	O
and	O
CYP2E1	B
ubiquitination	O
:	O
(	O
i	O
)	O
CHIP	O
(	O
carboxy	O
-	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
)	O
,	O
a	O
cytoplasmic	O
Hsc70	O
-	O
cochaperone	O
,	O
functions	O
with	O
its	O
cognate	O
UbcH5a	O
E2	O
and	O
Hsc70	O
/	O
Hsp40	O
co	O
-	O
chaperones	O
in	O
substrate	O
ubiquitination	O
,	O
.	O

The	O
individual	O
roles	O
of	O
CHIP	O
and	O
gp78	O
in	O
CYP3A	O
and	O
CYP2E1	B
ubiquitination	O
and	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
were	O
verified	O
upon	O
lentiviral	O
shRNA	O
interference	O
analyses	O
targeted	O
individually	O
against	O
each	O
of	O
these	O
E3s	O
in	O
cultured	O
rat	O
hepatocytes	O
,	O
.	O

Therefore	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
screened	O
for	O
the	O
inhibitory	O
potential	O
of	O
the	O
extracts	O
and	O
compounds	O
using	O
co	O
-	O
incubation	O
(	O
reversible	O
inhibition	O
)	O
and	O
pre	O
-	O
incubation	O
(	O
time	O
-	O
dependent	O
inhibition	O
)	O
with	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
Vivid	O
^	O
@	O
recombinant	O
enzymes	O
.	O

Plant	O
extracts	O
containing	O
high	O
levels	O
of	O
polyphenols	O
are	O
expected	O
to	O
have	O
inhibitory	O
effects	O
on	O
various	O
CYPs	O
including	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2D6	O
,	O
and	O
CYP3A4	B
.	O

Of	O
these	O
,	O
CYP3A4	B
is	O
commonly	O
involved	O
in	O
herb	O
-	O
drug	O
interactions	O
as	O
it	O
metabolizes	O
about	O
50	O
%	O
of	O
clinically	O
-	O
prescribed	O
medications	O
.	O

for	O
rats	O
ingesting	O
rooibos	O
tea	O
for	O
two	O
weeks	O
suggested	O
a	O
possible	O
interaction	O
between	O
rooibos	O
tea	O
and	O
medicines	O
mediated	O
by	O
CYP3A	B
.	O

GRT	O
containing	O
higher	O
levels	O
of	O
polyphenols	O
,	O
in	O
particular	O
ASP	O
(	O
12	O
.	O
78	O
%	O
compared	O
to	O
0	O
.	O
36	O
%	O
)	O
,	O
demonstrated	O
a	O
more	O
potent	O
inhibition	O
of	O
CYP3A4	B
activity	O
than	O
FRE	O
with	O
IC_50	O
values	O
of	O
31	O
.	O
33	O
4	O
.	O
69	O
g	O
/	O
mL	O
and	O
51	O
.	O
44	O
4	O
.	O
31	O
g	O
/	O
mL	O
,	O
respectively	O
.	O

ASP	O
,	O
as	O
the	O
major	O
compound	O
,	O
moderately	O
inhibited	O
CYP3A4	B
activity	O
with	O
an	O
IC_50	O
value	O
of	O
69	O
.	O
57	O
4	O
.	O
03	O
g	O
/	O
mL	O
.	O

Luteolin	O
,	O
the	O
aglycone	O
of	O
rooibos	O
flavone	O
glucosides	O
,	O
orientin	O
and	O
isoorientin	O
,	O
and	O
quercetin	O
,	O
the	O
aglycone	O
of	O
rooibos	O
flavonol	O
glycosides	O
,	O
quercetin	O
-	O
3	O
-	O
O	O
-	O
robinobioside	O
,	O
rutin	O
,	O
hyperoside	O
,	O
and	O
isoquercitrin	O
,	O
have	O
previously	O
been	O
shown	O
to	O
inhibit	O
CYP3A4	B
.	O

Quercetin	O
is	O
a	O
more	O
effective	O
inhibitor	O
of	O
CYP3A4	B
than	O
its	O
3	O
-	O
O	O
-	O
rutinoside	O
,	O
rutin	O
.	O

The	O
inhibition	O
of	O
CYP3A4	B
was	O
also	O
demonstrated	O
to	O
be	O
both	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
.	O

Therefore	O
,	O
they	O
could	O
potentially	O
interfere	O
with	O
the	O
metabolism	O
and	O
alter	O
the	O
pharmacodynamics	O
of	O
drugs	O
,	O
such	O
as	O
atorvastatin	O
,	O
cyclosporine	O
,	O
felodopine	O
,	O
simvastatin	O
,	O
midazolam	O
,	O
erythromycin	O
,	O
and	O
doxorubicin	O
,	O
known	O
to	O
be	O
metabolized	O
by	O
CYP3A4	B
.	O

This	O
study	O
demonstrates	O
that	O
GRT	O
and	O
FRE	O
inhibited	O
CYP2C8	O
and	O
CYP3A4	B
activity	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
whilst	O
inhibiting	O
CYP2C9	O
activity	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
only	O
.	O

ASP	O
could	O
only	O
be	O
implicated	O
in	O
CYP3A4	B
inhibition	O
.	O

Vivid	O
^	O
CYP2C8	O
Green	O
Screening	O
Kit	O
with	O
Vivid	O
^	O
substrate	O
,	O
di	O
-	O
[	O
benzyl	O
-	O
O	O
-	O
methyl	O
]	O
-	O
fluorescein	O
(	O
DBOMF	O
)	O
and	O
Vivid	O
^	O
CYP3A4	B
and	O
CYP2C9	O
Blue	O
Screening	O
Kits	O
with	O
Vivid	O
^	O
substrate	O
,	O
7	O
-	O
benzyl	O
-	O
oxymethyloxy	O
-	O
3	O
-	O
cyanocoumarin	O
(	O
BOMCC	O
)	O
were	O
purchased	O
from	O
Life	O
Technologies	O
^	O
(	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
effect	O
of	O
organic	O
solvents	O
such	O
as	O
methanol	O
,	O
acetonitrile	O
and	O
DMSO	O
on	O
Vivid	O
^	O
recombinant	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
assays	O
was	O
determined	O
.	O

CYP3A4	B
is	O
a	O
well	O
-	O
known	O
oxidative	O
enzyme	O
that	O
is	O
mostly	O
involved	O
in	O
the	O
metabolism	O
of	O
xenobiotics	O
,	O
and	O
is	O
the	O
most	O
expressed	O
isoform	O
in	O
human	O
liver	O
.	O

CYP3A4	B
was	O
not	O
analyzed	O
because	O
it	O
was	O
included	O
in	O
the	O
study	O
during	O
the	O
Western	O
Blot	O
analysis	O
and	O
we	O
did	O
not	O
find	O
any	O
change	O
of	O
expression	O
with	O
the	O
treatments	O
.	O

The	O
Western	O
Blot	O
results	O
of	O
CYP1A1	O
showed	O
the	O
same	O
non	O
-	O
induction	O
pattern	O
by	O
both	O
treatments	O
,	O
as	O
well	O
as	O
for	O
CYP3A4	B
(	O
c	O
,	O
d	O
)	O
.	O

Neither	O
CYP1A1	O
nor	O
CYP3A4	B
were	O
affected	O
by	O
both	O
treatments	O
in	O
differentiated	O
cells	O
.	O

We	O
also	O
observed	O
that	O
the	O
fluorescent	O
images	O
of	O
CYP3A4	B
did	O
not	O
report	O
a	O
preferential	O
localization	O
between	O
mitochondria	O
and	O
Endoplasmic	O
Reticulum	O
.	O

Nanostructures	O
of	O
diamond	O
,	O
graphene	O
oxide	O
and	O
graphite	O
inhibit	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
enzymes	O
and	O
downregulate	O
their	O
genes	O
in	O
liver	O
cells	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
if	O
DN	O
,	O
GO	O
and	O
GN	O
affect	O
three	O
isoforms	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
enzymes	O
,	O
namely	O
,	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
,	O
expressed	O
in	O
the	O
liver	O
.	O

The	O
most	O
important	O
members	O
of	O
the	O
CYP	O
family	O
are	O
CYP3A	B
isoforms	O
,	O
especially	O
CYP3A4	B
which	O
is	O
responsible	O
for	O
~	O
30	O
%	O
of	O
the	O
total	O
hepatic	O
activity	O
of	O
CYP	O
.	O

The	O
problem	O
with	O
disturbances	O
of	O
CYP	O
reactions	O
caused	O
by	O
nanomaterials	O
is	O
a	O
new	O
topic	O
,	O
studied	O
most	O
recently	O
on	O
metallic	O
nanoparticles	O
(	O
gold	O
or	O
silver	O
)	O
and	O
using	O
the	O
CYP3A4	B
isoform	O
.	O

Single	O
-	O
walled	O
carbon	O
nanotubes	O
(	O
SWCNT	O
)	O
inhibited	O
the	O
activity	O
of	O
the	O
CYP3A4	B
enzyme	O
by	O
direct	O
interaction	O
between	O
SWCNT	O
and	O
the	O
enzyme	O
.	O

We	O
turned	O
our	O
attention	O
to	O
other	O
carbon	O
nanostructures	O
,	O
such	O
as	O
diamond	O
nanoparticles	O
(	O
DN	O
)	O
,	O
graphene	O
oxide	O
(	O
GO	O
)	O
and	O
graphite	O
nanoparticles	O
(	O
GN	O
)	O
,	O
which	O
were	O
previously	O
shown	O
to	O
be	O
nontoxic	O
or	O
low	O
toxic	O
;	O
however	O
,	O
no	O
data	O
are	O
available	O
on	O
their	O
potential	O
interactions	O
with	O
CYP	O
isoenzymes	O
.	O
,	O
,	O
We	O
hypothesized	O
that	O
a	O
physicochemical	O
interaction	O
occurs	O
between	O
employed	O
carbon	O
nanostructures	O
and	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	O
enzymes	O
.	O

Additionally	O
,	O
the	O
control	O
Baculosomes	O
without	O
CYP450	O
expression	O
were	O
mixed	O
in	O
the	O
same	O
manner	O
as	O
the	O
Baculosomes	O
with	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	O
expression	O
.	O

Known	O
inhibitors	O
of	O
CYP450	O
enzymes	O
were	O
used	O
as	O
positive	O
controls	O
:	O
miconazole	O
for	O
CYP1A2	O
,	O
quinidine	O
for	O
CYP2D6	O
and	O
ketoconazole	O
for	O
CYP3A4	O
.	O

In	O
the	O
first	O
step	O
,	O
Vivid	O
Substrates	O
(	O
EOMCC	O
for	O
CYP1A2	O
and	O
CYP2D6	O
,	O
BOMCC	O
for	O
CYP3A4	O
)	O
were	O
reconstituted	O
in	O
anhydrous	O
acetonitrile	O
,	O
and	O
then	O
40	O
L	O
of	O
tested	O
compounds	O
(	O
DN	O
,	O
GO	O
,	O
GN	O
or	O
inhibitors	O
)	O
or	O
working	O
buffer	O
(	O
control	O
)	O
was	O
added	O
to	O
each	O
well	O
on	O
96	O
-	O
well	O
black	O
-	O
bottom	O
plate	O
(	O
Corning	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
.	O

The	O
inhibition	O
rate	O
of	O
CYP3A4	O
was	O
comparable	O
for	O
DN	O
,	O
GO	O
and	O
GN	O
at	O
all	O
concentrations	O
(	O
50	O
%	O
-	O
60	O
%	O
inhibition	O
)	O
;	O
however	O
,	O
at	O
the	O
highest	O
concentration	O
,	O
we	O
observed	O
an	O
effect	O
similar	O
to	O
the	O
one	O
in	O
CYP1A2	O
.	O

The	O
level	O
of	O
CYP3A4	O
was	O
decreased	O
in	O
all	O
nanostructure	O
groups	O
in	O
both	O
cell	O
lines	O
(	O
<	O
40	O
%	O
of	O
the	O
control	O
,	O
reaching	O
only	O
1	O
%	O
in	O
the	O
GO	O
group	O
in	O
HepaRG	O
cells	O
)	O
,	O
except	O
the	O
GN	O
group	O
in	O
HepaRG	O
cells	O
,	O
where	O
no	O
changes	O
occurred	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
CYP1A2	O
and	O
CYP3A4	O
was	O
lower	O
in	O
the	O
presence	O
of	O
the	O
highest	O
concentration	O
of	O
DN	O
and	O
GN	O
(	O
100	O
mg	O
/	O
L	O
)	O
,	O
which	O
could	O
be	O
related	O
to	O
the	O
formation	O
of	O
nanoparticle	O
agglomerates	O
in	O
higher	O
concentrations	O
and	O
then	O
reduction	O
of	O
their	O
surface	O
area	O
available	O
to	O
interact	O
.	O

It	O
was	O
previously	O
reported	O
that	O
SWCNT	O
inhibited	O
the	O
most	O
important	O
of	O
the	O
isoenzymes	O
,	O
CYP3A4	O
,	O
mostly	O
due	O
to	O
the	O
occurrence	O
of	O
-	O
stacking	O
interactions	O
between	O
the	O
nanotube	O
walls	O
and	O
aromatic	O
residues	O
of	O
the	O
enzyme	O
.	O

These	O
two	O
encoding	O
enzymes	O
were	O
highly	O
expressed	O
in	O
roots	O
than	O
stems	O
,	O
followed	O
by	O
CYP3A	B
family	O
members	O
(	O
6	O
.	O
1	O
%	O
)	O
and	O
CYP4	O
family	O
members	O
(	O
4	O
.	O
8	O
%	O
)	O
.	O

The	O
CYP3A	B
subfamily	O
of	O
enzymes	O
is	O
the	O
most	O
important	O
to	O
drug	O
metabolism	O
in	O
humans	O
because	O
these	O
enzymes	O
metabolize	O
the	O
majority	O
of	O
commercially	O
available	O
drugs	O
.	O

Surprisingly	O
,	O
sulfaphenazole	O
appeared	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
5hydroxylation	O
of	O
flucloxacillin	O
by	O
both	O
recombinant	O
CYP3A4	O
and	O
CYP3A7	O
.	O

There	O
are	O
large	O
interindividual	O
differences	O
in	O
plasma	O
concentrations	O
of	O
flucloxacillin	O
and	O
5hydroxymethyl	O
flucloxacillin	O
.	O
5Hydroxymethyl	O
flucloxacillin	O
is	O
much	O
more	O
toxic	O
to	O
biliary	O
epithelial	O
cells	O
than	O
flucloxacillin	O
.	O
A	O
previous	O
study	O
on	O
four	O
human	O
CYPs	O
showed	O
that	O
CYP3A4	O
exerted	O
the	O
highest	O
activity	O
of	O
flucloxacillin	O
hydroxylation	O
.	O

Nonrenal	O
clearance	O
of	O
flucloxacillin	O
occurs	O
predominantly	O
by	O
cytochrome	O
P450mediated	O
hydroxylation	O
of	O
flucloxacillin	O
to	O
5HMFLX	O
and	O
partly	O
by	O
hydrolysis	O
to	O
the	O
corresponding	O
penicilloic	O
acid	O
,	O
showed	O
that	O
CYP3A4	O
was	O
able	O
to	O
catalyse	O
the	O
5hydroxylation	O
of	O
flucloxacillin	O
.	O

Another	O
study	O
showed	O
that	O
flucloxacillin	O
induces	O
CYP3A4	O
in	O
cell	O
lines	O
exposed	O
to	O
200	O
-	O
400	O
M	O
flucloxacillin	O
(	O
Huwyler	O
et	O
al	O
.	O
,	O
.	O

Furthermore	O
,	O
a	O
major	O
involvement	O
of	O
CYP3A4	O
in	O
drug	O
metabolism	O
complicates	O
prediction	O
of	O
pharmacokinetics	O
based	O
on	O
enzyme	O
kinetics	O
because	O
of	O
the	O
occurrence	O
of	O
atypical	O
enzyme	O
kinetics	O
,	O
such	O
as	O
substrate	O
activation	O
(	O
Houston	O
and	O
Kenworthy	O
,	O
;	O
Ekins	O
et	O
al	O
.	O
,	O
;	O
Atkins	O
,	O
;	O
Houston	O
and	O
Galetin	O
,	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
CYP3A4	O
by	O
drugs	O
appears	O
to	O
be	O
substratedependent	O
,	O
further	O
complicating	O
prediction	O
of	O
drug	O
-	O
drug	O
interactions	O
(	O
Stresser	O
et	O
al	O
.	O
,	O
.	O

456264	O
)	O
,	O
CYP3A4	O
(	O
Lot	O
No	O
.	O

456207	O
)	O
,	O
CYP3A5	B
(	O
Lot	O
No	O
.	O

456256	O
)	O
and	O
CYP3A7	O
(	O
Lot	O
No	O
.	O

At	O
100	O
M	O
flucloxacillin	O
,	O
CYP3A7	O
was	O
the	O
most	O
active	O
CYP	O
followed	O
by	O
CYP3A4	O
.	O

The	O
three	O
inhibitors	O
of	O
CYP3A	B
isoforms	O
,	O
KCZ	O
,	O
miconazole	O
and	O
troleandomycin	O
,	O
showed	O
a	O
relatively	O
modest	O
and	O
differential	O
inhibitory	O
effect	O
on	O
5HMFLX	O
formation	O
.	O

Even	O
at	O
the	O
highest	O
concentration	O
of	O
ketoconazole	O
,	O
which	O
inhibits	O
the	O
CYP3A	B
family	O
,	O
still	O
only	O
50	O
%	O
inhibition	O
was	O
observed	O
at	O
both	O
concentrations	O
of	O
flucloxacillin	O
.	O

The	O
other	O
CYP3A4	O
inhibitors	O
showed	O
only	O
20	O
to	O
40	O
%	O
inhibition	O
at	O
10	O
M	O
flucloxacillin	O
concentration	O
.	O

To	O
study	O
whether	O
sulfaphenazole	O
has	O
the	O
ability	O
to	O
inhibit	O
CYP3Amediated	O
hydroxylation	O
of	O
flucloxacillin	O
,	O
the	O
inhibitor	O
was	O
added	O
at	O
different	O
concentrations	O
to	O
incubations	O
of	O
CYP3A4	O
and	O
CYP3A7	O
,	O
with	O
flucloxacillin	O
and	O
testosterone	O
as	O
substrates	O
.	O

As	O
shown	O
in	O
Figure	O
A	O
,	O
B	O
,	O
sulfaphenazole	O
appeared	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
recombinant	O
CYP3A4	O
and	O
CYP3A7	O
with	O
an	O
IC_50	O
of	O
4	O
.	O
1	O
0	O
.	O
4	O
M	O
and	O
6	O
.	O
1	O
0	O
.	O
5	O
M	O
respectively	O
.	O

At	O
these	O
sulfaphenazole	O
concentrations	O
,	O
no	O
inhibition	O
of	O
CYP3A4catalysed	O
6BETAhydroxylation	O
of	O
testosterone	O
was	O
observed	O
.	O

By	O
using	O
recombinant	O
CYPs	O
,	O
at	O
both	O
substrate	O
concentrations	O
used	O
,	O
CYP3A4	O
and	O
CYP3A7	O
appeared	O
to	O
be	O
the	O
most	O
active	O
enzymes	O
.	O

that	O
CYP3A4	O
is	O
likely	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
formation	O
of	O
5HMFLX	O
,	O
as	O
it	O
is	O
,	O
on	O
average	O
,	O
the	O
most	O
abundant	O
CYP	O
in	O
human	O
liver	O
(	O
mean	O
93	O
pmolmg	O
^	O
1	O
protein	O
)	O
(	O
Achour	O
et	O
al	O
.	O
,	O
.	O

These	O
results	O
bring	O
attention	O
to	O
possible	O
flavonoid	O
-	O
drug	O
interactions	O
on	O
the	O
level	O
of	O
CYP3A4	B
.	O

As	O
CYP3A4	B
is	O
the	O
most	O
significant	O
enzyme	O
for	O
the	O
metabolism	O
of	O
xenobiotics	O
including	O
drugs	O
,	O
further	O
in	O
vivo	O
studies	O
are	O
needed	O
to	O
assess	O
clinical	O
significance	O
of	O
the	O
observed	O
inhibitions	O
,	O
and	O
possible	O
drug	O
-	O
flavonoid	O
interactions	O
.	O

Effects	O
of	O
Flavonoids	O
in	O
Lysimachia	O
clethroides	O
Duby	O
on	O
the	O
Activities	O
of	O
Cytochrome	O
P450	O
CYP2E1	O
and	O
CYP3A4	B
in	O
Rat	O
Liver	O
Microsomes	O
.	O

Incubation	O
systems	O
were	O
established	O
to	O
investigate	O
the	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
Lysimachia	O
clethroides	O
Duby	O
on	O
the	O
activities	O
of	O
CYP2E1	O
and	O
CYP3A4	B
in	O
rat	O
liver	O
microsomes	O
in	O
vitro	O
.	O

The	O
results	O
suggested	O
that	O
kaempferol	O
exhibited	O
a	O
weak	O
inhibition	O
of	O
CYP2E1	O
activity	O
with	O
an	O
IC50	O
of	O
60	O
.	O
26	O
2	O
.	O
54	O
M	O
,	O
while	O
quercetin	O
and	O
kaempferol	O
caused	O
a	O
moderate	O
inhibition	O
of	O
CYP3A4	B
activity	O
with	O
IC50	O
values	O
of	O
18	O
.	O
77	O
1	O
.	O
69	O
M	O
and	O
32	O
.	O
65	O
1	O
.	O
32	O
M	O
,	O
respectively	O
.	O

Isoquercitrin	O
and	O
astragalin	O
had	O
no	O
effects	O
on	O
the	O
activities	O
of	O
either	O
CYP2E1	O
or	O
CYP3A4	B
.	O

It	O
could	O
be	O
speculated	O
from	O
these	O
results	O
that	O
the	O
inhibitory	O
effects	O
of	O
quercetin	O
and	O
kaempferol	O
on	O
the	O
activities	O
of	O
CYP2E1	O
and	O
CYP3A4	B
could	O
be	O
the	O
mechanisms	O
underlying	O
the	O
hepatoprotective	O
effects	O
of	O
L	O
.	O
clethroides	O
.	O

CYP3A4	B
,	O
a	O
major	O
enzyme	O
that	O
is	O
expressed	O
in	O
adult	O
liver	O
,	O
has	O
been	O
considered	O
to	O
be	O
an	O
important	O
factor	O
affecting	O
drug	O
absorption	O
.	O

CYP2E1	O
and	O
CYP3A4	B
are	O
not	O
only	O
the	O
metabolic	O
enzymes	O
directly	O
involved	O
in	O
hepatic	O
oxidative	O
damage	O
,	O
but	O
they	O
also	O
are	O
two	O
important	O
targets	O
of	O
the	O
oxidation	O
mechanism	O
of	O
acute	O
liver	O
injury	O
.	O

On	O
the	O
basis	O
of	O
previous	O
studies	O
,	O
the	O
impacts	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
on	O
the	O
activities	O
of	O
enzymes	O
CYP2E1	O
and	O
CYP3A4	B
in	O
rat	O
liver	O
microsomes	O
were	O
examined	O
,	O
aiming	O
to	O
investigate	O
the	O
correlation	O
between	O
the	O
hepatoprotective	O
effects	O
of	O
L	O
.	O
clethroides	O
and	O
the	O
antioxidant	O
activities	O
of	O
these	O
four	O
compounds	O
.	O

The	O
regressive	O
equations	O
obtained	O
by	O
the	O
Lineweaver	O
-	O
Burk	O
method	O
for	O
CYP2E1	O
and	O
CYP3A4	B
were	O
Y	O
=	O
835	O
.	O
9883X	O
+	O
9	O
.	O
1943	O
(	O
r	O
=	O
0	O
.	O
9864	O
)	O
and	O
Y	O
=	O
2388	O
.	O
0110X	O
+	O
14	O
.	O
1598	O
(	O
r	O
=	O
0	O
.	O
9961	O
)	O
respetively	O
.	O

The	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
L	O
.	O
clethroides	O
and	O
ketoconazole	O
(	O
positive	O
control	O
)	O
on	O
CYP3A4	B
activity	O
are	O
shown	O
in	O
and	O
.	O

Ketoconazole	O
strongly	O
inhibited	O
the	O
production	O
of	O
6BETA	O
-	O
hydroxytestosterone	O
(	O
IC_50	O
=	O
0	O
.	O
25	O
0	O
.	O
01	O
M	O
)	O
,	O
but	O
the	O
effects	O
of	O
the	O
four	O
flavonoids	O
in	O
L	O
.	O
clethroides	O
on	O
CYP3A4	B
were	O
very	O
weak	O
and	O
their	O
IC_50	O
values	O
could	O
not	O
be	O
calculated	O
.	O

CYP2E1	O
and	O
CYP3A4	B
are	O
two	O
important	O
metabolic	O
enzymes	O
involved	O
in	O
liver	O
injury	O
.	O

Radix	O
Glycyrrhizae	O
could	O
protect	O
the	O
liver	O
injury	O
caused	O
by	O
Rhizoma	O
dioscorea	O
bulbifera	O
,	O
possibly	O
due	O
to	O
its	O
induction	O
of	O
activity	O
of	O
CYP2E1	O
and	O
CYP3A4	B
and	O
inhibition	O
of	O
the	O
mRNA	O
expression	O
.	O

Clomethiazole	O
and	O
ketoconazole	O
act	O
as	O
the	O
positive	O
inhibitors	O
for	O
CYP2E1	O
and	O
CYP3A4	B
can	O
significantly	O
inhibit	O
the	O
formation	O
of	O
metabolites	O
.	O

The	O
IC_50	O
values	O
of	O
clomethiazole	O
and	O
ketoconazole	O
were	O
1	O
.	O
07	O
0	O
.	O
01	O
M	O
and	O
0	O
.	O
25	O
0	O
.	O
01	O
M	O
,	O
respectively	O
,	O
which	O
are	O
consistent	O
with	O
literature	O
values	O
,	O
suggesting	O
that	O
the	O
incubation	O
systems	O
in	O
vitro	O
can	O
meet	O
the	O
activities	O
of	O
measurement	O
of	O
CYP2E1	O
and	O
CYP3A4	B
.	O

Thus	O
,	O
kaempferol	O
has	O
a	O
weakly	O
inhibitory	O
effect	O
on	O
CYP2E1	O
,	O
while	O
quercetin	O
and	O
kaempferol	O
have	O
moderate	O
inhibitory	O
effects	O
on	O
CYP3A4	B
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
the	O
two	O
flavone	O
glycosides	O
(	O
isoquercitrin	O
and	O
astragalin	O
)	O
had	O
no	O
effect	O
on	O
the	O
activities	O
of	O
CYP2E1	O
and	O
CYP3A4	B
.	O

Cytochromes	O
P450	O
,	O
especially	O
CYP2E1	O
and	O
CYP3A4	B
,	O
are	O
responsible	O
for	O
metabolism	O
of	O
ethanol	O
,	O
CCl_4	O
and	O
other	O
solvents	O
in	O
the	O
body	O
.	O

In	O
the	O
model	O
of	O
alcohol	O
-	O
induced	O
liver	O
injury	O
,	O
the	O
expression	O
levels	O
of	O
CYP2E1	O
and	O
CYP3A4	B
were	O
enhanced	O
.	O

The	O
occurrence	O
of	O
liver	O
injury	O
can	O
be	O
reduced	O
or	O
even	O
suppressed	O
by	O
minimizing	O
the	O
activities	O
of	O
CYP2E1	O
and	O
CYP3A4	B
,	O
making	O
the	O
discovery	O
of	O
more	O
compounds	O
with	O
anti	O
-	O
oxidative	O
stress	O
from	O
natural	O
products	O
of	O
important	O
significance	O
.	O

The	O
incubation	O
conditions	O
of	O
CYP3A4	B
were	O
basically	O
the	O
same	O
as	O
those	O
described	O
in	O
but	O
the	O
volume	O
of	O
incubation	O
mixture	O
was	O
500	O
L	O
and	O
the	O
reactions	O
were	O
terminated	O
by	O
adding	O
700	O
L	O
of	O
ice	O
-	O
cold	O
acetonitrile	O
containing	O
25	O
M	O
phenacetin	O
.	O

The	O
effects	O
of	O
flavonoids	O
in	O
L	O
.	O
clethroides	O
on	O
CYP3A4	B
activity	O
were	O
basically	O
the	O
same	O
as	O
CYP2E1	O
.	O

The	O
positive	O
control	O
was	O
ketoconazole	O
,	O
and	O
Groups	O
2	O
and	O
3	O
experiments	O
were	O
performed	O
at	O
concentrations	O
of	O
0	O
.	O
02	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
2	O
,	O
1	O
and	O
5	O
M	O
.	O
In	O
vitro	O
rat	O
liver	O
microsomes	O
incubation	O
assay	O
methods	O
were	O
adopted	O
for	O
determining	O
the	O
effects	O
of	O
quercetin	O
,	O
kaempferol	O
,	O
isoquercitrin	O
and	O
astragalin	O
in	O
L	O
.	O
clethroides	O
on	O
the	O
activities	O
of	O
CYP2E1	O
and	O
CYP3A4	B
.	O

In	O
conclusion	O
,	O
kaempferol	O
has	O
a	O
weakly	O
inhibitory	O
effect	O
on	O
CYP2E1	O
,	O
while	O
quercetin	O
and	O
kaempferol	O
had	O
moderate	O
inhibitory	O
effects	O
on	O
CYP3A4	B
activity	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
speculated	O
that	O
the	O
active	O
hepatoprotective	O
ingredients	O
of	O
L	O
.	O
clethroides	O
include	O
quercetin	O
and	O
kaempferol	O
,	O
which	O
confer	O
the	O
inhibitory	O
effects	O
on	O
the	O
activities	O
of	O
CYP2E1	O
and	O
CYP3A4	B
.	O

The	O
reduction	O
of	O
CYP2E1	O
and	O
CYP3A4	B
activities	O
can	O
mitigate	O
the	O
biotransformation	O
of	O
CC1_4	O
and	O
prevent	O
the	O
production	O
of	O
liver	O
damaging	O
substances	O
to	O
exert	O
a	O
liver	O
protective	O
role	O
.	O

Cytochrome	O
P450	O
enzymes	O
,	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
,	O
are	O
important	O
in	O
the	O
metabolism	O
of	O
hypoglycemic	O
drugs	O
,	O
such	O
as	O
thiazolidinediones	O
(	O
TZDs	O
)	O
and	O
sulfonylureas	O
,	O
and	O
hypocholesterolemic	O
drugs	O
,	O
such	O
as	O
atorvastatin	O
.	O

Unfermented	O
(	O
GRT	O
)	O
and	O
fermented	O
(	O
FRE	O
)	O
rooibos	O
extracts	O
inhibited	O
the	O
activity	O
of	O
CYP2C8	O
(	O
7	O
.	O
69	O
8	O
.	O
85	O
g	O
/	O
mL	O
and	O
8	O
.	O
93	O
8	O
.	O
88	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
and	O
CYP3A4	B
(	O
31	O
.	O
33	O
4	O
.	O
69	O
g	O
/	O
mL	O
and	O
51	O
.	O
44	O
4	O
.	O
31	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
based	O
on	O
their	O
respective	O
IC50	O
concentrations	O
.	O

CYP3A4	B
showed	O
concentration	O
-	O
dependent	O
inhibition	O
by	O
ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
at	O
25	O
,	O
50	O
,	O
and	O
100	O
g	O
/	O
mL	O
concentrations	O
.	O

ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
time	O
-	O
dependently	O
inhibited	O
CYP3A4	B
activity	O
with	O
GRT	O
and	O
FRE	O
showing	O
a	O
more	O
potent	O
time	O
-	O
dependent	O
inhibition	O
,	O
comparable	O
to	O
erythromycin	O
.	O

Approximately	O
80	O
%	O
of	O
conventional	O
drugs	O
are	O
metabolized	O
by	O
specific	O
enzymes	O
(	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
and	O
CYP3A4	B
)	O
belonging	O
to	O
subfamilies	O
,	O
CYP1	O
,	O
CYP2	O
,	O
and	O
CYP3	O
.	O

Metformin	O
,	O
a	O
first	O
-	O
line	O
anti	O
-	O
diabetic	O
drug	O
,	O
is	O
metabolized	O
by	O
CYP2C11	O
,	O
CYP2D1	O
,	O
and	O
CYP3A1	O
/	O
2	O
,	O
while	O
glyburide	O
and	O
pioglitazone	O
,	O
other	O
known	O
hypoglycemic	O
drugs	O
,	O
are	O
metabolized	O
by	O
CYP2C9	O
,	O
CYP3A4	B
,	O
and	O
CYP2C8	O
.	O

Atorvastatin	O
used	O
to	O
treat	O
hypercholesterolemia	O
is	O
metabolized	O
by	O
CYP3A4	B
.	O

Most	O
drugs	O
and	O
xenobiotics	O
including	O
dietary	O
polyphenols	O
have	O
the	O
ability	O
to	O
bind	O
to	O
CYP3A4	B
as	O
substrates	O
.	O

Flavonoids	O
,	O
common	O
in	O
the	O
diet	O
,	O
are	O
responsible	O
for	O
the	O
modulation	O
of	O
the	O
clinically	O
relevant	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
enzymes	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
,	O
therefore	O
,	O
to	O
investigate	O
the	O
inhibitory	O
effects	O
of	O
polyphenol	O
-	O
enriched	O
unfermented	O
rooibos	O
extract	O
(	O
GRT	O
)	O
,	O
and	O
fermented	O
rooibos	O
extract	O
(	O
FRE	O
)	O
,	O
(	O
Z	O
-	O
2	O
-	O
(	O
BETA	O
-	O
d	O
-	O
glucopyranosyloxy	O
)	O
-	O
3	O
-	O
phenylpropenoic	O
acid	O
(	O
PPAG	O
)	O
and	O
aspalathin	O
(	O
ASP	O
)	O
on	O
Vivid	O
^	O
recombinant	O
CYP450	O
enzymes	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
.	O

Qualitative	O
screening	O
of	O
extracts	O
and	O
compounds	O
was	O
used	O
to	O
identify	O
potential	O
inhibitory	O
effects	O
on	O
CYP2C8	O
,	O
CYP2C9	O
and	O
CYP3A4	B
.	O

Quercetin	O
,	O
sulfaphenazole	O
,	O
and	O
ketoconazole	O
were	O
the	O
selected	O
positive	O
inhibitors	O
for	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
,	O
respectively	O
.	O

GRT	O
and	O
FRE	O
inhibited	O
the	O
reaction	O
rate	O
of	O
CYP2C8	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	B
as	O
measured	O
over	O
30	O
min	O
(	O
a	O
-	O
c	O
)	O
.	O

ASP	O
showed	O
24	O
%	O
inhibition	O
of	O
CYP2C9	O
at	O
100	O
g	O
/	O
mL	O
and	O
23	O
%	O
inhibition	O
of	O
CYP3A4	B
at	O
200	O
g	O
/	O
mL	O
activity	O
,	O
while	O
PPAG	O
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
enzymes	O
.	O

Both	O
extracts	O
moderately	O
inhibited	O
CYP3A4	B
activity	O
(	O
31	O
.	O
33	O
4	O
.	O
69	O
g	O
/	O
mL	O
and	O
51	O
.	O
44	O
4	O
.	O
31	O
g	O
/	O
mL	O
,	O
respectively	O
)	O
(	O
b	O
)	O
,	O
while	O
ASP	O
displayed	O
weak	O
inhibition	O
of	O
CYP3A4	B
activity	O
(	O
69	O
.	O
57	O
4	O
.	O
03	O
g	O
/	O
mL	O
)	O
(	O
b	O
)	O
.	O

ASP	O
,	O
GRT	O
,	O
and	O
FRE	O
reduced	O
CYP3A4	B
activity	O
at	O
25	O
g	O
/	O
mL	O
(	O
62	O
.	O
9	O
%	O
,	O
36	O
.	O
9	O
%	O
and	O
61	O
.	O
4	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
50	O
g	O
/	O
mL	O
(	O
44	O
.	O
5	O
%	O
,	O
13	O
.	O
5	O
%	O
and	O
29	O
.	O
7	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
100	O
g	O
/	O
mL	O
(	O
28	O
.	O
1	O
%	O
,	O
1	O
.	O
7	O
%	O
and	O
9	O
.	O
2	O
%	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
c	O
)	O
.	O

PPAG	O
demonstrated	O
time	O
-	O
dependent	O
inhibition	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
only	O
CYP3A4	B
(	O
c	O
)	O
.	O

An	O
interesting	O
finding	O
,	O
however	O
,	O
is	O
the	O
time	O
-	O
dependent	O
inhibition	O
of	O
CYP3A4	B
activity	O
by	O
GRT	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
FRE	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
displaying	O
a	O
similar	O
effect	O
to	O
that	O
of	O
erythromycin	O
(	O
c	O
)	O
.	O

These	O
constituents	O
include	O
various	O
bioactive	O
compounds	O
that	O
can	O
either	O
activate	O
or	O
inhibit	O
CYP3A4	B
.	O

Echinacea	O
purpurea	O
,	O
a	O
known	O
plant	O
-	O
based	O
product	O
with	O
constituents	O
such	O
as	O
caffeic	O
acid	O
derivatives	O
,	O
amides	O
,	O
flavonoids	O
,	O
and	O
glycosides	O
,	O
displayed	O
weak	O
inhibitory	O
effects	O
of	O
CYP3A4	B
activity	O
with	O
IC_50	O
values	O
of	O
354	O
-	O
5394	O
g	O
/	O
mL	O
,	O
and	O
modestly	O
induced	O
hepatic	O
CYP3A4	B
activity	O
,	O
thereby	O
lowering	O
the	O
effective	O
concentration	O
of	O
drugs	O
,	O
such	O
as	O
midazolam	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
in	O
SkinEthik	O
^	O
RHE	O
:	O
2	O
.	O
8	O
,	O
in	O
Episkin	O
^	O
:	O
9	O
.	O
1	O
,	O
in	O
Episkin	O
^	O
FTM	O
:	O
2	O
.	O
6	O
,	O
compared	O
with	O
human	O
skin	O
:	O
3	O
.	O
0	O
;	O
7	O
-	O
benzoxy	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
deethylase	O
activities	O
(	O
CYP3A5	B
/	O
3A7	O
-	O
selective	O
)	O
in	O
SkinEthik	O
^	O
RHE	O
:	O
13	O
.	O
3	O
,	O
in	O
Episkin	O
^	O
:	O
3	O
.	O
6	O
,	O
in	O
Episkin	O
^	O
FTM	O
:	O
3	O
.	O
3	O
,	O
compared	O
with	O
human	O
skin	O
:	O
3	O
.	O
8	O
;	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
dealkylase	O
activity	O
was	O
close	O
to	O
the	O
Limit	O
Of	O
Quantitation	O
of	O
0	O
.	O
5	O
in	O
all	O
three	O
skin	O
models	O
and	O
in	O
human	O
skin	O
.	O

CYP3A4	O
and	O
CYP3A5	B
Baron	O
et	O
al	O
.	O

showed	O
that	O
CYP3A5	B
,	O
but	O
not	O
CYP3A4	O
mRNA	O
was	O
constitutively	O
present	O
in	O
proliferating	O
human	O
skin	O
keratinocytes	O
in	O
culture	O
,	O
while	O
the	O
expression	O
of	O
CYP3A4	O
mRNA	O
was	O
induced	O
by	O
treatment	O
with	O
dexamethasone	O
.	O

Cyp3A4	O
mRNA	O
was	O
very	O
variably	O
expressed	O
in	O
various	O
skin	O
systems	O
,	O
whereby	O
it	O
was	O
not	O
clear	O
whether	O
CYP3A4	O
was	O
distinguished	O
from	O
CYP3A5	B
.	O

It	O
has	O
been	O
reported	O
that	O
elevated	O
concentration	O
of	O
S	O
-	O
Adenosylmethionine	O
reduces	O
CYP2E1	O
^	O
and	O
CYP39A	O
^	O
,	O
but	O
markedly	O
induces	O
CYP4A	B
^	O
in	O
Glycine	O
N	O
-	O
Methyltransferase	O
Knockout	O
mice	O
.	O

Interestingly	O
,	O
in	O
our	O
microarray	O
data	O
,	O
CYP4A	B
were	O
significantly	O
induced	O
up	O
to	O
4	O
-	O
to	O
6	O
-	O
fold	O
by	O
AAI	O
.	O

In	O
order	O
to	O
study	O
the	O
metabolic	O
capability	O
of	O
SH	O
-	O
SY5Y	O
cells	O
after	O
the	O
induction	O
of	O
Cytochrome	B
P450	I
isoforms	O
,	O
we	O
used	O
7	O
-	O
ethoxycoumarin	O
as	O
substrate	O
for	O
a	O
broad	O
number	O
of	O
Cytochrome	B
P450	I
isozymes	O
.	O

The	O
localization	O
of	O
Cytochrome	B
P450	I
in	O
mitochondria	O
can	O
contribute	O
to	O
the	O
bioactivation	O
/	O
detoxification	O
processes	O
of	O
neurotoxins	O
.	O

Therefore	O
,	O
other	O
Cytochrome	B
P450	I
isoforms	O
can	O
have	O
an	O
important	O
role	O
in	O
xenobiotic	O
metabolism	O
in	O
other	O
brain	O
regions	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
they	O
do	O
not	O
have	O
to	O
necessarily	O
be	O
associate	O
with	O
positive	O
effects	O
.	O

This	O
toxin	O
can	O
be	O
metabolized	O
by	O
the	O
Cytochrome	B
P450	I
system	O
as	O
already	O
reported	O
.	O

Since	O
Cytochrome	B
P450	I
is	O
not	O
able	O
to	O
metabolize	O
this	O
compound	O
,	O
we	O
confirmed	O
that	O
the	O
effects	O
observed	O
were	O
not	O
produced	O
by	O
the	O
inducers	O
itself	O
,	O
but	O
by	O
the	O
promotion	O
of	O
the	O
Cytochrome	B
P450	I
system	O
.	O

The	O
CYPs	O
activities	O
were	O
assayed	O
using	O
7	O
-	O
ethoxycoumarin	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
as	O
substrate	O
of	O
multiple	O
Cytochrome	B
P450	I
isoforms	O
or	O
dextromethorphan	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
as	O
CYP2D6	O
marker	O
substrate	O
.	O

The	O
enzyme	O
activities	O
were	O
expressed	O
as	O
pmol	O
metabolite	O
per	O
mg	O
of	O
protein	O
in	O
24	O
h	O
.	O
A	O
staining	O
approach	O
to	O
evaluate	O
the	O
Cytochrome	B
P450	I
location	O
in	O
SH	O
-	O
SY5Y	O
was	O
carried	O
out	O
by	O
confocal	O
imaging	O
.	O

Cytochrome	B
P450	I
,	O
a	O
superfamily	O
of	O
monooxygenase	O
,	O
plays	O
critical	O
roles	O
in	O
biosynthesis	O
of	O
plant	O
secondary	O
metabolites	O
such	O
as	O
triterpenes	O
,	O
alkaloids	O
,	O
and	O
sterols	O
.	O

Influence	O
of	O
mentioned	O
extracts	O
and	O
their	O
key	O
constituents	O
on	O
warfarin	O
pharmacodynamic	O
and	O
kinetic	O
actions	O
and	O
Cytochrome	B
P450	B
Enzymes	I
activity	O
were	O
evaluated	O
.	O

Furthermore	O
,	O
potential	O
involvement	O
in	O
Cytochrome	B
P450	I
Enzymes	O
inhibition	O
was	O
also	O
investigated	O
in	O
vitro	O
on	O
isolated	O
primary	O
rat	O
hepatocytes	O
.	O

In	O
addition	O
,	O
the	O
potential	O
inhibition	O
of	O
selected	O
Cytochrome	B
P450	I
Enzymes	O
enzymes	O
that	O
are	O
responsible	O
for	O
warfarin	O
metabolism	O
is	O
investigated	O
with	O
the	O
herbal	O
drugs	O
in	O
vitro	O
on	O
rat	O
isolated	O
primary	O
hepatocytes	O
.	O

After	O
16	O
h	O
of	O
incubation	O
,	O
each	O
well	O
of	O
cultured	O
rat	O
hepatocytes	O
were	O
treated	O
with	O
25	O
l	O
of	O
warfarin	O
,	O
guava	O
leaves	O
extract	O
,	O
quercetin	O
,	O
pomegranate	O
peel	O
extract	O
,	O
ellagic	O
acid	O
,	O
a	O
combination	O
of	O
warfarin	O
with	O
each	O
test	O
compound	O
in	O
addition	O
to	O
the	O
control	O
Cytochrome	B
P450	I
Enzymes	O
inhibitors	O
namely	O
;	O
ketoconazole	O
,	O
sulfamethoxazole	O
or	O
trimethoprim	O
.	O

Noteworthy	O
,	O
the	O
evaluation	O
of	O
CYP450	O
enzymes	O
,	O
namely	O
,	O
CYP2C9	O
,	O
2C8	O
,	O
3A4	O
was	O
based	O
on	O
cell	O
-	O
based	O
investigations	O
and	O
sufficient	O
inhibition	O
of	O
corresponding	O
well	O
-	O
known	O
Cytochrome	B
P450	I
Enzymes	O
control	O
inhibitors	O
including	O
,	O
sulfamethoxazole	O
,	O
trimethoprim	O
and	O
ketoconazole	O
confirms	O
that	O
in	O
vitro	O
investigation	O
of	O
mentioned	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
on	O
rat	O
hepatocyte	O
is	O
possible	O
,	O
as	O
raised	O
in	O
the	O
literature	O
[	O
,	O
.	O

In	O
regard	O
to	O
results	O
presented	O
for	O
ellagic	O
acid	O
,	O
and	O
since	O
it	O
is	O
known	O
to	O
exert	O
inhibition	O
on	O
CYP2C9	O
,	O
its	O
effect	O
may	O
be	O
due	O
to	O
a	O
decrease	O
in	O
hepatic	O
first	O
-	O
pass	O
metabolism	O
of	O
warfarin	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
such	O
Cytochrome	B
P450	I
Enzymes	O
isoform	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
guava	O
leaves	O
extract	O
and	O
quercetin	O
to	O
inhibit	O
some	O
of	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
associated	O
with	O
warfarin	O
metabolism	O
such	O
as	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
may	O
be	O
responsible	O
for	O
increasing	O
warfarin	O
plasma	O
concentration	O
[	O
,	O
.	O

In	O
vitro	O
warfarin	O
-	O
herb	O
interactions	O
and	O
their	O
effects	O
on	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
showed	O
that	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
activities	O
in	O
primary	O
isolated	O
and	O
cultured	O
rat	O
hepatocytes	O
were	O
not	O
affected	O
by	O
warfarin	O
.	O

Since	O
Cytochrome	B
P450	I
Enzymes	O
isoforms	O
other	O
than	O
2C9	O
,	O
2C8	O
and	O
3A4	O
are	O
involved	O
in	O
warfarin	O
metabolism	O
,	O
further	O
study	O
with	O
more	O
focus	O
on	O
pomegranate	O
peel	O
and	O
its	O
constituents	O
is	O
therefore	O
suggested	O
.	O

To	O
achieve	O
this	O
,	O
the	O
hit	O
compounds	O
evaluated	O
for	O
either	O
substrate	O
or	O
inhibitors	O
of	O
Cytochrome	B
P450	I
Enzymes	O
along	O
with	O
Cytochrome	B
P450	I
Enzymes	O
of	O
Human	O
Liver	O
Microsomes	O
.	O

These	O
metabolism	O
properties	O
were	O
explored	O
in	O
silico	O
and	O
summarized	O
by	O
predicting	O
the	O
metabolic	O
sites	O
as	O
well	O
as	O
metabolites	O
,	O
and	O
type	O
of	O
Cytochrome	B
P450	I
Enzymes	O
involved	O
enzymes	O
,	O
which	O
catalyzes	O
xenobiotics	O
/	O
drugs	O
in	O
phase	O
II	O
metabolism	O
and	O
transform	O
the	O
small	O
molecules	O
to	O
water	O
-	O
soluble	O
form	O
,	O
which	O
may	O
lead	O
to	O
the	O
easy	O
elimination	O
of	O
xenobiotics	O
.	O

Cytochrome	O
P450s	O
,	O
which	O
comprise	O
one	O
of	O
the	O
largest	O
and	O
oldest	O
gene	O
superfamilies	O
,	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
biosynthesis	O
of	O
secondary	O
metabolites	O
such	O
as	O
flavonoids	O
.	O

In	O
this	O
study	O
,	O
78	O
unigene	O
Differentially	O
Expressed	O
Genes	O
were	O
annotated	O
as	O
Cytochrome	O
P450s	O
.	O

Cytochrome	O
P450s	O
are	O
known	O
to	O
play	O
central	O
roles	O
in	O
the	O
evolution	O
of	O
metabolic	O
complexity	O
and	O
in	O
the	O
production	O
of	O
secondary	O
metabolites	O
,	O
including	O
flavonoid	O
metabolites	O
.	O

Two	O
Cytochrome	O
P450s	O
(	O
CfCYP93B	O
and	O
CfCYP706C	O
)	O
isolated	O
from	O
Coleus	O
forskohlii	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
flavonoids	O
and	O
CYP93B	O
isolated	O
from	O
hybrid	O
Gerbera	O
encodes	O
flavone	O
synthase	O
II	O
,	O
which	O
catalyzes	O
flavanones	O
into	O
flavones	O
.	O

The	O
expression	O
of	O
Cytochrome	O
P450s	O
also	O
has	O
a	O
significant	O
effect	O
on	O
the	O
content	O
of	O
flavonoids	O
in	O
plants	O
.	O

Several	O
enzymes	O
including	O
those	O
belonging	O
to	O
the	O
Cytochrome	B
P450	I
family	O
play	O
crucial	O
roles	O
in	O
the	O
generation	O
of	O
either	O
a	O
stable	O
plaque	O
or	O
progression	O
to	O
an	O
unstable	O
plaque	O
with	O
poor	O
prognosis	O
for	O
atherosclerosis	O
outcome	O
(	O
Silvestre	O
-	O
Roig	O
et	O
al	O
.	O
,	O
;	O
Song	O
et	O
al	O
.	O
,	O
;	O
Stefanadis	O
et	O
al	O
.	O
,	O
.	O

Cholesterol	O
also	O
acts	O
as	O
a	O
substrate	O
for	O
various	O
enzyme	O
activities	O
including	O
those	O
belonging	O
to	O
the	O
Cytochrome	B
P450	I
family	O
(	O
Pikuleva	O
,	O
;	O
Rogers	O
et	O
al	O
.	O
,	O
.	O

The	O
Cytochrome	B
P450	I
system	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
various	O
CVDs	O
including	O
atherosclerosis	O
and	O
aneurysms	O
(	O
Song	O
et	O
al	O
.	O
,	O
;	O
Thirunavukkarasu	O
et	O
al	O
.	O
,	O
.	O

The	O
cholesterol	O
metabolizing	O
ability	O
of	O
Cytochrome	B
P450	I
family	O
members	O
varies	O
depending	O
on	O
the	O
physiological	O
requirements	O
of	O
different	O
organs	O
and	O
in	O
vivo	O
cholesterol	O
levels	O
.	O

The	O
importance	O
of	O
Cytochrome	B
P450	I
in	O
mycobacteria	O
is	O
known	O
.	O

Iron	O
is	O
necessary	O
for	O
mycobacterial	O
Cytochrome	B
P450	I
(	O
Ouellet	O
et	O
al	O
.	O
,	O
)	O
activity	O
and	O
iron	O
has	O
been	O
recognized	O
as	O
a	O
crucial	O
element	O
for	O
the	O
survival	O
of	O
intracellular	O
mycobacteria	O
(	O
Ratledge	O
,	O
;	O
Janagama	O
et	O
al	O
.	O
,	O
;	O
Lamont	O
et	O
al	O
.	O
,	O
.	O

Thus	O
,	O
the	O
importance	O
of	O
Cytochrome	B
P450	I
from	O
the	O
pathogen	O
perspective	O
has	O
been	O
explored	O
albeit	O
not	O
in	O
depth	O
.	O

From	O
the	O
host	O
perspective	O
,	O
a	O
transcriptomic	O
analysis	O
of	O
Tuberculosis	O
granulomas	O
has	O
revealed	O
a	O
characteristic	O
downregulation	O
of	O
several	O
Cytochrome	B
P450	I
genes	O
in	O
cells	O
within	O
these	O
granulomas	O
(	O
Eisenreich	O
et	O
al	O
.	O
,	O
.	O

Cytochrome	B
P450	I
monooxygenases	O
are	O
involved	O
in	O
biosynthesis	O
of	O
oxysterols	O
(	O
Pikuleva	O
,	O
)	O
,	O
however	O
the	O
dynamics	O
between	O
the	O
expression	O
of	O
Cytochrome	B
P450	I
genes	O
in	O
granuloma	O
formation	O
and	O
cholesterol	O
metabolism	O
has	O
not	O
been	O
assessed	O
in	O
Mycobacterium	O
Tuberculosis	O
infection	O
.	O

Apart	O
from	O
their	O
direct	O
role	O
in	O
modulating	O
host	O
cholesterol	O
metabolism	O
,	O
members	O
of	O
the	O
Cytochrome	B
P450	I
family	O
such	O
as	O
Cyp4501b1	O
(	O
Cyp1b1	O
)	O
are	O
involved	O
in	O
the	O
metabolism	O
of	O
sex	O
steroidal	O
hormones	O
with	O
the	O
resultant	O
metabolites	O
produced	O
being	O
implicated	O
to	O
play	O
a	O
role	O
in	O
the	O
gender	O
differences	O
noticed	O
to	O
the	O
susceptibility	O
to	O
cardiac	O
and	O
renal	O
diseases	O
(	O
Jennings	O
et	O
al	O
.	O
,	O
;	O
Pingili	O
et	O
al	O
.	O
,	O
;	O
Song	O
et	O
al	O
.	O
,	O
;	O
Thirunavukkarasu	O
et	O
al	O
.	O
,	O
.	O

Therefore	O
,	O
extrapolating	O
from	O
the	O
evidence	O
for	O
Cyp1b1	O
in	O
gender	O
specific	O
pathogeneis	O
of	O
CVDs	O
,	O
it	O
would	O
be	O
worthwhile	O
to	O
explore	O
further	O
the	O
role	O
of	O
Cytochrome	B
P450	I
family	O
members	O
in	O
mycobacterial	O
infections	O
due	O
to	O
a	O
necessity	O
for	O
a	O
sex	O
-	O
tailored	O
therapeutic	O
approach	O
in	O
view	O
of	O
the	O
gender	O
related	O
susceptibility	O
to	O
disease	O
.	O

Kistamicin	O
contains	O
three	O
crosslinks	O
,	O
including	O
an	O
unusual	O
15	O
-	O
membered	O
A	O
-	O
O	O
-	O
B	O
ring	O
,	O
despite	O
the	O
presence	O
of	O
only	O
two	O
Cytochrome	B
P450	I
Oxy	O
enzymes	O
thought	O
to	O
catalyse	O
formation	O
of	O
such	O
crosslinks	O
within	O
the	O
biosynthetic	O
gene	O
cluster	O
.	O

The	O
most	O
abundant	O
in	O
the	O
plasma	O
is	O
sorafenib	O
N	O
-	O
oxide	O
(	O
M2	O
)	O
,	O
which	O
is	O
produced	O
by	O
Cytochrome	B
P450	I
3a4	I
and	O
exhibits	O
an	O
in	O
vitro	O
potency	O
similar	O
to	O
the	O
parental	O
drug	O
.	O

Given	O
the	O
key	O
role	O
of	O
Cytochrome	B
P450	I
3a4	I
and	O
Udp	O
Glucuronosyltransferase	O
1a9	O
in	O
sorafenib	O
metabolism	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
,	O
such	O
as	O
some	O
foods	O
and	O
co	O
-	O
administered	O
drugs	O
(	O
eg	O
,	O
carbamazepine	O
,	O
dexamethasone	O
,	O
phenobarbital	O
,	O
phenytoin	O
,	O
rifampin	O
,	O
rifabutin	O
,	O
St	O
.	O

The	O
liver	O
metabolism	O
of	O
regorafenib	O
,	O
even	O
if	O
less	O
well	O
-	O
characterized	O
,	O
is	O
comparable	O
with	O
that	O
of	O
sorafenib	O
and	O
occurs	O
through	O
an	O
oxidative	O
process	O
mediated	O
by	O
Cytochrome	B
P450	I
3a4	O
and	O
glucuronidation	O
mediated	O
by	O
Udp	O
Glucuronosyltransferase	O
1a9	O
.	O

A	O
descriptive	O
study	O
assessed	O
Cytochrome	B
P450	I
3a4	O
and	O
Udp	O
Glucuronosyltransferase	O
1a9	O
genetic	O
variability	O
by	O
sequencing	O
the	O
germline	O
DNA	O
of	O
three	O
patients	O
with	O
metastatic	O
colorectal	O
cancer	O
experiencing	O
severe	O
toxic	O
hepatitis	O
after	O
sorafenib	O
treatment	O
and	O
reported	O
that	O
two	O
patients	O
were	O
heterozygous	O
for	O
the	O
UGT1A9	O
*	O
22	O
(	O
rs3832043	O
)	O
polymorphism	O
.	O

This	O
drug	O
undergoes	O
hepatic	O
metabolism	O
by	O
Cytochrome	B
P450	I
3a4	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
CYP2C9	O
.	O

Lenvatinib	O
is	O
metabolized	O
in	O
liver	O
microsomes	O
mostly	O
through	O
Cytochrome	B
P450	I
3a4	O
(	O
>	O
80	O
%	O
)	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
aldehyde	O
oxidase	O
and	O
acts	O
as	O
a	O
substrate	O
for	O
Atp	O
-	O
Binding	O
Cassette	O
transporters	O
,	O
encoded	O
by	O
the	O
ABCB1	O
and	O
ABCG2	O
genes	O
,	O
such	O
as	O
BCRP	O
and	O
P	O
-	O
glycoprotein	O
.	O

Overexpression	O
of	O
a	O
Novel	O
Cytochrome	B
P450	I
Promotes	O
Flavonoid	O
Biosynthesis	O
and	O
Osmotic	O
Stress	O
Tolerance	O
in	O
Transgenic	O
Arabidopsis	O
.	O

However	O
,	O
the	O
explicit	O
regulation	O
mechanism	O
of	O
Cytochrome	O
P450s	O
related	O
to	O
flavonoid	O
biosynthesis	O
largely	O
remains	O
elusive	O
.	O

The	O
result	O
of	O
the	O
qRT	O
-	O
PCR	O
assays	O
indicated	O
that	O
the	O
expression	O
level	O
of	O
most	O
of	O
the	O
flavonoid	O
pathway	O
genes	O
,	O
including	O
PAL	O
(	O
Phenylalanine	O
ammonia	O
lyase	O
)	O
,	O
Chalcone	O
Isomerase	O
(	O
Chalcone	O
isomerase	O
)	O
,	O
CYP82G1	O
(	O
Cytochrome	B
P450	I
monooxygenase	O
)	O
,	O
F3H	O
(	O
flavonoid	O
3	O
-	O
hydroxylase	O
)	O
,	O
and	O
FLS	O
(	O
Flavonol	O
synthase	O
)	O
were	O
more	O
abundantly	O
up	O
-	O
regulated	O
in	O
the	O
ARB3	O
-	O
CtCYP82G24	O
overexpression	O
line	O
than	O
that	O
of	O
wild	O
-	O
type	O
plant	O
.	O

The	O
heme	O
-	O
containing	O
Cytochrome	B
P450	I
enzymes	O
activate	O
molecular	O
oxygen	O
utilizing	O
NADPH	O
as	O
an	O
electron	O
donor	O
.	O

Cytochrome	B
P450	I
enzymes	I
involved	O
in	O
steroidogenesis	O
can	O
be	O
divided	O
into	O
two	O
groups	O
based	O
on	O
their	O
intracellular	O
location	O
and	O
mode	O
of	O
electron	O
transfer	O
.	O

Cytochrome	B
P450	I
type	O
I	O
enzymes	O
are	O
located	O
within	O
the	O
inner	O
mitochondrial	O
membrane	O
and	O
are	O
dependent	O
on	O
ferredoxin	O
and	O
ferredoxin	O
reductase	O
for	O
the	O
delivery	O
of	O
their	O
electrons	O
from	O
NADPH	O
.	O

Ferredoxin	O
reductase	O
is	O
a	O
flavoprotein	O
that	O
oxidizes	O
NADPH	O
and	O
transfers	O
electrons	O
to	O
ferredoxin	O
,	O
a	O
small	O
iron	O
-	O
sulfur	O
protein	O
,	O
which	O
acts	O
as	O
a	O
mobile	O
electron	O
carrier	O
,	O
delivering	O
the	O
electrons	O
to	O
the	O
Cytochrome	B
P450	I
.	O

In	O
addition	O
to	O
the	O
steroidogenic	O
Cytochrome	B
P450	I
enzymes	I
described	O
in	O
Section	O
,	O
hepatic	O
xenobiotic	O
-	O
metabolizing	O
members	O
of	O
the	O
Cytochrome	O
P450	O
superfamily	O
are	O
able	O
to	O
modify	O
steroid	O
hormones	O
and	O
generate	O
a	O
plethora	O
of	O
minor	O
steroid	O
metabolites	O
.	O

Cytochrome	B
P450	I
enzymes	I
have	O
potential	O
uses	O
in	O
the	O
synthesis	O
and	O
discovery	O
of	O
drugs	O
,	O
as	O
well	O
as	O
drug	O
development	O
.	O

Cytochrome	B
P450	I
enzymes	I
metabolize	O
thousands	O
of	O
endogenous	O
and	O
exogenous	O
chemicals	O
.	O

Cytochrome	B
P450	I
enzymes	I
are	O
bound	O
to	O
membranes	O
within	O
a	O
cell	O
and	O
contain	O
a	O
heme	O
pigment	O
that	O
absorbs	O
light	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
when	O
exposed	O
to	O
carbon	O
monoxide	O
.	O

Cytochrome	B
P450	I
enzymes	I
play	O
a	O
role	O
in	O
the	O
synthesis	O
of	O
many	O
molecules	O
including	O
steroid	O
hormones	O
,	O
certain	O
Fatty	O
Acids	O
(	O
cholesterol	O
and	O
other	O
fatty	O
acids	O
)	O
,	O
and	O
acids	O
used	O
to	O
digest	O
Fatty	O
Acids	O
(	O
bile	O
acids	O
)	O
.	O

Liver	O
mRNA	O
expression	O
of	O
Cyp1a2	O
,	O
Cyp3a11	O
(	O
human	O
CYP3A4	O
)	O
and	O
Cyp2e1	B
was	O
increased	O
in	O
mice	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
(	O
100	O
,	O
200	O
,	O
400	O
,	O
800	O
mg	O
/	O
kg	O
)	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
liver	O
mRNA	O
expression	O
of	O
Cyp1a2	O
,	O
Cyp2e1	B
and	O
Cyp3a11	O
was	O
increased	O
in	O
mice	O
treated	O
with	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
(	O
800	O
mg	O
/	O
kg	O
)	O
for	O
4	O
h	O
,	O
8	O
h	O
,	O
and	O
12	O
h	O
enhanced	O
hepatic	O
CYP1A2	O
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
CYP1A2	O
expression	O
after	O
treated	O
mice	O
for	O
8	O
h	O
and	O
12	O
h	O
enhanced	O
hepatic	O
CYP2E1	O
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
only	O
increased	O
hepatic	O
CYP2E1	O
expression	O
after	O
treated	O
mice	O
for	O
12	O
h	O
enhanced	O
hepatic	O
CYP3A4	O
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
CYP3A4	O
expression	O
after	O
treated	O
mice	O
for	O
4	O
h	O
,	O
8	O
h	O
and	O
12	O
h	O
(	O
Fig	O
.	O

Determination	O
of	O
(	O
CD	O
-	O
1	O
)	O
mouse	O
cutaneous	O
RNA	O
levels	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
showed	O
transcripts	O
arising	O
from	O
Cyp4f13	O
and	O
4f16	O
(	O
most	O
abundant	O
)	O
,	O
Cyp4f18	O
and	O
4f39	O
(	O
intermediate	O
)	O
,	O
Cyp4f14	O
,	O
4f17	O
,	O
and	O
4f37	O
(	O
low	O
)	O
,	O
and	O
from	O
Cyp4f15	O
and	O
Cyp4f40	O
(	O
highly	O
variable	O
or	O
too	O
low	O
to	O
measure	O
in	O
some	O
animals	O
)	O
(	O
Du	O
et	O
al	O
.	O
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
the	O
Cyp1a1	B
,	O
Cyp1b1	O
,	O
Cyp2e1	O
genes	O
was	O
observed	O
in	O
(	O
C57BL	O
/	O
6J	O
)	O
mouse	O
skin	O
(	O
Flowers	O
et	O
al	O
.	O
.	O
Interestingly	O
,	O
recent	O
studies	O
by	O
Borland	O
et	O
al	O
.	O

Cyp1a1	B
,	O
Cyp1b1	O
and	O
Cyp3a11	O
,	O
but	O
not	O
Ahr	O
expression	O
in	O
the	O
skin	O
also	O
were	O
enhanced	O
by	O
7	O
,	O
12	O
-	O
Dimethylbenz	O
[	O
A	O
]	O
Anthracene	O
.	O

Despite	O
a	O
lower	O
constitutive	O
expression	O
of	O
Cyp4a10	O
in	O
the	O
female	O
hearts	O
,	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
caused	O
a	O
marked	O
induction	O
of	O
Cyp4a10	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
,	O
suggesting	O
that	O
this	O
enzyme	O
may	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
sexual	O
dimorphism	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

Such	O
a	O
study	O
would	O
lead	O
to	O
a	O
better	O
knowledge	O
of	O
what	O
combination	O
of	O
amino	O
acid	O
residues	O
in	O
a	O
P450	B
enzyme	I
distinguishes	O
a	O
ligand	O
(	O
a	O
bound	O
molecule	O
that	O
not	O
reaches	O
easily	O
the	O
productive	O
step	O
of	O
the	O
catalytic	O
cycle	O
)	O
from	O
a	O
substrate	O
(	O
a	O
bound	O
molecule	O
that	O
reaches	O
the	O
productive	O
step	O
)	O
.	O

For	O
example	O
,	O
St	O
Johns	O
wort	O
induces	O
microsomal	O
cytochrome	O
P450	B
enzyme	I
-	O
mediated	O
metabolism	O
of	O
warfarin	O
,	O
particularly	O
CYP2C9	O
and	O
increases	O
warfarin	O
clearance	O
.	O

P450	O
Oxidoreductase	O
contains	O
a	O
flavin	O
adenine	O
dinucleotide	O
and	O
a	O
flavin	O
mononucleotide	O
allowing	O
the	O
enzyme	O
to	O
oxidize	O
NADPH	O
and	O
reduce	O
the	O
Cytochrome	B
P450	I
enzyme	I
in	O
a	O
stepwise	O
manner	O
.	O

CYP1A	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
health	O
in	O
the	O
body	O
.	O
Image	O
1	O
The	O
cytochrome	O
P450	B
enzyme	I
is	O
one	O
of	O
the	O
most	O
abundant	O
and	O
diverse	O
superfamilies	O
,	O
which	O
contains	O
hemoprotein	O
.	O

The	O
levels	O
and	O
ratio	O
of	O
the	O
novel	O
constituents	O
varied	O
depending	O
on	O
the	O
P450	B
enzyme	I
,	O
with	O
CYP712K1	O
favoring	O
formation	O
of	O
6	O
and	O
CYP712K2	O
favoring	O
formation	O
of	O
5	O
.	O

The	O
O	O
-	O
conformation	O
is	O
the	O
one	O
observed	O
with	O
substrate	O
-	O
free	O
P450cam	B
at	O
low	O
potassium	O
ion	O
concentration	O
.	O

To	O
be	O
helpful	O
for	O
drug	O
development	O
,	O
we	O
combined	O
the	O
descriptive	O
models	O
and	O
the	O
CBC	O
-	O
IVIVE	O
further	O
to	O
extrapolate	O
the	O
CL_H	O
of	O
probe	O
drugs	O
for	O
six	O
Cytochrome	B
P450	B
Enzymes	I
.	O

A	O
drug	O
should	O
not	O
be	O
rapidly	O
metabolized	O
by	O
Cytochrome	B
P450	B
Enzymes	I
if	O
it	O
is	O
to	O
maintain	O
an	O
effective	O
concentration	O
.	O

In	O
addition	O
,	O
it	O
should	O
not	O
inhibit	O
drug	O
-	O
metabolizing	O
Cytochrome	B
P450	B
Enzymes	I
,	O
because	O
such	O
an	O
effect	O
could	O
elevate	O
the	O
concentration	O
of	O
a	O
co	O
-	O
administered	O
drug	O
and	O
potentially	O
lead	O
to	O
drug	O
overdose	O
-	O
an	O
effect	O
known	O
as	O
a	O
drug	O
-	O
drug	O
interaction	O
(	O
Murray	O
,	O
.	O

In	O
drug	O
development	O
,	O
in	O
vitro	O
assays	O
are	O
routinely	O
used	O
to	O
assess	O
interactions	O
between	O
drug	O
candidates	O
and	O
Cytochrome	B
P450	B
Enzymes	I
.	O

However	O
,	O
there	O
is	O
a	O
need	O
for	O
in	O
silico	O
models	O
that	O
assess	O
potential	O
interactions	O
with	O
Cytochrome	B
P450	B
Enzymes	I
in	O
the	O
early	O
stages	O
of	O
drug	O
development	O
.	O

For	O
all	O
Cytochrome	B
P450	B
Enzymes	I
,	O
we	O
classified	O
inhibitors	O
and	O
non	O
-	O
inhibitors	O
as	O
positives	O
and	O
negatives	O
,	O
respectively	O
.	O

Ligand	O
Access	O
Channels	O
in	O
Cytochrome	B
P450	B
Enzymes	I
:	O
A	O
Review	O
.	O

Nevertheless	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
dual	O
effect	O
of	O
Carbon	O
Monoxide	O
on	O
cytochrome	B
c	I
oxidase	O
activity	O
is	O
not	O
yet	O
clearly	O
disclosed	O
.	O

The	O
fact	O
that	O
Carbon	O
Monoxide	O
targets	O
mitochondria	O
,	O
in	O
particular	O
cytochrome	B
c	I
oxidase	O
,	O
originates	O
several	O
consequences	O
:	O
(	O
i	O
)	O
generation	O
of	O
ROS	O
for	O
downstream	O
signaling	O
,	O
(	O
ii	O
)	O
alterations	O
in	O
oxygen	O
consumption	O
implying	O
uncoupling	O
effects	O
and	O
/	O
or	O
improvement	O
of	O
mitochondrial	O
respiration	O
and	O
ATP	O
production	O
,	O
(	O
iii	O
)	O
regulation	O
of	O
mitochondrial	O
quality	O
control	O
,	O
including	O
mitochondrial	O
biogenesis	O
,	O
Mitochondria	O
Via	O
Autophagy	O
and	O
fusion	O
/	O
fission	O
.	O

Citrate	O
synthase	O
and	O
complex	O
I	O
-	O
IV	O
activities	O
were	O
determined	O
by	O
monitoring	O
appearance	O
or	O
disappearance	O
of	O
specific	O
substrates	O
at	O
specific	O
wavelengths	O
using	O
spectrophotometry	O
(	O
eg	O
,	O
oxidation	O
of	O
NADH	O
for	O
complex	O
I	O
activity	O
at	O
340	O
nm	O
in	O
the	O
presence	O
and	O
absence	O
of	O
rotenone	O
to	O
evaluate	O
complex	O
I	O
-	O
specific	O
activity	O
,	O
reduction	O
of	O
cytochrome	B
c	I
for	O
complex	O
III	O
activity	O
at	O
550	O
nm	O
)	O
.	O

Porcine	O
deltacoronavirus	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
through	O
activation	O
of	O
the	O
cytochrome	B
c	I
-	O
mediated	O
intrinsic	O
mitochondrial	O
pathway	O
.	O

PDCoV	O
-	O
mediated	O
Mitochondrial	O
Outer	O
Membrane	O
Permeabilization	O
resulted	O
in	O
apoptogenic	O
cytochrome	B
c	I
release	O
into	O
the	O
cytoplasm	O
.	O

Mitochondrial	O
cytochrome	B
c	I
leakage	O
executed	O
apoptotic	O
cell	O
death	O
in	O
Porcine	O
Deltacoronavirus	O
infection	O
.	O

Experimental	O
data	O
indicated	O
that	O
Porcine	O
Deltacoronavirus	O
infection	O
led	O
to	O
Bax	O
-	O
mediated	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
,	O
resulting	O
in	O
specific	O
relocation	O
of	O
the	O
mitochondrial	O
cytochrome	B
c	I
(	O
cyt	O
c	O
)	O
into	O
the	O
cytoplasm	O
.	O

Antibodies	O
specific	O
for	O
cytochrome	B
c	I
(	O
cyt	O
c	O
)	O
,	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
Bax	O
,	O
Sp1	O
,	O
and	O
BETA	O
-	O
actin	O
and	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
-	O
conjugated	O
secondary	O
antibodies	O
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

In	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
,	O
confocal	O
Raman	O
microscopy	O
with	O
excitation	O
resonant	O
to	O
the	O
heme	O
c	O
moiety	O
of	O
cytochrome	B
c	I
was	O
used	O
to	O
compare	O
the	O
cytochrome	B
c	I
content	O
and	O
activity	O
of	O
stressed	O
and	O
unstressed	O
Nitrosomonas	O
europaea	O
(	O
Nm	O
50	O
)	O
,	O
Nitrosomonas	O
eutropha	O
(	O
Nm	O
57	O
)	O
,	O
Nitrosospira	O
briensis	O
(	O
Nsp	O
10	O
)	O
,	O
and	O
Nitrosospira	O
species	O
(	O
Nsp	O
02	O
)	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
cells	O
with	O
predominantly	O
ferrous	O
cytochrome	B
c	I
content	O
were	O
found	O
in	O
deprived	O
Nitrosomonas	O
eutropha	O
and	O
Nitrosospira	O
samples	O
,	O
which	O
may	O
be	O
indicative	O
of	O
ongoing	O
electron	O
storage	O
at	O
the	O
time	O
of	O
measurement	O
.	O

The	O
electron	O
transport	O
along	O
these	O
pathways	O
is	O
predominantly	O
performed	O
by	O
several	O
cytochrome	B
c	I
proteins	O
,	O
some	O
of	O
which	O
hold	O
more	O
than	O
one	O
heme	O
c	O
in	O
their	O
protic	O
matrix	O
.	O

For	O
a	O
scheme	O
of	O
the	O
electron	O
transport	O
and	O
the	O
ammonia	O
oxidation	O
pathways	O
for	O
N	O
.	O
europaea	O
,	O
including	O
the	O
associated	O
cytochrome	B
c	I
proteins	O
,	O
see	O
Sedlacek	O
et	O
al	O
.	O
.	O
A	O
comparative	O
quantitative	O
proteomic	O
study	O
of	O
growing	O
and	O
ammonia	O
-	O
starved	O
N	O
.	O
europaea	O
cells	O
by	O
Pellitteri	O
-	O
Hahn	O
et	O
al	O
.	O

found	O
that	O
energy	O
-	O
starved	O
cells	O
shifted	O
their	O
cellular	O
activity	O
from	O
biosynthesis	O
toward	O
cellular	O
survival	O
functions	O
,	O
reporting	O
a	O
significantly	O
increased	O
abundance	O
of	O
cytochrome	B
c	I
in	O
the	O
ammonia	O
-	O
starved	O
cells	O
as	O
compared	O
to	O
growing	O
cells	O
,	O
which	O
was	O
interpreted	O
as	O
a	O
cellular	O
strategy	O
for	O
a	O
rapid	O
growth	O
response	O
.	O

The	O
mRNA	O
levels	O
for	O
cytochrome	B
c	I
reported	O
by	O
Wei	O
et	O
al	O
.	O

While	O
the	O
crucial	O
enzymes	O
AMO	O
,	O
HAO	O
,	O
and	O
NOR	O
of	O
the	O
ammonia	O
oxidation	O
pathways	O
were	O
not	O
directly	O
accessible	O
with	O
Raman	O
microscopy	O
in	O
vivo	O
,	O
it	O
was	O
possible	O
to	O
target	O
the	O
cytochrome	B
c	I
responsible	O
for	O
the	O
required	O
electron	O
transport	O
along	O
these	O
pathways	O
with	O
resonance	O
Raman	O
micro	O
-	O
spectroscopy	O
,	O
a	O
technique	O
also	O
uniquely	O
positioned	O
to	O
determine	O
conformational	O
changes	O
of	O
cytochrome	B
c	I
and	O
its	O
redox	O
state	O
(	O
ferrous	O
versus	O
ferric	O
hemes	O
c	O
)	O
.	O

Hu	O
et	O
al	O
.	O
,	O
in	O
their	O
annotation	O
of	O
the	O
resonance	O
Raman	O
spectra	O
of	O
extracted	O
cytochrome	B
c	I
,	O
previously	O
reported	O
large	O
changes	O
in	O
both	O
the	O
resonant	O
excitation	O
wavelength	O
and	O
the	O
specifically	O
enhanced	O
molecular	O
vibrations	O
dependent	O
on	O
the	O
redox	O
state	O
of	O
the	O
protein	O
.	O

cm	O
^	O
1	O
,	O
which	O
at	O
532	O
nm	O
excitation	O
is	O
one	O
of	O
the	O
strongest	O
Raman	O
lines	O
in	O
ferrous	O
cytochrome	B
c	I
,	O
but	O
is	O
very	O
weak	O
if	O
the	O
protein	O
is	O
in	O
ferric	O
state	O
.	O

used	O
Raman	O
microscopy	O
with	O
cytochrome	O
-	O
c	O
-	O
resonant	O
excitation	O
at	O
532	O
nm	O
,	O
using	O
the	O
redox	O
state	O
of	O
cytochrome	B
c	I
as	O
a	O
crucial	O
indicator	O
for	O
cell	O
apoptosis	O
,	O
while	O
Kakita	O
et	O
al	O
.	O

monitored	O
photothermally	O
induced	O
mitochondrially	O
mediated	O
apoptosis	O
in	O
situ	O
based	O
on	O
the	O
Raman	O
spectrum	O
of	O
cytochrome	B
c	I
,	O
using	O
surface	O
-	O
enhanced	O
resonant	O
Raman	O
microscopy	O
with	O
gold	O
nanoparticles	O
and	O
785	O
nm	O
excitation	O
.	O

for	O
the	O
quantitative	O
detection	O
of	O
cytochrome	B
c	I
in	O
living	O
cells	O
,	O
and	O
Zhu	O
et	O
al	O
.	O

studied	O
the	O
influence	O
of	O
redox	O
state	O
on	O
cytochrome	B
c	I
release	O
in	O
apoptosis	O
using	O
Raman	O
microscopy	O
with	O
nickel	O
substrates	O
.	O

In	O
this	O
work	O
,	O
we	O
present	O
a	O
proof	O
of	O
concept	O
of	O
the	O
use	O
of	O
straightforward	O
confocal	O
Raman	O
microscopy	O
with	O
532	O
nm	O
excitation	O
,	O
resonant	O
to	O
the	O
Q	O
-	O
band	O
of	O
the	O
heme	O
c	O
moiety	O
in	O
cytochrome	B
c	I
,	O
to	O
non	O
-	O
invasively	O
and	O
in	O
vivo	O
analyze	O
the	O
response	O
of	O
four	O
species	O
of	O
AOB	O
,	O
Nitrosomonas	O
europaea	O
,	O
Nitrosomonas	O
eutropha	O
,	O
Nitrosospira	O
briensis	O
,	O
and	O
Nitrosospira	O
species	O
.	O

to	O
oxygen	O
deprivation	O
in	O
comparison	O
to	O
non	O
-	O
oxygen	O
-	O
deprived	O
cultures	O
based	O
on	O
1000	O
individual	O
cells	O
per	O
sampling	O
,	O
confirming	O
elevated	O
cytochrome	B
c	I
content	O
and	O
activity	O
following	O
oxygen	O
deprivation	O
in	O
a	O
purely	O
optical	O
measurement	O
with	O
low	O
impact	O
on	O
culture	O
volumes	O
.	O

A	O
frequency	O
-	O
doubled	O
continuous	O
-	O
wave	O
Nd	O
:	O
YAG	O
laser	O
at	O
531	O
.	O
9	O
nm	O
,	O
suitable	O
for	O
resonantly	O
enhancing	O
the	O
Q	O
-	O
band	O
of	O
the	O
heme	O
c	O
moiety	O
of	O
cytochrome	B
c	I
in	O
its	O
ferrous	O
(	O
Fe	O
^	O
2	O
+	O
)	O
state	O
,	O
was	O
used	O
for	O
excitation	O
.	O

The	O
Raman	O
lines	O
of	O
the	O
four	O
main	O
vibrations	O
of	O
resonantly	O
excited	O
cytochrome	B
c	I
,	O
_15	O
,	O
_22	O
,	O
_21	O
,	O
and	O
_19	O
at	O
750	O
,	O
1130	O
,	O
1314	O
,	O
and	O
1587	O
rel	O
.	O

This	O
fit	O
perfectly	O
with	O
the	O
results	O
of	O
Hu	O
et	O
al	O
.	O
,	O
who	O
analyzed	O
reconstituted	O
cytochrome	B
c	I
protein	O
in	O
potassium	O
phosphate	O
buffer	O
solution	O
,	O
identifying	O
the	O
lines	O
in	O
the	O
complete	O
resonance	O
Raman	O
spectra	O
of	O
ferrous	O
and	O
ferric	O
cytochrome	B
c	I
.	O
With	O
532	O
nm	O
excitation	O
,	O
they	O
found	O
the	O
Raman	O
line	O
of	O
the	O
_15	O
vibration	O
at	O
750	O
rel	O
.	O

cm	O
^	O
1	O
to	O
be	O
among	O
the	O
strongest	O
lines	O
in	O
the	O
spectrum	O
of	O
ferrous	O
cytochrome	B
c	I
,	O
but	O
among	O
the	O
weakest	O
lines	O
in	O
ferric	O
cytochrome	B
c	I
,	O
whereas	O
the	O
Raman	O
line	O
of	O
the	O
_19	O
vibration	O
at	O
1587	O
rel	O
.	O

cm	O
^	O
1	O
and	O
used	O
it	O
to	O
differentiate	O
between	O
healthy	O
and	O
apoptotic	O
and	O
pre	O
-	O
apoptotic	O
brain	O
cells	O
of	O
Mongolian	O
gerbils	O
,	O
associating	O
the	O
line	O
shift	O
with	O
cytochrome	B
c	I
deformation	O
due	O
to	O
the	O
protein	O
binding	O
to	O
membrane	O
elements	O
.	O

A	O
similar	O
observation	O
was	O
reported	O
earlier	O
by	O
Murgida	O
and	O
Hildebrandt	O
,	O
who	O
saw	O
a	O
10	O
cm	O
^	O
1	O
upshift	O
in	O
the	O
line	O
of	O
the	O
_19	O
vibration	O
in	O
ferrous	O
compared	O
to	O
ferric	O
cytochrome	B
c	I
adsorbed	O
to	O
a	O
surface	O
-	O
enhanced	O
Raman	O
active	O
substrate	O
.	O

cm	O
^	O
1	O
,	O
which	O
would	O
be	O
caused	O
by	O
such	O
a	O
shift	O
in	O
the	O
spectra	O
of	O
some	O
but	O
not	O
all	O
the	O
cytochrome	B
c	I
within	O
the	O
respective	O
cell	O
,	O
therefore	O
indicated	O
that	O
the	O
observed	O
differences	O
in	O
the	O
summarized	O
cytochrome	B
c	I
resonant	O
Raman	O
spectra	O
of	O
the	O
bacteria	O
were	O
indeed	O
primarily	O
due	O
to	O
the	O
redox	O
state	O
of	O
the	O
cytochrome	B
c	I
,	O
as	O
analyzed	O
by	O
Hu	O
et	O
al	O
.	O
,	O
and	O
thus	O
to	O
their	O
electron	O
transport	O
function	O
,	O
and	O
not	O
due	O
to	O
deformations	O
caused	O
by	O
other	O
stress	O
reactions	O
of	O
the	O
respective	O
cells	O
.	O

Therefore	O
,	O
the	O
relative	O
intensity	O
(	O
I_Raman	O
)	O
of	O
the	O
two	O
Raman	O
lines	O
(	O
relRI	O
)	O
could	O
be	O
used	O
as	O
a	O
functional	O
marker	O
for	O
the	O
summarized	O
redox	O
state	O
(	O
ferrous	O
versus	O
ferric	O
)	O
of	O
all	O
the	O
cytochrome	B
c	I
of	O
the	O
respective	O
bacterial	O
cell	O
,	O
and	O
thus	O
its	O
ongoing	O
electron	O
transport	O
activity	O
at	O
the	O
time	O
of	O
measurement	O
with	O
I_Raman	O
being	O
the	O
intensity	O
of	O
the	O
Raman	O
line	O
associated	O
with	O
the	O
respective	O
vibration	O
in	O
the	O
spectrum	O
of	O
that	O
individual	O
bacterial	O
cell	O
.	O

The	O
elevated	O
cytochrome	B
c	I
activity	O
of	O
oxygen	O
-	O
deprived	O
N	O
.	O
eutropha	O
and	O
Nitrosospira	O
fit	O
well	O
with	O
the	O
results	O
reported	O
by	O
Sedlacek	O
et	O
al	O
.	O

and	O
Pellitteri	O
-	O
Hahn	O
et	O
al	O
.	O
,	O
whose	O
works	O
indicated	O
a	O
significant	O
increase	O
in	O
the	O
cytochrome	B
c	I
content	O
of	O
stressed	O
cells	O
,	O
but	O
contradicted	O
Wei	O
et	O
al	O
.	O
,	O
who	O
reported	O
mRNA	O
levels	O
for	O
cytochrome	B
c	I
in	O
growing	O
cells	O
to	O
exceed	O
those	O
of	O
energy	O
-	O
starved	O
cells	O
by	O
a	O
factor	O
of	O
10	O
.	O

used	O
transcriptomics	O
on	O
stressed	O
N	O
.	O
europaea	O
to	O
elucidate	O
the	O
stress	O
response	O
to	O
either	O
ammonia	O
or	O
oxygen	O
limitation	O
,	O
reporting	O
that	O
the	O
transcripts	O
for	O
protein	O
-	O
encoding	O
genes	O
related	O
to	O
energy	O
production	O
and	O
conservation	O
,	O
including	O
for	O
the	O
proteins	O
AMO	O
,	O
HAO	O
,	O
and	O
NOR	O
,	O
were	O
increased	O
during	O
oxygen	O
-	O
deprived	O
growth	O
,	O
while	O
three	O
cytochrome	B
c	I
proteins	O
associated	O
with	O
the	O
ammonia	O
-	O
oxidizing	O
pathway	O
were	O
even	O
among	O
the	O
top	O
20	O
%	O
of	O
genes	O
transcribed	O
under	O
stress	O
conditions	O
.	O

Kozlowski	O
et	O
al	O
.	O
,	O
who	O
compared	O
the	O
metabolism	O
pathways	O
of	O
several	O
AOB	O
based	O
on	O
micro	O
-	O
respirometry	O
and	O
genome	O
analysis	O
,	O
confirmed	O
that	O
these	O
enzymes	O
and	O
cytochrome	B
c	I
proteins	O
are	O
encoded	O
in	O
multiple	O
copies	O
by	O
N	O
.	O
europaea	O
,	O
N	O
.	O
eutropha	O
,	O
and	O
Nitrosospira	O
,	O
including	O
the	O
associated	O
cytochrome	B
c	I
proteins	O
.	O

The	O
observed	O
differences	O
in	O
cytochrome	B
c	I
activity	O
of	O
Nitrosospira	O
briensis	O
and	O
Nitrosospira	O
species	O
(	O
Nsp	O
02	O
)	O
correlated	O
well	O
with	O
their	O
respective	O
oxygenation	O
histories	O
(	O
compare	O
.	O

Nitrosospira	O
briensis	O
has	O
been	O
reported	O
to	O
have	O
decreasing	O
AMO	O
mRNA	O
expression	O
during	O
starvation	O
,	O
but	O
to	O
rapidly	O
recover	O
after	O
starvation	O
periods	O
of	O
up	O
to	O
two	O
weeks	O
,	O
with	O
only	O
small	O
changes	O
in	O
the	O
soluble	O
proteins	O
,	O
including	O
cytochrome	B
c	I
,	O
between	O
growing	O
and	O
ammonium	O
-	O
starved	O
cells	O
.	O

However	O
,	O
the	O
relRI	O
trends	O
of	O
N	O
.	O
europaea	O
did	O
not	O
show	O
an	O
elevated	O
cytochrome	B
c	I
activity	O
indicative	O
of	O
a	O
noticeable	O
stress	O
response	O
in	O
its	O
cells	O
at	O
all	O
(	O
see	O
b	O
)	O
.	O

Interestingly	O
,	O
the	O
oxygen	O
-	O
deprived	O
N	O
.	O
eutropha	O
appeared	O
to	O
have	O
a	O
significantly	O
more	O
evenly	O
distributed	O
cytochrome	B
c	I
activity	O
,	O
with	O
its	O
relRI	O
ranging	O
from	O
1	O
.	O
7	O
to	O
1	O
.	O
9	O
,	O
than	O
non	O
-	O
deprived	O
N	O
.	O
eutropha	O
,	O
with	O
a	O
relRI	O
range	O
from	O
1	O
.	O
2	O
to	O
1	O
.	O
75	O
(	O
see	O
.	O

Since	O
cytochrome	B
-	I
c	I
-	O
resonant	O
Raman	O
spectra	O
always	O
contain	O
a	O
fluorescent	O
background	O
originating	O
from	O
the	O
cytochrome	O
itself	O
,	O
the	O
Raman	O
spectra	O
were	O
baseline	O
corrected	O
using	O
the	O
IMM	O
algorithm	O
developed	O
by	O
Koch	O
et	O
al	O
.	O
,	O
which	O
combines	O
computational	O
efficiency	O
with	O
reliable	O
maintaining	O
of	O
line	O
shapes	O
and	O
relative	O
intensities	O
against	O
the	O
background	O
of	O
strong	O
fluorescence	O
often	O
found	O
in	O
Raman	O
spectra	O
recorded	O
in	O
vivo	O
.	O

Human	O
thromboxane	O
synthase	O
belongs	O
to	O
the	O
cytochrome	B
P450	I
superfamily	I
(	O
CYP5A1	O
)	O
.	O

^	O
While	O
MCF	O
-	O
7	O
cells	O
used	O
to	O
develop	O
the	O
ER	O
-	O
Luc	O
cells	O
express	O
metabolic	O
enzymes	O
from	O
the	O
cytochrome	B
P450	I
superfamily	I
(	O
and	O
thus	O
possess	O
the	O
ability	O
for	O
endogenous	O
biotransformation	O
of	O
chemicals	O
)	O
,	O
formation	O
of	O
MBP	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
S9	O
enzymes	O
.	O

and	O
the	O
highest	O
andrographolide	O
was	O
detected	O
in	O
leaf	O
as	O
compared	O
to	O
other	O
panchang	O
(	O
Pandey	O
and	O
Mandal	O
;	O
Sharma	O
et	O
al	O
.	O
.	O
Therefore	O
,	O
some	O
other	O
isomers	O
of	O
cytochrome	B
p450	I
(	O
cytochrome	B
p450	I
98	O
,	O
cytochrome	B
p450	I
706	O
,	O
etc	O
.	O
)	O

Ellipticine	O
oxidation	O
does	O
not	O
only	O
occur	O
in	O
the	O
presence	O
of	O
the	O
coenzymes	O
of	O
POR	O
,	O
NADPH	O
,	O
but	O
also	O
in	O
the	O
presence	O
of	O
NADH	O
,	O
which	O
is	O
the	O
exclusive	O
coenzyme	O
of	O
another	O
microsomal	O
reductase	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
.	O

These	O
findings	O
demonstrated	O
that	O
cytochrome	B
b	I
_5	I
is	O
included	O
in	O
the	O
reduction	O
of	O
CYP3A4	O
catalyzed	O
both	O
by	O
the	O
NADPH	O
/	O
POR	O
system	O
and	O
a	O
system	O
consisting	O
exclusively	O
of	O
NADH	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
,	O
and	O
thus	O
also	O
without	O
any	O
participation	O
of	O
NADPH	O
and	O
POR	O
.	O

Our	O
data	O
confirmed	O
previous	O
results	O
found	O
for	O
CYP3A4	O
and	O
for	O
CYP1A1	O
that	O
NADH	O
:	O
cytochrome	B
b	I
_5	O
reductase	O
/	O
cytochrome	B
b	I
_5	O
/	O
NADH	O
can	O
replace	O
NADPH	O
/	O
POR	O
in	O
the	O
catalytic	O
cycle	O
of	O
the	O
CYP	O
reactions	O
in	O
the	O
monooxygenase	O
system	O
[	O
,	O
.	O

The	O
results	O
of	O
our	O
present	O
study	O
as	O
well	O
as	O
those	O
reported	O
previously	O
indicated	O
that	O
cytochrome	B
b	I
_5	O
can	O
play	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	O
-	O
mediated	O
oxidation	O
of	O
ellipticine	O
.	O

The	O
finding	O
that	O
cytochrome	B
b	I
_5	O
with	O
its	O
reductase	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	O
reductase	O
,	O
functions	O
as	O
an	O
exclusive	O
donor	O
for	O
both	O
electrons	O
in	O
the	O
first	O
and	O
second	O
reduction	O
steps	O
of	O
the	O
CYP3A4	O
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
opens	O
the	O
door	O
for	O
further	O
research	O
.	O

However	O
,	O
because	O
they	O
are	O
microsomes	O
(	O
particles	O
of	O
broken	O
endoplasmic	O
reticulum	O
)	O
,	O
other	O
enzymes	O
(	O
proteins	O
)	O
of	O
the	O
endoplasmic	O
reticulum	O
membrane	O
(	O
ie	O
NADH	O
:	O
cytochrome	B
b	I
_5	O
reductase	O
and	O
cytochrome	B
b	I
_5	O
)	O
are	O
also	O
expressed	O
at	O
basal	O
levels	O
in	O
these	O
Supersomes	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

We	O
also	O
utilized	O
CYP3A4	O
-	O
Supersomes	O
which	O
also	O
contained	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	O
,	O
in	O
a	O
molar	O
ratio	O
of	O
CYP3A4	O
to	O
cytochrome	B
b	I
_5	O
of	O
1	O
-	O
5	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Incubation	O
mixtures	O
used	O
to	O
study	O
the	O
ellipticine	O
metabolism	O
by	O
human	O
hepatic	O
microsomes	O
or	O
Supersomes	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
0	O
.	O
025	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
005	O
cm	O
^	O
3	O
dimethyl	O
sulfoxide	O
,	O
DMSO	O
)	O
and	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	O
.	O

The	O
incubation	O
mixtures	O
for	O
measuring	O
the	O
testosterone	O
metabolism	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
:	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
50	O
mol	O
dm	O
^	O
3	O
testosterone	O
(	O
0	O
.	O
0025	O
cm	O
^	O
3	O
of	O
stock	O
methanol	O
solution	O
per	O
incubation	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
and	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	O
.	O

Incubation	O
mixtures	O
used	O
to	O
assess	O
DNA	O
adduct	O
formation	O
by	O
ellipticine	O
contained	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	O
,	O
0	O
.	O
1	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
0075	O
cm	O
^	O
3	O
methanol	O
)	O
,	O
and	O
0	O
.	O
5	O
mg	O
of	O
calf	O
thymus	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
75	O
cm	O
^	O
3	O
as	O
described	O
previously	O
[	O
,	O
.	O

The	O
incubation	O
mixture	O
included	O
5	O
pmol	O
wild	O
-	O
type	O
CYP3A4	O
*	O
1	O
or	O
other	O
CYP3A4	O
mutants	O
,	O
5	O
pmol	O
purified	O
cytochrome	B
b5	I
,	O
lidocaine	O
and	O
100	O
mmol	O
/	O
L	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
.	O

However	O
,	O
reduction	O
of	O
CoM	O
-	O
S	O
-	O
S	O
-	O
CoB	O
is	O
catalyzed	O
by	O
a	O
membrane	O
-	O
bound	O
heterodisulfide	O
reductase	O
,	O
which	O
obtains	O
electrons	O
from	O
reduced	O
methanophenazine	O
(	O
MPhH_2	O
,	O
functionally	O
analogous	O
to	O
quinoles	O
)	O
via	O
its	O
cytochrome	B
b	I
subunit	O
,	O
which	O
is	O
coupled	O
to	O
the	O
generation	O
of	O
a	O
proton	O
motive	O
force	O
.	O

During	O
hydrogenotrophic	O
methanogenesis	O
,	O
a	O
membrane	O
-	O
bound	O
(	O
F_420	O
non	O
-	O
reducing	O
)	O
hydrogenase	O
(	O
Vho	O
)	O
oxidizes	O
H_2	O
and	O
transfers	O
electrons	O
via	O
cytochrome	B
b	I
to	O
oxidized	O
methanophenazine	O
,	O
again	O
generating	O
a	O
proton	O
motive	O
force	O
.	O

Sort	O
=	O
Bait	O
,	O
cytochromes	O
P450	O
(	O
limonene	O
6	O
-	O
monooxygenase	O
(	O
CYP2C19	O
)	O
,	O
steroid	O
-	O
20	O
,	O
22	O
-	O
lyase	O
(	O
CYP11A1	O
)	O
,	O
steroid	O
-	O
11BETA	O
-	O
hydroxylase	O
(	O
CYP11V1	O
)	O
,	O
aldosterone	O
synthase	O
(	O
CYP11B2	O
)	O
,	O
taurochenodeoxycholate	O
-	O
6ALPHA	O
-	O
monooxygenase	O
(	O
CYP3A4	O
)	O
,	O
cyclic	O
hydrocarbon	O
hydroxylase	O
(	O
CYP3A5	O
)	O
,	O
4	O
-	O
nitrophenol	O
-	O
2	O
-	O
hydroxylase	O
(	O
CYP2E1	O
)	O
,	O
microsomal	O
cytochrome	O
b5	O
(	O
CYB5A	O
)	O
,	O
NADPH	O
-	O
cytochrome	O
-	O
P450	O
-	O
reductase	O
,	O
NADPH	O
-	O
adrenodoxin	O
reductase	O
,	O
adrenodoxin	O
,	O
and	O
ferrochelatase	O
,	O
SMAD4	O
,	O
RAB27B	O
)	O
were	O
prepared	O
at	O
the	O
Institute	O
of	O
Bioorganic	O
Chemistry	O
(	O
Republic	O
of	O
Belarus	O
)	O
by	O
molecular	O
cloning	O
and	O
heterologous	O
expression	O
in	O
a	O
bacterial	O
system	O
(	O
E	O
.	O
coli	O
)	O
,	O
followed	O
by	O
purification	O
using	O
metal	O
-	O
affinity	O
and	O
ion	O
exchange	O
chromatography	O
[	O
,	O
.	O

The	O
electron	O
leakage	O
in	O
the	O
electron	O
transport	O
chain	O
during	O
respiration	O
is	O
generally	O
considered	O
as	O
the	O
main	O
source	O
of	O
mitochondrial	O
Reactive	O
Oxygen	O
Species	O
but	O
other	O
mitochondrial	O
enzymatic	O
systems	O
,	O
such	O
as	O
monoamine	O
oxidase	O
and	O
cytochrome	O
b5	O
reductase	O
in	O
the	O
outer	O
membranes	O
,	O
cytochromes	O
P450	O
enzymes	O
in	O
the	O
inner	O
membranes	O
,	O
or	O
several	O
matrix	O
enzymes	O
such	O
as	O
aconitase	O
,	O
can	O
also	O
produce	O
Reactive	O
Oxygen	O
Species	O
(	O
Andreyev	O
,	O
Kushnareva	O
,	O
Murphy	O
,	O
&	O
Starkov	O
,	O
;	O
Andreyev	O
,	O
Kushnareva	O
,	O
&	O
Starkov	O
,	O
.	O

(	O
presence	O
of	O
CYP	O
and	O
cytochrome	O
b5	O
)	O
.	O

Here	O
we	O
demonstrate	O
the	O
feasibility	O
of	O
dynamic	O
nuclear	O
polarization	O
(	O
DNP	O
)	O
magic	O
-	O
angle	O
-	O
spinning	O
NMR	O
techniques	O
,	O
along	O
with	O
a	O
judiciously	O
designed	O
stable	O
isotope	O
labeling	O
scheme	O
,	O
to	O
measure	O
atomistic	O
-	O
resolution	O
transmembrane	O
-	O
transmembrane	O
interactions	O
of	O
full	O
-	O
length	O
mammalian	O
~	O
72	O
-	O
kDa	O
cytochrome	O
P450	O
-	O
cytochrome	B
b5	I
complex	O
in	O
lipid	O
bilayers	O
.	O

Additionally	O
,	O
the	O
DNP	O
sensitivity	O
-	O
enhanced	O
two	O
-	O
dimensional	O
13C	O
/	O
13C	O
chemical	O
shift	O
correlations	O
via	O
proton	O
driven	O
spin	O
diffusion	O
provided	O
distance	O
constraints	O
to	O
characterize	O
protein	O
-	O
lipid	O
interactions	O
and	O
revealed	O
the	O
transmembrane	O
topology	O
of	O
cytochrome	B
b5	I
.	O

However	O
,	O
the	O
CYP1A1	O
protein	O
level	O
and	O
microsomal	O
EROD	B
activity	O
were	O
induced	O
by	O
B	O
(	O
a	O
)	O
P	O
in	O
the	O
liver	O
,	O
but	O
not	O
the	O
ovaries	O
.	O

Our	O
findings	O
revealed	O
that	O
neither	O
CYP1A1	O
/	O
1B1	O
protein	O
levels	O
nor	O
EROD	B
activity	O
in	O
MCF	O
-	O
7	O
cells	O
were	O
significantly	O
affected	O
by	O
protoberberines	O
at	O
a	O
non	O
-	O
cytotoxic	O
concentration	O
(	O
10	O
M	O
)	O
.	O

In	O
this	O
experiment	O
,	O
the	O
natural	O
-	O
abundance	O
^	O
13C	O
magnetizations	O
of	O
U	O
-	O
^	O
15N	O
cytochrome	O
P450	O
selected	O
by	O
the	O
^	O
15N	O
-	O
^	O
13C	O
REDOR	O
scheme	O
,	O
which	O
are	O
encoded	O
during	O
the	O
t	O
_1	O
evolution	O
,	O
and	O
are	O
subsequently	O
correlated	O
to	O
the	O
neighboring	O
^	O
13C	O
nuclei	O
of	O
selectively	O
^	O
13C	O
-	O
labeled	O
cytochrome	B
b_5	I
during	O
a	O
long	O
PDSD	O
mixing	O
time	O
(	O
~	O
3	O
s	O
)	O
in	O
order	O
to	O
obtain	O
the	O
^	O
13C	O
-	O
^	O
13C	O
chemical	O
shift	O
correlation	O
shown	O
in	O
Fig	O
.	O

Purified	O
labeled	O
proteins	O
,	O
both	O
rabbit	O
cytochrome	B
b_5	I
and	O
cytochrome	O
2B4	O
,	O
were	O
first	O
assembled	O
into	O
a	O
complex	O
,	O
and	O
then	O
reconstituted	O
into	O
DMPC	O
lipid	O
bilayers	O
hydrated	O
with	O
AMUPol	O
solutions	O
containing	O
[	O
D_8	O
]	O
glycerol	O
/	O
D_2O	O
/	O
H_2O	O
(	O
60	O
:	O
30	O
:	O
10	O
volume	O
ratio	O
)	O
as	O
described	O
in	O
the	O
materials	O
and	O
methods	O
section	O
.	O

The	O
full	O
-	O
length	O
cytochrome	O
P450	O
2B4	O
is	O
known	O
to	O
form	O
the	O
functional	O
complex	O
with	O
the	O
second	O
electron	O
donor	O
,	O
cytochrome	B
b_5	I
,	O
in	O
lipid	O
bilayer	O
environments	O
as	O
confirmed	O
by	O
the	O
alternation	O
of	O
spin	O
states	O
,	O
termed	O
type	O
I	O
spectral	O
changes	O
under	O
the	O
sample	O
preparation	O
in	O
this	O
study	O
^	O
,	O
.	O

At	O
these	O
cryogenic	O
temperatures	O
,	O
cytochrome	B
b_5	I
maintains	O
its	O
topology	O
and	O
ALPHA	O
-	O
helical	O
structure	O
in	O
the	O
transmembrane	O
region	O
,	O
hence	O
the	O
functional	O
transmembrane	O
complex	O
of	O
cytochromes	O
can	O
be	O
retained	O
under	O
the	O
experimental	O
conditions	O
employed	O
in	O
this	O
study	O
.	O

These	O
structural	O
constraints	O
from	O
transmembrane	O
-	O
transmembrane	O
interactions	O
obtained	O
from	O
DNP	O
-	O
MAS	O
-	O
ssNMR	O
spectroscopy	O
allow	O
us	O
to	O
construct	O
a	O
structural	O
model	O
for	O
the	O
full	O
-	O
length	O
cytochrome	O
P450	O
-	O
cytochrome	B
b_5	I
complex	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

In	O
this	O
structural	O
model	O
,	O
high	O
-	O
resolution	O
NMR	O
structure	O
of	O
the	O
full	O
-	O
length	O
rabbit	O
cytochrome	B
b_5	I
in	O
lipid	O
bilayers	O
,	O
soluble	O
domain	O
interactions	O
,	O
and	O
the	O
transmembrane	O
ALPHA	O
-	O
helix	O
of	O
cytochrome	O
P450	O
were	O
obtained	O
from	O
our	O
previous	O
studies	O
^	O
,	O
.	O

According	O
to	O
these	O
studies	O
,	O
the	O
molecular	O
interactions	O
in	O
the	O
soluble	O
domains	O
of	O
cytochromes	O
exhibit	O
dynamic	O
encounter	O
complexes	O
mediated	O
by	O
both	O
hydrophobic	O
and	O
electrostatic	O
interactions	O
with	O
multiple	O
complex	O
formations	O
,	O
which	O
were	O
explained	O
through	O
the	O
mutagenesis	O
studies	O
and	O
line	O
-	O
broadening	O
of	O
unformly	O
-	O
^	O
15N	O
labeled	O
cytochrome	B
b_5	I
using	O
solution	O
NMR	O
spectroscopy	O
^	O
.	O

In	O
fact	O
,	O
based	O
on	O
our	O
reported	O
complex	O
structural	O
model	O
in	O
the	O
soluble	O
domain	O
,	O
some	O
labeled	O
positions	O
(	O
eg	O
,	O
Leu41	O
,	O
Ala59	O
,	O
Val66	O
,	O
Ala72	O
,	O
and	O
Leu75	O
)	O
can	O
be	O
close	O
to	O
the	O
cytochrome	O
P450	O
-	O
cytochrome	B
b_5	I
complex	O
interface	O
^	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
highly	O
conserved	O
LxxxL	O
motif	O
between	O
L121	O
and	O
L125	O
was	O
observed	O
in	O
the	O
amino	O
acid	O
sequences	O
of	O
cytochrome	B
b_5	I
from	O
various	O
eukaryotes	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

Based	O
on	O
previous	O
in	O
vitro	O
studies	O
,	O
cytochrome	B
P450	I
3A4	I
(	O
CYP3A4	O
)	O
has	O
been	O
regarded	O
as	O
the	O
main	O
CYP	O
isoform	O
responsible	O
for	O
the	O
de	O
-	O
ethylation	O
of	O
lidocaine	O
to	O
its	O
primary	O
metabolite	O
,	O
MEGX	O
.	O
,	O
CYP3A4	O
,	O
as	O
a	O
member	O
of	O
P450	O
enzyme	O
superfamily	O
,	O
is	O
the	O
most	O
important	O
drug	O
-	O
metabolizing	O
enzyme	O
in	O
human	O
liver	O
and	O
gastrointestinal	O
tract	O
.	O

Various	O
molecules	O
such	O
as	O
heme	O
,	O
fatty	O
acid	O
2	O
-	O
hydroxylase	O
,	O
cytochrome	B
P	I
-	I
450	I
enzymes	O
,	O
insulin	O
receptor	O
,	O
epidermal	O
growth	O
factor	O
receptor	O
,	O
Erbb2	O
,	O
and	O
membrane	O
progestin	O
receptor	O
ALPHA	O
(	O
mPRALPHA	O
,	O
PAQR7	O
)	O
can	O
interact	O
and	O
associate	O
with	O
Pgrmc1	O
.	O

Similarly	O
,	O
the	O
blue	O
light	O
induced	O
the	O
expression	O
of	O
putative	O
LDA	O
enzymes	O
including	O
aryl	O
-	O
alcohol	O
dehydrogenase	O
(	O
XLOC_008717	O
)	O
,	O
pyranose	O
2	O
-	O
oxidase	O
(	O
XLOC_009983	O
)	O
,	O
and	O
monooxygenase	O
(	O
XLOC_003435	O
)	O
and	O
the	O
red	O
light	O
influenced	O
the	O
expression	O
of	O
cytochrome	B
P	I
-	I
450	I
(	O
XLOC_007791	O
,	O
XLOC_00671	O
,	O
XLOC_006683	O
,	O
XLOC_001969	O
,	O
and	O
XLOC_007717	O
)	O
.	O

Cytochrome	B
c	I
release	O
from	O
the	O
mitochondria	O
to	O
the	O
cytoplasm	O
is	O
a	O
crucial	O
event	O
,	O
which	O
activates	O
metacaspase	O
,	O
thereby	O
inducing	O
apoptosis	O
(	O
Wu	O
et	O
al	O
.	O
,	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
Rabbit	O
anti	O
-	O
LC3B	O
antibody	O
(	O
PM063	O
)	O
from	O
MBL	O
,	O
Nagoya	O
,	O
Japan	O
;	O
rabbit	O
anti	O
-	O
PINK1	O
(	O
BC100	O
-	O
494	O
)	O
,	O
rabbit	O
anti	O
-	O
Parkin	O
(	O
NB100	O
-	O
91921	O
)	O
,	O
and	O
mouse	O
anti	O
-	O
p62	O
(	O
H00008878	O
-	O
M01	O
)	O
antibodies	O
from	O
Novus	O
Biologicals	O
(	O
Briarwood	O
Avenue	O
,	O
Building	O
IV	O
Centennial	O
,	O
CO	O
,	O
USA	O
)	O
;	O
goat	O
anti	O
-	O
pan	O
-	O
cathepsin	O
(	O
sc	O
-	O
6499	O
)	O
,	O
mouse	O
anti	O
-	O
Parkin	O
(	O
sc	O
-	O
32282	O
)	O
,	O
mouse	O
anti	O
-	O
Actin	O
(	O
sc	O
-	O
47778	O
)	O
,	O
and	O
mouse	O
anti	O
-	O
cytochrome	O
c	O
(	O
7H8	O
)	O
:	O
(	O
sc	O
-	O
13560	O
)	O
antibodies	O
from	O
Santa	O
Cruz	O
Biologicals	O
(	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
;	O
rabbit	O
anti	O
-	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
and	O
rabbit	O
anti	O
-	O
iNOS	O
(	O
ab15323	O
)	O
antibodies	O
from	O
Abcam	O
Biologicals	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
;	O
rabbit	O
anti	O
-	O
TFEB	O
(	O
MBS9125929	O
)	O
from	O
MyBioSource	O
Biologicals	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
;	O
and	O
rabbit	O
anti	O
-	O
Cytochrome	B
c	I
oxidase	O
(	O
COX	O
)	O
IV	O
(	O
3E11	O
)	O
from	O
cell	O
signaling	O
Biologicals	O
(	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Cytochrome	B
c	I
showed	O
a	O
significant	O
response	O
to	O
Bombyx	O
Mori	O
Nucleopolyhedrovirus	O
infection	O
in	O
our	O
previous	O
transcriptome	O
study	O
.	O

In	O
addition	O
,	O
the	O
blood	O
circulation	O
time	O
of	O
Mycophenolic	O
Acid	O
also	O
increased	O
by	O
QC	O
through	O
inhibition	O
of	O
Mycophenolic	O
Acid	O
metabolism	O
mediated	O
by	O
cytochrome	B
P450	I
enzyme	I
as	O
discussed	O
blow	O
in	O
pharmacokinetic	O
analysis	O
.	O

Importantly	O
,	O
common	O
functional	O
polymorphisms	O
in	O
CYP2B6	B
alter	O
enzyme	O
activity	O
in	O
a	O
substratedependent	O
manner	O
,	O
,	O
and	O
thus	O
it	O
is	O
important	O
to	O
evaluate	O
these	O
enzyme	O
variants	O
for	O
any	O
CYP2B6	B
substrate	O
.	O

The	O
differences	O
we	O
report	O
,	O
both	O
for	O
(	O
S	O
)	O
nicotine	O
and	O
(	O
R	O
)	O
nicotine	O
,	O
confirm	O
the	O
expectation	O
of	O
altered	O
activities	O
for	O
common	O
variants	O
including	O
CYP2B6	B
.	O
6	O
and	O
CYP2B6	B
.	O
9	O
,	O
relative	O
to	O
the	O
reference	O
allele	O
enzyme	O
,	O
CYP2B6	B
.	O
1	O
.	O

Of	O
particular	O
interest	O
are	O
the	O
differences	O
in	O
activity	O
related	O
to	O
the	O
two	O
amino	O
acid	O
changes	O
,	O
Q172H	O
and	O
K262R	O
,	O
which	O
individually	O
define	O
the	O
CYP2B6	B
*	O
9	O
and	O
CYP2B6	B
*	O
4	O
variants	O
respectively	O
,	O
and	O
together	O
define	O
the	O
very	O
common	O
CYP2B6	B
*	O
6	O
haplotype	O
.	O

For	O
most	O
substrates	O
,	O
activity	O
of	O
the	O
CYP2B6	B
.	O
9	O
variant	O
is	O
exceptionally	O
low	O
,	O
activity	O
of	O
the	O
CYP2B6	B
.	O
4	O
variant	O
is	O
similar	O
or	O
greater	O
than	O
that	O
of	O
the	O
reference	O
allele	O
,	O
while	O
the	O
activity	O
of	O
CYP2B6	B
.	O
6	O
lies	O
between	O
CYP2B6	B
.	O
4	O
and	O
CYP2B6	B
.	O
9	O
,	O
depending	O
on	O
substrate	O
.	O
,	O
This	O
demonstrates	O
that	O
the	O
K262R	O
amino	O
acid	O
change	O
can	O
partially	O
compensate	O
for	O
the	O
Q172H	O
lossoffunction	O
,	O
depending	O
on	O
substrate	O
,	O
and	O
we	O
find	O
this	O
to	O
be	O
the	O
case	O
for	O
nicotine	O
as	O
well	O
.	O

CYP2B6	B
*	O
6	O
is	O
the	O
most	O
commonly	O
studied	O
variant	O
haplotype	O
because	O
of	O
its	O
high	O
population	O
frequency	O
and	O
has	O
been	O
associated	O
with	O
low	O
activity	O
in	O
vivo	O
.	O
,	O
However	O
,	O
it	O
is	O
also	O
important	O
to	O
note	O
that	O
part	O
of	O
this	O
loss	O
of	O
activity	O
may	O
be	O
due	O
to	O
differences	O
in	O
mRNA	O
or	O
protein	O
expression	O
or	O
splicing	O
,	O
and	O
not	O
strictly	O
related	O
to	O
catalytic	O
activity	O
.	O
,	O
CYP2B6	B
*	O
6	O
(	O
and	O
CYP2B6	B
*	O
9	O
)	O
have	O
also	O
been	O
reportedly	O
associated	O
with	O
more	O
rapid	O
in	O
vivo	O
nicotine	O
metabolism	O
.	O

The	O
genes	O
that	O
are	O
overexpressed	O
in	O
Theca	O
cells	O
(	O
cluster	O
4	O
)	O
are	O
particularly	O
involved	O
in	O
cholesterol	O
import	O
(	O
SCARB1	O
,	O
STARD5	O
)	O
,	O
bile	O
acid	O
metabolism	O
(	O
CH25H	O
)	O
,	O
HDL	O
-	O
mediated	O
lipid	O
transport	O
(	O
APOA1	O
,	O
PLTP	O
,	O
SCARB1	O
)	O
,	O
lipid	O
degradation	O
(	O
LPL	O
,	O
PLIN5	O
)	O
,	O
and	O
steroidogenesis	O
(	O
CYP27A	O
,	O
CYP7B1	O
,	O
TM7SF2	O
)	O
.	O

Numerous	O
oxidative	O
metabolic	O
functions	O
were	O
identified	O
in	O
these	O
bins	O
,	O
including	O
oxygen	O
respiration	O
,	O
thiosulfate	O
oxidation	O
through	O
the	O
Sox	O
pathway	O
and	O
metal	O
oxidation	O
via	O
multiheme	O
cytochrome	B
C	I
.	O
A	O
strong	O
metabolic	O
potential	O
for	O
degradation	O
of	O
various	O
organic	O
compounds	O
,	O
including	O
urea	O
,	O
hydrocarbons	O
and	O
aromatic	O
compounds	O
was	O
also	O
identified	O
.	O

Apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
increased	O
,	O
and	O
cell	O
viability	O
decreased	O
following	O
bubble	O
contact	O
for	O
10	O
,	O
20	O
or	O
30	O
minutes	O
,	O
but	O
not	O
for	O
1	O
or	O
5	O
minutes	O
.	O

Cell	O
viability	O
,	O
apoptosis	O
rate	O
and	O
expressions	O
of	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
were	O
determined	O
prior	O
to	O
the	O
experiment	O
for	O
assessing	O
endothelial	O
function	O
at	O
12	O
hours	O
following	O
bubble	O
contact	O
.	O

We	O
showed	O
an	O
effective	O
targeting	O
and	O
Cytochrome	B
P450	I
3a4	I
inhibition	O
following	O
intravenous	O
injection	O
of	O
PLGA	O
-	O
Ga	O
Bergamottin	O
nanoparticles	O
.	O

The	O
results	O
demonstrate	O
that	O
cytochrome	B
b	I
5	I
plays	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	O
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
:	O
(	O
1	O
)	O
cytochrome	B
b	I
5	I
mediates	O
CYP3A4	O
catalytic	O
activities	O
by	O
donating	O
the	O
first	O
and	O
second	O
electron	O
to	O
this	O
enzyme	O
in	O
its	O
catalytic	O
cycle	O
,	O
indicating	O
that	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
can	O
substitute	O
NADPH	O
-	O
dependent	O
POR	O
in	O
this	O
enzymatic	O
reaction	O
and	O
(	O
2	O
)	O
cytochrome	B
b	I
5	I
can	O
act	O
as	O
an	O
allosteric	O
modifier	O
of	O
the	O
CYP3A4	O
oxygenase	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
function	O
of	O
cytochrome	B
b	I
_5	I
in	O
this	O
reaction	O
is	O
complex	O
.	O

We	O
found	O
that	O
oxidation	O
of	O
ellipticine	O
by	O
human	O
CYP3A4	O
in	O
the	O
natural	O
microsomal	O
system	O
of	O
human	O
liver	O
or	O
in	O
Supersomes	O
,	O
where	O
the	O
reductases	O
POR	O
and	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
are	O
expressed	O
,	O
is	O
enhanced	O
by	O
cytochrome	B
b	I
_5	I
.	O

Cyp1a2	B
Knockout	O
mice	O
liver	O
cDNA	O
microarray	O
analysis	O
showed	O
that	O
Cyp1a2	B
deficiency	O
affected	O
insulin	O
function	O
,	O
lipogenesis	O
,	O
fatty	O
acid	O
biosynthesis	O
and	O
cholesterol	O
biosynthesis	O
.	O

A	O
higher	O
expression	O
of	O
Cyp3a11	O
in	O
female	O
mice	O
than	O
males	O
was	O
reported	O
earlier	O
(	O
;	O
.	O

Sort	O
=	O
Bait	O
CYP11B2	B
complex	O
formation	O
was	O
a	O
new	O
and	O
unexpected	O
result	O
,	O
since	O
CYP11B2	B
was	O
not	O
identified	O
as	O
a	O
protein	O
partner	O
of	O
Https	O
:	O
/	O
/	O
Thebiogrid	O
.	O
org	O
/	O
112778	O
/	O
Summary	O
/	O
Homo	O
-	O
Sapiens	O
/	O
Tbxas1	O
.	O
Html	O
?	O

These	O
data	O
are	O
quite	O
comparable	O
,	O
they	O
are	O
not	O
due	O
to	O
the	O
false	O
-	O
negative	O
results	O
of	O
molecular	O
fishing	O
,	O
and	O
can	O
be	O
explained	O
in	O
terms	O
of	O
the	O
tissue	O
-	O
specific	O
CYP11B2	B
expression	O
profile	O
(	O
preferential	O
expression	O
in	O
the	O
adrenal	O
tissue	O
)	O
,	O
which	O
appears	O
from	O
the	O
information	O
in	O
the	O
open	O
Internet	O
resources	O
Proteinatlas	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
proteinatlas	O
.	O
org	O
)	O
and	O
Genecards	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genecards	O
.	O
org	O
)	O
and	O
publications	O
[	O
38	O
]	O
.	O

Sort	O
=	O
Bait	O
and	O
CYP11B2	B
.	O

CYP11A1	B
performs	O
the	O
22R	O
-	O
C	O
hydroxylation	O
of	O
cholesterol	O
,	O
followed	O
by	O
20R	O
-	O
C	O
hydroxylation	O
(	O
B	O
)	O
.	O

CYP11A1	B
displays	O
a	O
cavity	O
,	O
called	O
a	O
sterol	O
-	O
binding	O
pocket	O
,	O
which	O
interacts	O
with	O
the	O
3BETA	O
-	O
hydroxyl	O
group	O
of	O
cholesterol	O
.	O

A	O
major	O
difference	O
between	O
CYP11A1	B
and	O
CYP90B1	O
is	O
the	O
stereo	O
specificity	O
.	O

Finally	O
,	O
CYP11B1	B
,	O
located	O
in	O
the	O
mitochondria	O
of	O
the	O
zona	O
fasciculata	O
cells	O
,	O
facilitates	O
the	O
final	O
step	O
in	O
glucocorticoid	O
biosynthesis	O
by	O
catalyzing	O
the	O
conversion	O
of	O
11	O
-	O
deoxycortisol	O
to	O
cortisol	O
.	O

Treatment	O
of	O
resveratrol	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
,	O
ellipticine	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
,	O
or	O
tryptamine	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
significantly	O
reduced	O
the	O
viral	O
load	O
in	O
CCS	O
-	O
EVs	O
exposed	O
U1	O
cells	O
,	O
suggesting	O
the	O
role	O
of	O
CYP	B
1A1	I
and	O
2A6	O
,	O
and	O
oxidative	O
stress	O
on	O
viral	O
load	O
increase	O
in	O
U1	O
cells	O
(	O
A	O
,	O
B	O
)	O
.	O

These	O
results	O
indicated	O
allele	O
A	O
and	O
H	O
of	O
mitochondrial	O
cytochrome	B
B	I
gene	O
may	O
be	O
predominant	O
in	O
animals	O
with	O
the	O
high	O
or	O
low	O
replicative	O
pattern	O
of	O
WHV	O
infection	O
,	O
respectively	O
.	O

All	O
of	O
the	O
animals	O
belong	O
to	O
the	O
same	O
subspecies	O
M	O
.	O
himalayana	O
robusta	O
identified	O
by	O
the	O
analysis	O
of	O
mitochondrial	O
cytochrome	B
B	I
sequences	O
.	O

Based	O
on	O
the	O
profiles	O
of	O
the	O
nucleotide	O
substitutions	O
,	O
eight	O
different	O
alleles	O
of	O
mitochondrial	O
cytochrome	B
B	I
gene	O
were	O
identified	O
in	O
the	O
animals	O
used	O
in	O
this	O
study	O
.	O

Estrogen	O
deficiency	O
in	O
men	O
with	O
mutations	O
in	O
the	O
gene	O
codifying	O
for	O
aromatase	O
(	O
CYP19A1	O
,	O
the	O
enzyme	O
converting	O
testosterone	O
in	O
estrogen	O
)	O
show	O
impaired	O
glucose	O
and	O
lipid	O
liver	O
metabolism	O
(	O
,	O
.	O

Thus	O
,	O
CYP2B1	B
and	O
CYP2C11	O
,	O
in	O
cultured	O
rat	O
hepatocytes	O
treated	O
with	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
inhibitors	O
[	O
3	O
-	O
methyladenine	O
(	O
3MA	O
)	O
/	O
NH_4Cl	O
]	O
or	O
heterologously	O
expressed	O
in	O
a	O
vacuolar	O
(	O
lysosomal	O
)	O
degradation	O
-	O
deficient	O
S	O
.	O
cerevisiae	O
strain	O
,	O
are	O
stabilized	O
relative	O
to	O
those	O
expressed	O
in	O
wild	O
-	O
type	O
or	O
proteasomal	O
-	O
subunit	O
defective	O
strains	O
,	O
.	O

Elevated	O
levels	O
of	O
miRs	O
,	O
including	O
miR	O
-	O
21	O
,	O
can	O
contribute	O
to	O
the	O
post	O
-	O
transcriptional	O
downregulation	O
of	O
ovary	O
CYP1A1	B
protein	I
expression	O
.	O

Although	O
one	O
immunoblot	O
showed	O
a	O
weak	O
to	O
mild	O
elevation	O
in	O
CYP1A1	B
protein	I
in	O
MCF	O
-	O
7	O
cells	O
exposed	O
to	O
10	O
-	O
40	O
M	O
berberine	O
for	O
48	O
h	O
,	O
the	O
statistical	O
significance	O
has	O
not	O
been	O
proven	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
and	O
PROD	B
activities	O
were	O
increased	O
by	O
treatment	O
with	O
3	O
-	O
methylcholanthrene	O
,	O
while	O
PROD	B
and	O
7	O
-	O
methoxy	O
-	O
4	O
-	O
trifluoromethylcoumarin	O
O	O
-	O
dealkylase	O
activities	O
remained	O
undetected	O
even	O
after	O
treatment	O
with	O
CITCO	O
(	O
6	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
imidazo	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
[	O
1	O
,	O
3	O
]	O
thiazole	O
-	O
5	O
-	O
carbaldehyde	O
-	O
O	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorobenzyl	O
)	O
oxime	O
)	O
or	O
rifampicin	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
PROD	B
or	O
BROD	B
activities	O
(	O
LOD	O
1	O
,	O
4	O
and	O
1	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
)	O
.	O

Paliperidone	O
is	O
not	O
metabolized	O
by	O
CYP	B
2D6	I
cytochrome	O
system	O
.	O

Considering	O
the	O
ability	O
of	O
CYP26B1	B
to	O
metabolize	O
retinoic	O
acid	O
,	O
there	O
is	O
support	O
for	O
the	O
observed	O
effect	O
of	O
rs62150087	O
on	O
worse	O
patient	O
survival	O
.	O

The	O
involvement	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
in	O
electron	O
transfer	O
reactions	O
of	O
PSII	O
indicates	O
that	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
is	O
a	O
redox	O
active	O
component	O
that	O
can	O
potentially	O
reduce	O
O_2	O
.	O

It	O
has	O
been	O
shown	O
that	O
fast	O
,	O
dark	O
reoxidation	O
of	O
the	O
PQ	O
pool	O
in	O
thylakoid	O
membranes	O
is	O
not	O
caused	O
by	O
direct	O
oxidation	O
of	O
PQH_2	O
by	O
O_2	O
,	O
and	O
it	O
was	O
suggested	O
that	O
the	O
Low	O
Potential	O
form	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
can	O
transfer	O
an	O
electron	O
to	O
O_2	O
and	O
thereby	O
act	O
as	O
a	O
PQH_2	O
:	O
O_2	O
oxidoreductase	O
.	O

In	O
isolated	O
PSII	O
membranes	O
,	O
O_2	O
has	O
been	O
shown	O
to	O
compete	O
with	O
prenylquinones	O
for	O
oxidation	O
of	O
the	O
Low	O
Potential	O
form	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
,	O
suggesting	O
that	O
Low	O
Potential	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
can	O
form	O
O_2	O
^	O
.	O

This	O
finding	O
was	O
interpreted	O
to	O
indicate	O
that	O
these	O
quinones	O
reduce	O
Low	O
Potential	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
,	O
which	O
then	O
undergoes	O
spontaneous	O
autoxidation	O
,	O
resulting	O
in	O
O_2	O
^	O
formation	O
.	O

However	O
,	O
the	O
reduction	O
in	O
O_2	O
by	O
Low	O
Potential	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
is	O
thermodynamically	O
unfavorable	O
,	O
taking	O
into	O
account	O
that	O
the	O
redox	O
potential	O
of	O
the	O
Low	O
Potential	O
form	O
is	O
usually	O
within	O
20	O
-	O
110	O
mV	O
in	O
untreated	O
membranes	O
,	O
although	O
sometimes	O
an	O
Low	O
Potential	O
form	O
with	O
a	O
negative	O
potential	O
is	O
observed	O
.	O

The	O
CDS	O
sequence	O
of	O
Bombyx	O
Mori	O
Cytc	O
and	O
those	O
in	O
other	O
species	O
were	O
derived	O
from	O
NCBI	O
,	O
which	O
were	O
used	O
to	O
analyze	O
the	O
evolutionary	O
relationships	O
of	O
Cytochrome	B
C	I
among	O
different	O
species	O
.	O

The	O
homologous	O
gene	O
sequences	O
of	O
Bombyx	O
Mori	O
Cytc	O
in	O
M	O
.	O
musculus	O
and	O
Arabidopsis	O
shared	O
a	O
low	O
sequence	O
identity	O
with	O
Bombyx	O
Mori	O
Cytc	O
,	O
indicating	O
that	O
Cytochrome	B
C	I
gene	O
in	O
the	O
earlier	O
species	O
might	O
have	O
diverged	O
before	O
the	O
appearance	O
of	O
these	O
orders	O
during	O
evolution	O
.	O

The	O
most	O
active	O
compound	O
,	O
12n	O
,	O
fitted	O
the	O
active	O
sites	O
of	O
CYP17A1	O
(	O
6CIZ	O
)	O
well	O
.	O

The	O
X	O
-	O
ray	O
structures	O
and	O
data	O
of	O
protein	O
targets	O
were	O
obtained	O
from	O
the	O
protein	O
data	O
bank	O
(	O
www	O
.	O
rcsb	O
.	O
org	O
)	O
:	O
CYP17A1	O
(	O
17a	O
-	O
hydroxylase	O
/	O
C17	O
,	O
20	O
-	O
lyase	O
,	O
Protein	O
Data	O
Bank	O
ID	O
:	O
6CIZ	O
,	O
6CHI	O
,	O
6CIR	O
,	O
5UYS	O
,	O
4NKZ	O
,	O
4NKX	O
,	O
4NKV	O
,	O
4NKW	O
,	O
and	O
3RUK	O
)	O
and	O
CYP19A1	O
(	O
aromatase	O
,	O
Protein	O
Data	O
Bank	O
ID	O
:	O
3S7S	O
)	O
.	O

Interestingly	O
,	O
enzymes	O
with	O
20BETA	O
-	O
HSD	O
and	O
17	B
,	I
20	I
-	I
lyase	I
activity	O
have	O
been	O
recently	O
identified	O
in	O
a	O
microbial	O
inhabitant	O
of	O
the	O
urinary	O
tract	O
.	O

Only	O
three	O
enzymes	O
(	O
CYP27A1	O
,	O
CYP46A1	B
,	O
and	O
SOAT1	O
)	O
metabolize	O
intracellular	O
(	O
unesterified	O
)	O
cholesterol	O
in	O
the	O
retina	O
with	O
retinal	O
cholesterol	O
content	O
being	O
almost	O
doubled	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	O
^	O
/	O
mice	O
and	O
normal	O
in	O
Soat1	O
^	O
/	O
mice	O
.	O

Similarly	O
,	O
by	O
generating	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
we	O
expected	O
an	O
additive	O
genotype	O
effect	O
due	O
to	O
simultaneous	O
blockage	O
of	O
the	O
two	O
major	O
pathways	O
of	O
retinal	O
cholesterol	O
output	O
-	O
cholesterol	O
removal	O
via	O
metabolism	O
(	O
CYP27A1	O
and	O
CYP46A1	B
)	O
and	O
Lipoprotein	O
Particles	O
containing	O
Apolipoprotein	O
E	O
which	O
accepts	O
cholesterol	O
effluxed	O
from	O
cells	O
.	O

However	O
,	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
retina	O
had	O
lower	O
,	O
not	O
higher	O
,	O
total	O
cholesterol	O
levels	O
than	O
the	O
Apoe	O
^	O
/	O
retina	O
(	O
B	O
)	O
,	O
also	O
an	O
indication	O
of	O
the	O
compensatory	O
responses	O
.	O

The	O
levels	O
of	O
lathosterol	O
were	O
decreased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
as	O
compared	O
to	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
retina	O
,	O
and	O
both	O
sterols	O
were	O
decreased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
retina	O
as	O
compared	O
to	O
the	O
Apoe	O
^	O
/	O
retina	O
(	O
C	O
,	O
D	O
)	O
.	O

These	O
decreases	O
suggested	O
that	O
the	O
retinal	O
cholesterol	O
biosynthesis	O
is	O
decreased	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
and	O
represents	O
a	O
compensatory	O
response	O
to	O
the	O
triple	O
gene	O
ablations	O
.	O

Next	O
,	O
we	O
assessed	O
the	O
apolipoprotein	O
-	O
mediated	O
retinal	O
cholesterol	O
traffic	O
by	O
measuring	O
the	O
mRNA	O
for	O
different	O
apolipoproteins	O
and	O
conducting	O
retinal	O
proteomics	O
on	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
mice	O
(	O
;	O
.	O

Rather	O
,	O
retinal	O
proteomics	O
pointed	O
to	O
enhanced	O
vesicle	O
formation	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
as	O
an	O
expression	O
of	O
7	O
proteins	O
from	O
the	O
endosomal	O
,	O
secretory	O
,	O
and	O
protrusion	O
formation	O
pathways	O
(	O
CHGA	O
,	O
HDAC6	O
,	O
PAFAH1B	O
,	O
SEPT6	O
,	O
SRP19	O
,	O
TAGLN2	O
,	O
and	O
TAGLN3	O
,	O
)	O
was	O
increased	O
in	O
the	O
former	O
.	O

Membrane	O
-	O
associated	O
rapid	O
response	O
steroid	O
-	O
binding	O
proteins	O
,	O
such	O
as	O
GRP58	O
,	O
ERp57	O
,	O
ERp60	O
,	O
and	O
Pdia3	O
^	O
,	O
could	O
be	O
involved	O
in	O
calcium	O
absorption	O
in	O
the	O
small	O
intestine	O
,	O
and	O
it	O
is	O
presumed	O
that	O
the	O
remarkable	O
difference	O
in	O
the	O
plasma	O
calcium	O
concentration	O
between	O
Vdr	O
(	O
R270L	O
)	O
rats	O
and	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
based	O
on	O
the	O
Vdr	O
-	O
independent	O
effects	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
.	O

As	O
with	O
Vdr	O
(	O
R270L	O
)	O
rats	O
,	O
administration	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
exerted	O
pronounced	O
effects	O
on	O
Cyp27b1	B
-	O
KO	O
rats	O
,	O
resulting	O
in	O
normalization	O
of	O
plasma	O
calcium	O
and	O
Parathyroid	O
Hormone	O
levels	O
,	O
osteogenesis	O
,	O
and	O
infertility	O
in	O
females	O
.	O

However	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
was	O
detected	O
in	O
the	O
blood	O
of	O
Cyp27b1	B
-	O
KO	O
rats	O
at	O
the	O
same	O
levels	O
as	O
in	O
wild	O
-	O
type	O
rats	O
.	O

As	O
described	O
in	O
our	O
previous	O
study	O
,	O
the	O
generation	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
following	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
was	O
also	O
observed	O
in	O
Cyp27b1	B
-	O
KO	O
mice	O
^	O
.	O

1ALPHA	O
-	O
Hydroxylase	O
activity	O
toward	O
25	O
(	O
OH	O
)	O
D_3	O
in	O
a	O
liver	O
mitochondrial	O
fraction	O
prepared	O
from	O
Cyp27b1	B
-	O
KO	O
rats	O
suggested	O
that	O
Cyp27a1	O
,	O
a	O
1ALPHA	O
-	O
hydroxylase	O
abundant	O
in	O
the	O
liver	O
,	O
is	O
most	O
likely	O
responsible	O
for	O
the	O
generation	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
.	O

It	O
should	O
be	O
noted	O
that	O
25	O
(	O
OH	O
)	O
D_3	O
administration	O
is	O
highly	O
effective	O
in	O
type	O
I	O
rickets	O
models	O
,	O
such	O
as	O
Cyp27b1	B
-	O
KO	O
rats	O
.	O

By	O
contrast	O
,	O
the	O
Cyp27b1	B
-	O
KO	O
rats	O
for	O
analysis	O
were	O
continuously	O
fed	O
the	O
CE	O
-	O
2	O
diet	O
because	O
most	O
male	O
Cyp27b1	B
-	O
Knockout	O
rats	O
were	O
not	O
able	O
to	O
survive	O
more	O
than	O
10	O
weeks	O
when	O
fed	O
the	O
F	O
-	O
2	O
diet	O
(	O
data	O
not	O
shown	O
)	O
.	O

